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General introduction
Pneumococcal disease
Streptococcus pneumoniae (pneumococcus) is an important contributor to 
morbidity and mortality worldwide 1,2. This encapsulated Gram-positive bacterium 
with a diplococcus shape causes diseases ranging from mild respiratory tract 
infections to severe diseases, such as pneumonia, sepsis and meningitis, also 
referred to as invasive pneumococcal disease (IPD). S. pneumoniae colonizes the 
human nasopharynx with carriage rates up to 60% in infants, mostly without 
causing any harm 3,4. S. pneumoniae is spread from person to person via droplets 
or aerosols. Colonization and mucosal infections, like acute otitis media, can 
occasionally result in the development of severe invasive infections 5. The 
significance of S. pneumoniae as a human pathogen is highlighted by the estimate 
that globally pneumococcal disease causes 0.7-1.0 million deaths annually 
among children aged <5 years, most of which live in developing countries 2,6. The 
burden of disease of elderly in developing countries is not yet well defined 2. In 
the Western world, children <2 years and elderly people are more susceptible to 
develop pneumococcal disease 2. Another important group with an increased 
risk to develop pneumococcal disease are immunocompromised individuals, for 
instance those with HIV infection or immunodeficiencies 7-9. 
An important virulence factor of S. pneumoniae is its polysaccharide capsule. There 
are over 90 different serotypes identified according to the chemical structures 
of their capsular polysaccharide 10. The development of protein conjugate 
vaccines, which contains selected capsular serotypes, has significantly reduced 
the burden of invasive pneumococcal disease 6,11,12. However, the plasticity of the 
pneumococcal genome results in adaptation to the selective pressure of vaccines. 
This causes serotype replacement by which pneumococci may circumvent the 
vaccine. The prevalence of non-vaccine types following introduction of the 
vaccine has substantially increased 13. This phenomenon is of concern, since it may 
dampen the effectiveness of the current vaccines. In addition, widespread increase 
of pneumococcal resistance to antibiotics has been detected 14. Altogether, this 
indicates that S. pneumoniae still remains an important human pathogen. 
For effective prevention and treatment of pneumococcal disease it is of importance 
to understand the molecular mechanisms by which S. pneumoniae and the host 
interact. Recent findings in host-pathogen interactions in other infectious diseases 
suggest that complement factor H, a key negative regulator of the complement 
system, affects the susceptibility or outcome of many infectious diseases 15-
17. It is already known that S. pneumoniae has the ability to bind human factor 
H as a possible immune evasion strategy. The studies described in this thesis 
were designed to clarify the role of complement factor H in pneumococcal-host 
interactions.
The complement system as part of human host defence
The immune system
Defence against invading pathogens is mediated by intact epithelial barriers 
and by components of the immune system specialized in host defence and 
inflammatory responses. The human immune system can be divided into innate 
and adaptive immunity. Innate immunity uses genetic germ-line encoded 
receptors and secreted proteins to recognize common features of pathogens. The 
non-specific early defences of the innate immune system are essential to prevent 
or to slow infections to allow time for the adaptive immunity to develop and 
respond. Adaptive immunity uses a process of somatic cell gene rearrangement to 
recognize pathogen’s unique antigens to generate an antigen-specific response to 
eliminate the pathogen. 
S. pneumoniae colonizes the nasopharynx asymptomatically, but may become 
invasive and penetrate the mucosal barrier and enter the blood stream. This 
immediately triggers host innate immune responses on the mucosa and 
systemically. Mucosal immunity at mucosa-associated tissues (MALT) has an 
important barrier function. Soluble mediators present in the mucus, such as 
collectin, lactoferrin, lysozyme and defensins prevent that microorganisms pass 
the mucus. Although differences exist between mucosal and systemic immunity, 
many of the immune responses described below occur at both sites. 
An important innate immune response upon S. pneumoniae infection is activation 
of the complement system. The complement system consists of over 30 plasma 
and membrane proteins present on the mucosa and systemically. Upon activation, 
these proteins contribute to clearance of the pathogen. The importance of 
the complement system is apparent in individuals with genetic complement 
deficiencies who are more susceptible for invasive infections 18. In the next 
paragraph we describe the role of complement activation in inflammation and 
phagocytosis. 
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Role of complement in inflammation 
Most invading pathogens induce inflammatory responses upon recognition by 
the host immune system. The induction of cytokines and chemokines conveys 
important signals to other immune cells needed for activation and coordination 
of host immune responses. Innate immune receptors play an important role in 
the first recognition of an invading pathogen. An important group of pattern 
recognition receptors (PRRs) are Toll-like receptors (TLRs), which detect micro-
organisms through the recognition of conserved molecular motifs. Among the 
various TLR receptors, TLR2 recognizes lipoteichoic acid that is present in bacterial 
membranes, including pneumococci 19. Furthermore, TLR9 detects pneumococcal 
DNA containing unmethylated CpG motifs within endosomes and TLR4 has 
been found to be activated by the pneumocooccal pneumolysin 19. Another 
group of pattern recognition receptors (PRRs) are cytosolic NOD-like receptors 
and DNA sensors, which also contribute to the recognition of S. pneumoniae 
infection 19. These PRRs regulate the production of proinflammatory mediators, 
including TNF-α, IL-1β, IL-6 (IL-12). These secreted cytokines induce the acute-
phase response resulting in elevation of the body temperature, vasodilatation 
and increased vascular permeability. In addition, acute-phase proteins, such as 
C-reactive protein (CRP) and mannose binding lectins, are released. Furthermore, 
the inflammatory response stimulates the recruitment of immune cells such as 
neutrophils and macrophages, and shapes the adaptive immune response to 
control the infection. Another immune activation mechanism is recognition of the 
Fc part of antibody bound to their target by Fc-receptors on surfaces of immune 
cells such as monocytes, macrophages and neutrophils 20. Fc-receptor binding of 
these immune complexes stimulates cytokine production, release of inflammatory 
mediators and phagocytosis 20 (Figure 1). 
In addition to the activation of multiple innate immune receptors, pathogens also 
activate the complement system. Crosstalk between the complement system, Toll-
like receptors (TLRs) and Fcγ receptors modulates the extent of the proinflammatory 
cytokine responses 21-26 (Figure 1). In the cascade of complement activation, 
activation products C3a and C5a, also called anaphylatoxins, are released. Various 
studies report that C5a binding to its receptor (C5aR) (also called CD88) modulates 
the inflammatory response induced by different bacterial pathogens, including 
Escherichia coli, Staphylococcus aureus and Neisseria meningitidis 27-29. In addition, 
C3a and the more potent C5a, function as chemoattractant for neutrophils to 
migrate towards the site of infection 21.
However, the inflammatory response can be excessive and contribute to local 
tissue damage in focal infections or can be detrimental in patients with sepsis. 
High inflammatory responses by massive secretion of cytokines and excessive 
complement activation may result in fever, vascular permeability, tissue damage 
and organ failure. It is therefore of importance to study how the complement 
system is regulated and how its activation affects the host inflammatory response. 
In addition, therapies targeting the complement system may reduce the extremely 
high inflammatory response associated with the severe outcome of sepsis. 
Role of complement in phagocytosis 
Phagocytic white blood cells, such as macrophages and neutrophils, are of major 
importance for killing Gram-positive pathogens, such as S. pneumoniae, since these 
innate immune cells are able to engulf and kill invading bacteria. Mature monocytes 
leave the circulation to migrate into tissues where they further differentiate into 
macrophages. Neutrophils are abundant in blood, but can also migrate into tissues 
upon infection. Importantly, these phagocytes need to recognize the bacterium. 
This process is mediated by opsonins such as antibodies, complement factors 
and CRP (Figure 1). Several studies demonstrate that opsonisation by antibodies 
and by complement components is required for protective immunity against 
S. pneumoniae 30,31. However, it has also been shown that neutrophils can kill 
pneumococci in the absence of opsonins. This killing is mediated by phagocyte 
receptors that recognize certain proteins on the pathogen surface 32,33. 
The Fc-region of antibodies bound to the bacteria is recognized by Fc receptors 
on phagocytes which facilitates killing 34,35. Five different antibody isotypes exist 
namely IgM, IgG, IgA, IgE and IgD. Antibodies of isotype IgG are most abundant 
in blood, followed by IgA and IgM. Each class plays a different role in the immune 
defence. IgA is the predominant class in extravascular secretions, whereas IgG 
can cross the placenta and provide protection to the fetus. IgM is a pentamer or 
hexamer that is released by plasma cells in the early immune response. Antibodies 
that are produced without prior immune activation are commonly referred to as 
natural antibodies. These types of antibodies may be present without antigenic 
exposure. In contrast to this, immune antibodies arise after specific immune 
exposure or vaccination 36. 
Another important opsonin is the deposition of complement C3 on the bacterial 
surface 37. Complement activation coats a pathogen surface with complement 
fragments, such as C3b, and its inactive derivate iC3b (Figure 1). These opsonins 
are recognized by complement receptors (CRs) on phagocytes and thereby 
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promote uptake and removal (Figure 1). Various complement receptors, including 
CR1 and CR3, are known to be present on macrophages, monocytes and neutrophils 
38. In addition, complement C5a binding to the C5aR on macrophages/monocytes 
and neutrophils activates the cell for phagocytosis of opsonised pathogens 
(Figure 1) 39. Activation of the complement system by one of the three complement 
activation routes is mediated in various ways. The binding of antibodies to the bacterial 
surface plays an important role in initiation of the classical pathway. C1q recognizing 
the Fc region of bound IgG and IgM antibodies results in classical pathway activation 
and leads to C3b deposition on the bacterial surface. Due to its polymeric structure, 
IgM is particularly effective in classical complement pathway activation 40.
It is important to realize that the complement system is not functioning alone, 
as various immune responses interact to induce and regulate inflammation 
and phagocytosis. This is illustrated in Figure 1, which shows how complement 
activation contributes to phagocytosis and to the induction of inflammatory 
responses. 
Complement system and its role in diseases
Evolution and discovery of complement 
The complement system is an evolutionary ancient immune response. A primitive 
version composed of the central protein C3 and two activation proteases is proposed 
to be established in the common ancestor of Cnidaria (e.g. sea anemones) more 
than 1 billion years ago 41. It is suggested that a version more similar to the human 
complement system has developed by the time of the teleost/mammalian divergence 
around 500 million years ago 41. The human complement system involves many plasma 
and membrane bound proteins. Part of its function was first discovered in the late 19th 
century. Jules Bordet was awarded the 1919 Nobel Prize in Physiology or Medicine, 
for his discovery that bacterial killing of Gram-negative Vibrio cholera required heat 
labile components of the serum in addition to the heat stable antibodies. The heat 
stable antibodies against the bacteria developed following previous exposure to the 
pathogen, which was named “immunization” 42,43. In contrast, heat labile components 
were already present before immunization and named “complement”. Subsequently, 
many complement proteins were detected and named in the order in which they were 
discovered. The antibody dependent classical pathway was identified first followed 
by the alternative pathway 44. The lectin pathway was discovered more recently, 
approximately two decades ago 45,46. Nowadays, the critical role of the complement 
system is increasingly acknowledged not only in infections but also in many other 
inflammatory diseases and clearance of the body’s cellular debris. 
Complement activation upon pneumococcal infection
The three main pathways for complement activation are the classical, lectin and 
alternative pathway. IgG and IgM binding to the bacterium enable C1q binding to 
the Fc-region of the antibodies. This results in a cascade of reactions classified as 
the classical pathway. Another important classical pathway activator is the acute 
Figure 1. This figure schematically illustrates the function of complement in phagocytosis and 
inflammation. Antibodies (Ab) that recognize antigens on the bacteria bind to the bacterial surface, 
which contributes to complement activation resulting in cleavage of C3 into the opsonin C3b. In 
addition, complement activation products are released, C3a and C5a, of which C5a binding to 
C5aR is especially potent in stimulating phagocytosis and inflammation. Fc-receptors (Fc R) on 
phagocytes, such as monocytes, macrophages and neutrophils recognize antibodies bound to the 
bacteria. In addition, complement receptors (CR) recognize C3b deposited on the bacterial surface. 
Binding of these receptors stimulate engulfment and clearance of the pathogen by phagocytosis. 
In addition, complement activation modulates the inflammatory response. Crosstalk between 
complement C5a binding to the C5aR, Toll-like receptor (TLR) binding and Fc receptors recognizing 
antibodies bound to the pathogen, modulate the host inflammatory cytokine response. 
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phase protein CRP, which binds phosphocholine residues on the pneumococcal 
surface 47. Other danger signals such as bacterial DNA, RNA, lipopolysaccharides, 
and certain small polysaccharides are also able to induce classical pathway 
activation 48. The initiation of the classical pathway by binding of C1q generates 
an enzyme capable of cleaving C4 and C2 which leads to the formation of a C3 
convertase (C4bC2a) (Figure 2). The lectin pathway is activated by mannose-
binding lectin (MBL) binding to mannose-containing surface proteins on the 
pathogen. In addition, binding of ficolins can initiate the lectin pathway 49. Similar 
to the classical pathway, lectin pathway activation results in cleavage of C2 and C4 
which results in the formation of a C3 convertase (C4bC2a) (Figure 2). 
C3 convertase cleaves the central complement protein C3 into C3a and C3b (Figure 
2). C3a is an anaphylatoxin and diffuses, whereas C3b binds to the bacterial surface 
aiding phagocytosis 50-52. High concentrations of locally deposited C3b lead to 
the formation of C5-convertases, which cleaves C5 into C5a and C5b. The highly 
proinflammatory peptide C5a diffuses whereas C5b reacts with C6-C9 resulting in 
formation of the membrane attack complex (MAC) by the incorporation of C5b-9 
in the membrane 53. The MAC is functionally involved in killing of Gram-negative 
bacteria by lysis, whereas in Gram-positive bacteria, such as S. pneumoniae, 
the MAC can be detected on the bacterial surface but seems not to affect the 
viability 54. This distinction between Gram-negative and Gram-positive is due to 
difference in cell surface composition. Gram-negative bacteria consist of an inner 
and an outer membrane separated by a periplasmic space and a thin peptidoglycan 
layer, whereas the cell wall of Gram-positive bacteria only has one membrane 
surrounded by a thick peptidoglycan layer 55. Thus, the membrane attack complex 
required for bacterial cell lysis cannot reach the cell membrane of Gram-positive 
bacteria, making these microbes resistant to lysis.
The alternative pathway and its amplification loop 
In contrast to the classical and lectin pathway, the alternative pathway is 
continuously activated at low levels. Spontaneous hydrolysis of the internal thioester 
bond of C3 generates a C3b-like molecule, C3(H2O). The alternative pathway can 
also amplify complement activation initiated by the classical, lectin and alternative 
pathway (Figure 3). Subsequent binding of factor B to C3(H2O) and cleavage by 
factor D makes a short lived soluble C3 convertase (C3(H2O) Bb complex) that can 
cleave C3 to C3b. Moreover, surface bound or fluid phase C3b interacts with factor 
B in a Mg2+-dependent manner and cleavage by factor D results in an alternative 
pathway C3 convertase (C3bBb) that can cleave more C3. This alternative pathway 
amplification loop multiplies the initial C3b deposition by all three pathways by 
Figure 2. Simplified scheme of complement activation by the classical and lectin pathway. 
Activation leads to a cascade of reactions leading to the formation of C4b2a, which is a C3 
convertase. Cleavage of C3 by the convertase results in the release of C3a and the C3b, which serves 
as an opsonin when bound to a nearby surface. Cell surface bound C3b can be formed into a C5 
convertase, which cleaves C5 into C5a and C5b. C5a together with C3a are anaphylatoxins, whereas 
C5b reacts with C6-9 to form the membrane attack complex. 
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generating alternative pathway C3 convertase from any C3b generated (Figure 3). 
The alternative pathway convertase is very labile and spontaneously dissociates 
with a half life of about 90 s at 37 °C. Binding of the positive alternative pathway 
regulator properdin stabilises the enzyme and extends its half-life more than 10-
fold 17,44. Complement factor H is a key negative regulator of alternative pathway 
activation, both in the plasma as well as on the cell surfaces. Whereas, properdin 
stabilises the alternative pathway C3 convertase, factor H accelerates its decay. In 
addition, factor H acts as a co-factor for factor I mediated inactivation of C3b 
in to iC3b 56-59. iC3b cannot form an active convertase and thereby inhibits the 
alternative pathway amplification loop. Factor H is an abundant plasma protein 
containing binding sites for glycosaminoglycans (GAGs) to protect self tissues.
The importance of the alternative pathway has long been underestimated. 
However, this pathway is now acknowledged as a critical pathway since the 
amplification loop may contribute up to 80% of the total complement activation 
60-62. Others demonstrated the importance of both the classical and lectin pathway 
in S. pneumoniae infections using animal models 63,64. It appears that both the 
classical pathway and the lectin pathway are important in initiating complement 
activation, whereas the alternative pathway determines the final amount of C3 
deposition on the bacterial surface 63,65. 
Alternative pathway activity and disease 
Complement regulators on cells and in plasma control activation of the alternative 
pathway. However, an imbalance of alternative pathway activation has been 
associated with diseases. Combinations of common polymorphisms in genes 
encoding alternative pathway proteins are known to affect the alternative pathway 
activity 17,66. These genetic polymorphisms, also referred to as ‘complotypes’, are 
found in components of the alternative pathway amplification loop, C3, factor 
B and factor D, or in the control proteins such as factor H and factor I 17. It has 
been proposed that alternative pathway enhancing polymorphisms lead to a 
predisposition in chronic inflammatory diseases, such as haemolytic uremic 
syndrome, age-related macular degeneration, and dense deposit disease 17. 
In addition, reduced alternative pathway activity may increase an individual’s 
susceptibility for infections 17.
Variation in complement factor H seems to play an important role in an individual’s 
alternative pathway activity. The crucial function of factor H to regulate the 
alternative pathway activity is apparent in rare cases of complete factor H 
deficiency in humans in which uncontrolled alternative pathway activation 
results in a secondary C3 deficiency 67. These individuals are susceptible to 
meningococcal infections, C3 glomerulopathy and haemolytic uraemic syndrome 
(HUS) 67. Additionally, genetic variation in factor H has been associated with 
diseases such as age-related macular degeneration, atypical haemolytic uremic 
syndrome (aHUS), C3 glomerulopathy, including dense deposit disease and C3 
glomerulonephritis 66,68-70. Polymorphisms may affect factor H binding to host cells, 
regulation of alternative pathway activity, or factor H expression levels 17,71,72. 
Interestingly, a genome wide associations study (GWAS) for meningococcal 
disease identified risk polymorphisms in the complement factor H gene (CFH) 
and complement factor H related protein 3 (CFHR3) 15. Others demonstrated that 
a single-nucleotide polymorphism in the promoter region of CFH increases serum 
factor H levels, resulting in reduced bactericidal activity against N. meningitidis 16. 
This suggests that polymorphisms in CFH may affect factor H expression and 
an individual’s susceptibility for disease. Within the human population, factor H 
plasma levels show a large variation (range, 63.5-847.6 µg/mL) 16,73-76. This variation 
is due to both environmental factors (e.g. smoking) and genetic factors 74. 
Figure 3. Simplified scheme of the alternative pathway amplification loop. In contrast to the classical 
and lectin pathway, the alternative pathway is continuously activated at low levels. The alternative 
pathway can amplify complement activation initiated by the classical, lectin and alternative 
pathway, known as the alternative pathway amplification loop. Factor H is a key inhibitor of the 
alternative pathway and the alternative pathway amplification loop. 
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Pneumococcal complement evasion
Evolutionary models propose that S. pneumoniae evolved from a pneumococcus-like 
bacteria presumably pathogenic to the common immediate ancestor of hominoids 
77,78. This suggests a long history of pneumococcal adaptation to the human host. 
S. pneumoniae is mainly isolated from humans and not from other mammals. 
However, S. pneumoniae infection has been diagnosed in wild chimpanzees in Taï 
National Park, Côte d’Ivoire 79. The ability to regulate natural competence for genetic 
transformation and uptake of DNA from other pneumococci or other pathogens 
provides S. pneumoniae into a successful human pathogen with mechanisms to 
evade human immune defences including the complement system. 
The pneumococcal capsular serotype 
The polysaccharide capsule is a major pneumococcal virulence factor and is an 
important antiphagocytic component. The more than 90 capsular serotypes 
all contain structurally unique polysaccharide capsules with varying degrees of 
resistance to phagocytosis 33,80,81. Studies comparing isolates from patients with 
invasive disease and carriage isolates from the same region and time period 
suggest that a strain’s invasive disease potential largely depends on the capsular 
serotype 82-84. Serotypes, such as 1, 4 and 7F, are more often found in invasive 
disease whereas other serotypes are more frequently found in carriage 84. 
Infections by serotypes with a low invasive disease potential were often found in 
patients with underlying diseases and are associated with high mortality rates 8,84. 
These serotypes are referred to as more opportunistic, whereas serotypes found in 
previously healthy individuals are indicated as primary pathogens 8. Importantly, 
both pneumococcal virulence and the host immune response determine the risk 
and outcome of infection.
The pneumococcal capsule affects resistance to phagocytosis by various 
mechanisms 85. Absence of a capsule increases surface C3 deposition compared 
to its encapsulated wild-type strain 85. In addition, increased binding of classical 
pathway mediators such as IgG and C-reactive protein (CRP) to non-capsulated 
strains has been observed 85. The capsule masks subcapsular antigens and thus 
reduces antibody binding and CRP binding. In accordance, non-capsulated 
mutants show reduced virulence and enhanced clearance from the circulation in 
animal models 86. Moreover, gene expression for capsular synthesis is a dynamic 
and complex process 87. Within a serotype, spontaneous opaque/transparent phase 
variation affects polysaccharide capsule thickness and pneumococcal resistance 
to complement 88,89. Opaque phase pneumococci with increased amounts of 
capsular polysaccharide show enhanced complement resistance, which has 
been associated with better survival in blood 90-92. Whereas transparent phase 
pneumococci are more often carriage isolates 89. Similar to non-capsulated strains, 
transparent phase pneumococci show increased antibody binding to subcapsular 
antigens and increased binding of CRP 88. Even in the absence of opsonins, the 
capsular serotype affects the interaction with neutrophils 33. 
Pneumococcal proteins involved in complement evasion
In addition to the important role of the pneumococcal capsule, pneumococcal 
genotype affects complement resistance and its invasive disease potential 84,93. 
Significant differences in complement C3 deposition between isolates within the 
same serotype have been observed, indicating that the strain genetic background 
affects complement resistance 94. It is therefore of interest to gain more insight 
into how genetic variation affects complement resistance and aids pneumococcal 
virulence. 
Pneumococcal surface proteins interact with the complement system to reduce 
complement deposition. Various pneumococcal proteins play a role in complement 
evasion, including pneumolysin, pneumococcal histidine triad proteins (Pht), 
pneumococcal surface protein A (PspA) and pneumococcal surface protein C (PspC) 
95-98. Pneumolysin is a pneumococcal virulence protein released during infection. It 
has been suggested that pneumolysin activates the immune system by its interaction 
with C1q, which keeps the complement deposition away from the pneumococcal 
surface 98. Pneumococcal surface protein A (PspA) contributes to pneumococcal 
virulence in mice and has been suggested to play a role in complement resistance, as 
PspA has been shown to reduce C3 deposition on the bacterial surface 96,97. PspA may 
compete with the binding of C-reactive protein to cell-surface phosphocholine and 
thereby affect complement activation 97. Pht proteins PhtA, PhtB, PhtD, and PhtE are 
a family of surface proteins that may play a role in complement evasion. Pht deletion 
resulted in increased C3 deposition on a serotype 4 strain but not on serotype 2, 
3, and 19F strains 99. The mechanism by which Pht proteins mediate complement 
resistance remains unclear.
Sequestering of host inhibitory complement regulators is an evasion mechanism 
often seen in invasive pathogens. S. pneumoniae binds complement alternative 
pathway inhibitor factor H through pneumococcal surface protein C (PspC, also 
referred to by CbpA, SpsA, PbcA and Hic) 100-104. This is considered as a mechanism to 
evade host alternative pathway activation because factor H increases C3 cleavage 
into iC3b, circumventing the formation of a C3 convertase and thereby reducing 
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C3b deposition on the bacterial surface (Figure 4). However, the function of PspC 
binding factor H varies between different serotypes. In some serotypes, loss of 
PspC results in decreased complement deposition, whereas in other serotypes loss 
of PspC increases complement deposition or has no effect 105,106 80. These differences 
in function of PspC in complement evasion may be the result of capsular serotype 
differences or other genetic differences, for example antigenic variation in PspC 105. 
Importantly, factor H binding to PspC is species specific as mice or rat factor H do 
not bind pneumococcal PspC 107. 
Factor H binding by S. pneumoniae strains is not only dependent on the presence 
of PspC, but also influenced by capsular serotype. Capsule switch experiments, 
where different capsules are expressed by the same strain, demonstrated the 
ability to bind factor H and to evade opsonisation is largely capsule dependent 80. 
Nevertheless, within one serotype large variation in factor H binding was observed 
between different clinical isolates suggesting that other factors besides capsule 
serotype affect factor H binding 80. Interestingly, PspC itself is heterogeneous and 
has been classified into different PspC types based on sequence comparisons. 
However, it is not known whether variation in PspC type, independent of capsule 
differences, affects pneumococcal factor H binding and its ability to evade 
complement deposition.
Aim and outline 
The overall aim of this thesis is to contribute to a better understanding of the role 
of complement factor H in S. pneumoniae infection. 
More specifically, the aims are:
(i)  To study the role of complement alternative pathway activity 
regulated by factor H on pneumococcal induced inflammation
(ii)  To study whether serum factor H levels affect pneumococcal 
clearance from blood
(iii)  To study whether differences in PspC types affect pneumococcal 
factor H binding and resistance to complement.
Invasive pneumococcal infections are often associated with high inflammatory 
responses, which contribute to the disease pathology. In Chapter 2 we studied 
the role of the complement alternative pathway in pneumococcal induced 
proinflammatory cytokine responses by human PBMCs. Complement factor H is an 
important inhibitor of the alternative pathway activity. In chapter 3 we examined 
whether exogenous factor H can attenuate inflammation and vascular leakage in 
experimental pneumococcal sepsis in mice. 
Within the human population, a large variation in plasma factor H levels is 
observed. In chapter 4 we show by using an experimental mouse model and a 
human whole blood killing assay the effects of serum complement factor H levels 
on resistance to pneumococcal invasive disease. In chapter 5, we describe the use 
of a whole blood killing assay that makes it possible to study bacterial clearance in 
human blood with an intact complement system.
In chapter 6, we focus on the ability of pneumococci to bind human factor H. 
S. pneumoniae binds human factor H by PspC, which is considered as a possible 
mechanism to evade complement deposition. PspC is a variable protein and has 
been classified into different PspC types based on sequence comparisons. We 
studied the effect of PspC type specific differences on pneumococcal factor H 
binding and complement evasion. 
Figure 4. S. pneumoniae surface consisting of a cell membrane, peptidoglycan layer and a 
polysaccharide capsule. (A) PspC on the bacterial surface binds human factor H which inhibits 
alternative pathway mediated C3b deposition on the bacterial surface. This enhances pneumococcal 
complement resistance. (B) Whereas in the absence of PspC there is no binding of factor H which 
results in enhanced C3b deposition on the bacterial surface. Making the bacteria more sensitive for 
complement mediated phagocytosis. 
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Factor H modulates pneumococcal induced cytokine responses
Abstract
Bacterial pathogens not only stimulate innate immune receptors, but also activate 
the complement system. Crosstalk between complement C5a receptor (C5aR) and 
other innate immune receptors is known to enhance the proinflammatory cytokine 
response. An important determinant of the magnitude of complement activation 
is the activity of the alternative pathway, which serves as an amplification 
mechanism for complement activation. Both alternative pathway activity 
as well as plasma levels of factor H, a key inhibitor of the alternative pathway, 
show large variation within the human population. Here, we studied the effect 
of factor H-mediated regulation of the alternative pathway on bacterial-induced 
proinflammatory cytokine responses. We used the human pathogen Streptococcus 
pneumoniae as a model stimulus to induce proinflammatory cytokine responses in 
human peripheral blood mononuclear cells. Serum containing active complement 
enhanced pneumococcal induced proinflammatory cytokine production through 
C5a release and C5aR crosstalk. We found that inhibition of the alternative pathway 
by factor H, with a concentration equivalent to a high physiological level, strongly 
reduced C5a levels and decreased proinflammatory cytokine production in human 
peripheral blood mononuclear cells. This suggests that variation in alternative 
pathway activity due to variation in factor H plasma levels affects individual 
cytokine responses during infection.
Introduction
The host innate immune system is activated immediately upon infection. 
Induction of inflammatory responses are essential for recruitment of immune cells 
and the control of adaptive immune responses. Pathogens, containing complex 
macromolecular surfaces, present multiple antigens to the host immune system 
that not only stimulate specific pattern-recognition receptors (PRRs), but also 
activate the complement system. Several studies indicate that there is crosstalk 
between the complement system, Toll-like receptors (TLRs) and Fcγ receptors, 
which modulates the proinflammatory cytokine responses 1-6. It is known that 
complement activation product C5a is a potent inflammatory protein 7. Addition 
of recombinant C5a to human peripheral blood mononuclear cells (PBMCs) 
stimulated with TLR ligands enhances cytokine production, whereas C5a alone has 
no effect 4. In addition, it has been demonstrated that C5a binding to its receptor 
(C5aR) (also called CD88) modulates the inflammatory response induced by many 
bacterial pathogens, including Escherichia coli, Staphylococcus aureus and Neisseria 
meningitides 8-10. Therefore it is important to study the mechanism by which 
complement activation contributes to the inflammatory response upon infection. 
The complement cascade can be activated by three distinct pathways; (i) the 
classical pathway activated by C1q binding to antibody-antigen complexes; 
(ii) the lectin pathway activated by recognition of polysaccharide structures on 
pathogens; and (iii) the alternative pathway activated continuously at low levels 
by spontaneous hydrolysis of C3. In addition, the alternative pathway amplification 
loop plays a crucial role in the amplification of the initial activation of the classical 
and lectin pathway 11. The alternative pathway may account for up to 80% of total 
complement activation, even if initially triggered by the classical pathway 12. 
A key negative regulator of the alternative pathway is complement factor H, which 
is essential for inhibiting alternative pathway activation in the fluid phase and on 
cellular surfaces 13. Factor H acts as a co-factor for factor I mediated inactivation 
of C3b and also accelerates the decay of the alternative pathway C3 convertase 
14. Polymorphisms in the gene encoding complement factor H (CFH) have been 
associated with human diseases such as hemolytic uremic syndrome, age related 
macular degeneration and dense deposit disease 13,15. Polymorphisms may affect 
factor H binding to host cells, regulation of alternative pathway activity, or factor 
H expression levels 14-16. Factor H plasma concentrations vary widely between 
individuals 17-21. In the MRC Fenland population study of 1514 individuals, factor 
H serum levels ranged from 63.5 to 847.6 μg/mL (median 226.6 µg/mL) 20. The 
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observed variation may be due to environmental factors (e.g. smoking) and genetic 
factors 13,19. In addition, factor H serum levels may vary depending on an individual’s 
disease state. Reduced factor H levels were observed during acute meningococcal 
disease compared to patients at convalescence. As noted above, the serum factor 
H concentration in the healthy control group in this study varied widely, ranging 
from 31 to 953 µg/mL (median 395 µg/mL) 17. We have also demonstrated the 
importance of factor H levels and variation in alternative pathway activity on the 
host defense against Streptococcus pneumoniae 22.
In the current study, we aim to assess the role of factor H levels and alternative 
pathway activity on bacterial-induced proinflammatory cytokine production. 
We used the human pathogen S. pneumoniae as a model stimulus to induce 
proinflammatory cytokine responses by PBMCs. Our results clearly show that 
complement activation enhances the inflammatory response through C5a 
release and C5aR-mediated crosstalk. Moreover, alternative pathway inhibition by 
exogenous soluble phase factor H strongly reduces C5aR crosstalk and pathogen 
induced proinflammatory cytokine responses. Thus variation in alternative 
pathway activity due to variation in factor H plasma levels may affect an individual’s 
cytokine responses during infection.
Material and Methods
Bacterial strains and growth conditions
Wild-type S. pneumoniae strain TIGR4 was used in all PBMC stimulation 
experiments 23. In factor H binding assays only, a TIGR4 ΔpspC deletion mutant was 
used as S. pneumoniae has been described to bind human factor H by expressing 
pneumococcal surface protein C (PspC) 24. The TIGR4 ΔpspC deletion mutant was 
constructed by allelic replacement of the target gene with an antibiotic resistance 
marker as described previously 25. Briefly, overlap extension PCR was used to 
insert the spectinomycin resistance cassette of the pR412 plasmid between the 
two 500-bp flanking sequences adjacent of the target gene. The resulting PCR 
products were introduced by competence-stimulating peptide (CSP-2) induced 
transformation into TIGR4. Directed mutants were obtained by selective plating 
and were checked for correct integration of the antibiotic resistance cassette 
into the target gene by PCR using control primers located inside the gene. 
Subsequently, the TIGR4 wild-type strain was transformed with chromosomal DNA 
isolated from the mutants, to prevent the accumulation of inadvertent mutations 
elsewhere on the chromosome. The primer sequences are presented in table 1 of 
the supplementary data. 
Bacteria were grown on Columbia blood agar plates (Becton Dickinson) and in 
Todd-Hewitt broth supplemented with 5 g/L yeast extract at 37°C and 5% CO2 until 
an OD620 of 0.3 was reached. The number of colony forming units per milliliter was 
determined by plating serial 10-fold dilutions on blood agar plates. Subsequently, 
bacteria were heat killed at 65°C for 30 min and stored at -80°C. Heat killed 
pneumococci were used in order to avoid variation in bacterial numbers due 
to growth which could affect the host inflammatory response. Previous studies 
demonstrate that most TLR ligands remain functional after heat killing, although it 
has been shown that this can lower TLR9 dependent signaling 26. 
Isolation of PBMCs and stimulation assays
After informed consent was obtained, a venous blood specimen was collected 
from the median cubital vein of healthy volunteers (age, 20-40 years; both males 
and females) into 10-mL EDTA tubes (BD). To isolate the PBMC fraction, blood 
was diluted in an equal volume of phosphate buffered saline (PBS), added onto 
15 ml Lymphoprep (Axis Shield) and centrifuged at 800 × g for 20 min at room 
temperature. The PBMCs were harvested, washed three times in cold PBS and 
resuspended in culture medium (RPMI 1640 GlutaMAX-I medium, Invitrogen). Five 
hundred thousand cells in 100 µl were added to a round-bottom 96-well plate 
(Nunc) and incubated with 50 µl of stimuli and 50 µl of diluted serum resulting in a 
total volume of 200 µL/well. The stimuli were 105 heat-killed TIGR4 bacteria, or the 
TLR2 agonist Pam3Cys (Invivogen) (final concentration 1 µg/mL) or RPMI (negative 
control). The serum was diluted in RPMI to obtain a final concentration of 10% 
serum/well. Pooled normal human serum (NHS) (Sigma-Aldrich or GTI Diagnostics) 
or heat-inactivated serum (HI-NHS; 30 min at 56°C) or RPMI (negative control) was 
used. Specific PBMC stimulations using 10% NHS were supplemented with 0.1 or 
1 µM C5a receptor antagonist, PMX53 (R&D Systems) or with 5, 25 or 50 µg/mL 
purified human factor H (Comp. Tech). The factor H concentration in the pooled NHS 
was 460 µg/mL, which in diluted serum gave a final factor H concentration of 46 
µg/mL. Therefore adding 50 µg/mL of exogenous factor H doubled the amount of 
factor H already present in the serum. Each stimulation was prepared in duplicate. 
After 24 hours at 37°C and 5% CO2, the cells were pelleted by centrifugation at 
650 × g at room temperature, after which the supernatants were pooled and stored 
at -20°C for further analysis.
Inflammatory response analysis
The concentrations of human interleukin-(IL)6, IL-1β, tumor necrosis factor (TNF-α) 
and IL-8 produced by the PBMCs were measured using commercial enzyme-linked 
immunosorbent assay (ELISA) kits (Pelikine Compact, Sanquin) according to 
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manufacturers’ instructions. Levels of complement activation product C5a were 
measured using a commercial human C5a ELISA kit (HK349, Hycult). 
Factor H binding assay
TIGR4 heat killed or alive bacteria (1x107) were pelleted in a 96-well plate and 
resuspended in 10% (vol/vol) pooled normal human serum (Sigma-Aldrich) in 
Hanks Buffered Salt Solution (HBSS) to a total volume of 100 µL. The bacterial 
suspension was incubated for 30 min at 37°C in 5% CO2. After incubation the 
bacteria were washed and labeled with polyclonal sheep anti-human factor H 
(Abcam). After a further 30 min incubation and washing, the bacteria were labeled 
with FITC-donkey anti-sheep IgG antibody (Jackson immunoresearch) followed by 
fixation in 2% paraformaldehyde. Factor H binding was measured using a FACScan 
flow cytometer (BD Biosciences). Data were analysed using FlowJo v10.1. 
Statistics
Statistically significant differences were determined by the Wilcoxon or the 
Friedman test (nonparametric one-way ANOVA) followed by the Dunn’s test to 
calculate multiplicity-adjusted P values. The data shown represents the mean ± 
standard error of the mean (SEM) of two or three independent experiments using 
PBMCs isolated from 5 or 6 different donors. 
Results
Complement activation enhances pneumococcal induced 
PBMC cytokine production 
PBMCs were stimulated for 24 hours with heat-killed S. pneumoniae or the TLR2 
ligand Pam3Cys in the presence of normal human serum (NHS) or heat inactivated 
NHS (HI-NHS). HI-NHS is devoid of active complement since complement is a 
heat-labile component of human serum 27. In the absence of active complement, 
using HI-NHS, PBMCs stimulated with S. pneumoniae produced proinflammatory 
cytokines IL-6, IL-1β, TNF-α and IL-8 (Figure 1). The presence of active complement 
in NHS significantly increased the release of proinflammatory cytokines upon 
stimulation with S. pneumoniae thus indicating that complement activation 
augments cytokine release by PBMCs (Figure 1). PBMCs stimulated with Pam3Cys 
induced IL-6, IL-1β, and IL-8 which was not affected by the absence or presence of 
active complement indicating that pneumococcal-induced complement activation 
was necessary for augmented cytokine release. 
Pneumococcal induced PBMC cytokine production is 
enhanced through C5aR crosstalk
In order to study whether complement activation acts via the C5a-C5aR signaling 
pathway to enhance inflammatory cytokine release, PBMCs were stimulated with 
heat-killed S. pneumoniae in the presence of C5aR antagonist PMX53. Inhibition of 
C5aR in the presence of active complement led to decreased cytokine release in 
a dose-dependent manner to levels observed for HI-NHS. This demonstrates that 
the enhanced inflammatory response in the presence of active complement was 
largely C5aR mediated (Figure 2). 
Alternative pathway inhibition by exogenous factor H 
strongly reduces C5aR crosstalk
In order to study the role of alternative pathway activation on the pneumococcal 
induced inflammatory response, we used the natural alternative pathway inhibitor 
factor H. PBMCs were stimulated with heat-killed S. pneumoniae in the presence 
of NHS with increasing concentrations of purified human factor H. As observed 
Figure 1. Complement enhances pneumococcal induced cytokine responses. Human PBMCs were 
stimulated with heat-killed S. pneumoniae TIGR4 (Sp), Pam3cys or culture media alone, in the 
presence of 10% pooled normal human serum (NHS) or heat-inactivated pooled normal human 
serum (HI-NHS) for 24 hours. Supernatants were collected and IL-6, IL-1β, TNF-α and IL-8 measured 
by ELISA. The data shown represent the mean and SEM of three independent experiments using 
PBMCs isolated from 5 donors. Statistically significant differences were determined by the paired 
Wilcoxon test. *P < 0.05
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previously, the presence of active complement in NHS significantly increased 
cytokine release by PBMCs compared to HI-NHS (Figure 3). Adding exogenous 
factor H decreased cytokine release in a dose-dependent manner, where addition 
of 50 µg/mL factor H, which doubles the absolute factor H serum concentration, 
reduced cytokine release to levels found with HI-NHS (Figure 3). In order to 
demonstrate the effect of factor H on complement activation, we measured C5a 
levels. Addition of exogenous factor H inhibited complement activity in a dose-
dependent manner, as demonstrated by decreased C5a levels (Figure 4). Heat-
killed S. pneumoniae TIGR4 used for the stimulations did not bind human factor H 
when incubated in serum, as opposed to live S. pneumoniae which bound factor H 
Figure 2. Complement mediated enhancement of cytokine induction is mediated by C5aR crosstalk. 
Human PBMCs were stimulated with heat-killed S. pneumoniae TIGR4 (Sp) or culture media alone, in 
the presence of 10% pooled normal human serum (NHS) or heat-inactivated pooled normal human 
serum (HI-NHS) for 24 hours. 0.1 or 1 µM of C5aR inhibitor (PMX53) was added to stimulations 
with 10% NHS. Supernatants were collected and IL-6, IL-1β, TNF-α and IL-8 measured by ELISA. The 
data shown represent the mean and SEM of three independent experiments using PBMCs isolated 
from 5 different donors. Statistically significant differences were determined with the Friedman 
test (non-parametric one-way ANOVA) followed by Dunn’s test to calculate multiplicity-adjusted P 
values. *P < 0.05, **P < 0.01. NS= not significant
via the pneumococcal surface protein C (PspC) (supplementary data). Use of heat-
killed S. pneumoniae allowed us to demonstrate that only soluble phase factor H 
alternative pathway inhibition was sufficient to down-regulate pathogen induced 
proinflammatory cytokine release. 
Figure 3. Alternative pathway inhibition by exogenous factor H strongly reduces pneumococcal 
cytokine responses. Human PBMCs were stimulated with heat-killed S. pneumoniae TIGR4 (Sp) or 
culture media alone, in the presence of 10% pooled normal human serum (NHS) or heat-inactivated 
pooled normal human serum (HI-NHS) for 24 hours. Increasing concentrations of purified human 
factor H (FH) were added to the PBMC stimulation in 10% NHS. Supernatants were collected and 
TNF-α, IL-1β, IL-6 and IL-8 measured by ELISA. The data shown represent the mean and SEM of three 
independent experiments using PBMCs isolated from 6 different donors. Statistically significant 
differences were determined with the Friedman test (non-parametric one-way ANOVA) followed 
by Dunn’s test to calculate multiplicity-adjusted P values. *P < 0.05, **P < 0.01, ***P < 0.001, NS= 
not significant
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Discussion 
This study demonstrates a critical role of fluid phase factor H on pneumococcal 
induced proinflammatory cytokine responses. Induction of proinflammatory 
cytokines IL-6, IL-1β, TNF-α and IL-8 were measured upon stimulation of human 
PBMCs with S. pneumoniae in the absence of active complement. This pathogen 
contains multiple antigens that are recognized by multiple innate immune 
receptors such as TLR2, TLR4, TLR9, NOD-like receptors (NLRs) and DNA sensors 
26,28. Several reports demonstrate that signaling by these innate immune receptors 
induces cytokine secretion 26,28,29. We showed in our study that PBMC stimulation 
with the TLR2 ligand Pam3Cys induced IL-6, IL-1 β and IL-8 release to the same 
extent in the presence or absence of complement active serum. 
Figure 4. Exogenous factor H reduces C5a generation. Human PBMCs were stimulated with 
heat-killed S. pneumoniae TIGR4, in the presence of 10% pooled normal human serum (NHS) or 
heat-inactivated pooled normal human serum (HI-NHS) for 24 hours. Increasing concentration 
of purified human factor H (FH) were added to the PBMC stimulation in 10% NHS. Supernatants 
were collected and C5a measured by ELISA. The data shown represent the mean and SEM of three 
independent experiments using PBMCs isolated from 6 different donors. Dash line indicates lower 
limit of detection. Statistically significant differences were determined with the Friedman test (non-
parametric one-way ANOVA) followed by Dunn’s test to calculate multiplicity-adjusted P values. 
*P < 0.05
Interaction of S. pneumoniae with human serum leads to complement activation 
by the classical, lectin and alternative pathway resulting in a cascade of reactions 
and the release of the complement activation product C3a and C5a 28,30. Our 
results show the importance of complement activation and C5aR crosstalk on 
S. pneumoniae induced inflammatory cytokine responses in PBMCs. These results 
are in line with previous studies that demonstrated the effect of recombinant 
C5a on TLR ligand induced cytokine responses 4,5. Other studies, where the 
inflammatory response was induced by Neisseria meningitidis, Candida albicans or 
Staphylococcus aureus, also demonstrate an important role for C5aR crosstalk 4,9,10. 
We are the first to show that the presence of relative high factor H levels strongly 
reduce whole pathogen induced inflammatory responses from human PBMCs, 
as measured by proinflammatory cytokine production. As the heat-killed 
S. pneumoniae strain TIGR4 failed to bind human factor H to its surface 
(supplemental Figure), our assessment focused solely on soluble phase factor H 
alternative pathway regulation. Previous studies demonstrated that exogenous 
purified factor H acted on fluid phase complement activity as determined by 
haemolytic activity of serum 31. 
In line with our findings, other studies have demonstrated that alternative 
pathway inhibition by anti-factor D reduced the oxidative burst of monocytes 
and granulocytes in a human whole blood model of meningococcal sepsis 10. 
Furthermore, inhibition of the alternative pathway by anti-factor D in PBMCs 
stimulated with C. albicans reduced proinflammatory cytokine production 4. 
Our study shows that factor H, in a dose-dependent manner, reduced C5a 
release and subsequent proinflammatory cytokine production, which indicated 
that alternative pathway-mediated C5aR crosstalk is essential for the release of 
cytokines by PBMCs.
Our results may help to understand inter-individual differences in inflammatory 
responses. Human factor H concentrations vary greatly between individuals 
(range, 63.5-847.6 µg/mL) and may affect an individual’s alternative pathway 
activity 17-21. Furthermore, combinations of polymorphisms in alternative pathway 
proteins have been described to influence alternative pathway activity 15. 
Particular combinations of polymorphisms may result in a hyper-inflammatory 
state and predispose for chronic inflammatory diseases, such as haemolytic 
uremic syndrome, age-related macular degeneration and dense deposit disease 15. 
In contrast, other combinations may result in a hypo-inflammatory state and 
may predispose to infections by ineffective immune activation 15. An association 
44 45
2
Factor H modulates pneumococcal induced cytokine responses
between factor H plasma levels, plasma C5a levels and inflammatory activity has 
been observed for clinical diseases such as anti-neutrophil cytoplasmic antibody 
associated vasculitis and age-related macular degeneration 16,32,33. 
In conclusion, we have found that factor H, the alternative pathway inhibitor, 
modulates pneumococcal induced proinflammatory cytokine responses by 
inhibiting C5aR crosstalk. Variation in factor H levels within the physiological range 
of serum affected C5aR crosstalk in PBMCs stimulated with S. pneumoniae. This 
may explain the mechanism by which an individual’s alternative pathway activity 
not only affects the susceptibility to chronic inflammatory diseases, but also the 
extent of the inflammatory response during infectious diseases. 
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Supplementary data
Table 1. Primers used to construct the TIGR4 ΔpspC deletion mutant.
Primers for mutant generation:
Spn2190_L1 Spn -2190 pspC 5’-TTG AGG CAA TGG TGC ACA AG-3’
EMspn2190_L2 Spn -2190 pspC 5’-CCACTAGTTCTAGAGCGGCTACACTAGCTACTCCAACAC-3’
EMspn2190_R1 Spn -2190 pspC 5’-CAAGATGAAGATCGCCTACG-3’
EMspn2190_R2a Spn -2190 pspC 5’-GCGTCAATTCGAGGGGTATCGCTATGGAGTCAATGCCAAT-3’
EMspn2190_C Spn -2190 pspC 5’-TCG TTC TCT GTC GCA TGA AC-3’
PBMrTn9 Specres cassette 5’-CAATGGTTCAGATACGACGAC-3’
PBpR412_L Specres cassette 5’-GCCGCTCTAGAACTAGTGG-3’
PBpR412_R Specres cassette 5’-GATACCCCTCGAATTGACGC-3’
Supplementary figure 1. Pneumococcal heat-killing abolishes the ability to bind factor H in 
human serum. A total of 1 × 108 colony-forming units/mL S. pneumoniae TIGR4 wild-type or Δ 
pspC alive or heat killed (HK) were incubated in 10% pooled human serum. After 30 minutes of 
incubation at 37°C, pneumococcal factor H was measured by flow cytometry. Intensity factor H 
binding on bacteria are indicated by mean fluorescence intensity (MFI). Each bar represents the 
mean ± standard error of the mean for results obtained from 3 separate experiments in duplicate. 
Comparisons between groups were performed using a one-way ANOVA followed by Dunn’s test to 
calculate multiplicity-adjusted P values.**P < .01.
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Abstract 
Streptococcus pneumoniae is a common cause of sepsis. Effective complement 
activation is an important component of host defence against invading pathogens, 
whilst excessive complement activation has been associated with endothelial 
dysfunction and organ damage. The alternative pathway amplification loop is 
important for the enhancement of complement activation. Factor H is a key 
negative regulator of the alternative pathway amplification loop and contributes to 
tight control of complement activation. We assessed the effect of inhibition of the 
alternative pathway on sepsis associated inflammation and disease severity using 
human factor H treatment in a clinically relevant mice model of pneumococcal 
sepsis. Mice were infected intravenously with live Streptococcus pneumoniae. At 
the first clinical signs of infection, 17 hours post-infection, mice were treated with 
ceftriaxone antibiotic. At the same time purified human factor H or in controls 
PBS was administered. Treatment with human factor H did not attenuate disease 
scores, serum proinflammatory cytokines, or vascular permeability and did not 
significantly affect C3 and C3a production at 26 h post-infection. Therefore, we 
conclude that inhibition of the alternative complement pathway by exogenous 
human factor H fails to attenuate inflammation and vascular leakage at a clinically 
relevant intervention time point in pneumococcal sepsis in mice.
Introduction
The Gram-positive pathogen Streptococcus pneumoniae is a major human pathogen 
and one of the most common causes of pneumonia, meningitis and sepsis. Young 
children, the elderly and immune-compromised individuals are especially at risk 
to develop invasive pneumococcal disease 1,2. Despite the availability of effective 
antibiotic agents, case fatality rates of pneumococcal sepsis are still high 3. A major 
problem in sepsis is the ongoing inflammation and organ dysfunction following 
the antibiotic treatment 4.
The complement system is a major human defence and clearance system and 
is highly activated during sepsis 5. Complement mediated C3 opsonisation 
and phagocytosis play a vital role in clearance of encapsulated Gram-positive 
pathogens, such as S. pneumoniae. Individuals with a deficiency in complement C3 
activation or regulation thereof are more susceptible to invasive pneumococcal 
diseases 6. Importantly, in the cascade of complement reactions, complement 
activation products also referred to as anaphylatoxins are released. These 
anaphylatoxins, C3a and in particular C5a, both promote inflammation via cross 
talk with Toll-like receptors 7. Increased generation of complement activation 
products C3a and C5a has been associated with severity of sepsis 8-10. Furthermore, 
increased complement activation has been found to enhance cytokine production, 
endothelial permeability and cardiac dysfunction 11-14.
The classical pathway of complement activation has long been recognized as the 
dominant complement activation route in host defence to S. pneumoniae 15. The 
classical pathway is activated by C1q binding to antibody-antigen complexes on 
the bacterial surface. More recent the significance of the lectin pathway has been 
recognized 16. This pathway is activated by binding of ficolin A or collectin 11 to the 
pneumococcal surface 16. Importantly, the alternative pathway amplification loop 
plays a crucial role in the amplification of the initial activation of the classical and 
lectin pathway 17. In the alternative pathway, spontaneous low-level hydrolysis of 
plasma C3 leads to deposition of C3b on the activating surface. Consequently, C3b 
formed by one of the three pathways can be amplified by the alternative pathway 
amplification loop, initiating a positive feedback loop resulting in enhanced 
complement activation. The quantitative contribution of alternative pathway 
amplification to classical pathway-induced C5a generation can be up to 80% 18. 
This indicates a major contribution of the alternative pathway on the release of 
complement activation products 5. 
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The alternative pathway is closely regulated. Complement factor H is a key negative 
regulator of alternative pathway activation both in the plasma as well as on the 
cell surfaces. Factor H recognizes host cell surfaces and inhibits activity of the C3 
convertase to avert injury of host tissues 19. Factor H binds to C3b, accelerates the 
decay of the alternative pathway C3 convertase and acts as a co-factor for factor I 
mediated inactivation of C3b 19-22. 
We hypothesize that after the onset of sepsis and initiation of antibiotic therapy, 
inhibition of alternative pathway activation is desirable to ameliorate sepsis 
associated inflammation and vascular leakage. Moreover, several other animal 
studies demonstrated the efficacy of adjuvant therapy inhibiting complement 
activation in animal models of sepsis 23-27. The aim of our study was to investigate 
whether inhibition of the alternative pathway amplification loop by administering 
exogenous human factor H at a clinically relevant time point, at the first onset 
of clinical symptoms, combined with antibiotic treatment could attenuate 
inflammation and vascular leakage in a mouse model of pneumococcal sepsis. 
Methods
Ethics Statement
This study was carried out in accordance with the recommendations of ‘OECD 
Guidance Document on the Recognition, Assessment, and Use of Clinical Signs 
as Humane Endpoints for Experimental Animals Used in Safety Evaluation’ (OECD 
Guidance Document 19, 2000). The protocol was approved by the Animal Ethics 
Committee of Radboud University, Nijmegen, The Netherlands (Permit Number: 
2012-274). 
Animals
Eight weeks old female C57BL/6 (wild-type) mice (n=36) obtained from Charles River 
Laboratory were used for the experiment. Mice were maintained in individually 
ventilated cages under a 12h light/12h dark cycle with controlled temperature 
(22 ± 2°C) and relative humidity (55 ± 5%). The mice had an average weight of 
20.0 gram (± 1.0) before the start of the experiment. 
Bacterial strains and growth conditions
A mouse-passaged S. pneumoniae strain TIGR4 (serotype 4) was used for infection 28. 
The mouse-passaged TIGR4 strain was grown in Todd-Hewitt broth supplemented 
with 5 g/L yeast extract (THY) or on Columbia blood agar plates (Becton Dickinson) 
at 37°C and 5% CO2 to an optical density at 620 nm of 0.2 and stored in aliquots 
at -80°C in 15% glycerol. The number of colony forming units (CFU) per milliliter 
(CFU/mL) was determined by plating serial 10-fold dilutions on blood agar plates. 
Experimental procedure
Mice were randomly divided into 4 groups; infected mice injected intraperitoneally 
(i.p.) with human factor H (n=10), or with i.p. phosphate buffered saline (PBS) as 
control treatment (n=10), uninfected mice were injected i.p. with human factor H 
(n=6) or i.p. PBS (n=10) respectively. The study was divided in four experiments to 
allow sufficient time to perform all the measurements at the end of the experiment. 
In each experiment 2 or 3 mice from every group were used. 
Mice were infected intravenously in the tail vein with 1x107 CFU in 100 µl PBS 
(control mice received PBS alone). Previous work showed that human factor 
H was able to restore complement C3 levels in homozygous factor H deficient 
mice demonstrating that human factor H is functional in mice 29. Furthermore, 
it was demonstrated that human factor H inhibited cleavage of mouse C3 and 
mouse factor B in plasma 30. Expression of human factor H completely protected 
homozygous factor H deficient mice from developing kidney abnormalities 
associated with the loss of factor H 30. We choose to administer 600 µg purified 
human factor H intraperitoneally (i.p) (Complement technologies) (600 µl of the 
1 µg/µL purified human factor H diluted in PBS) as i.p injection with a volume 
up to 600 µl was well tolerated. Earlier work documents, that a dose of 500 µg 
human factor H injected i.p. is sufficient to restore complement C3 levels in 
completely factor H deficient mice, demonstrating this dose is effective under 
extreme conditions 29. Analogous to previous studies human factor H was injected 
i.p 29. At the first onset of clinical signs (t=17 h) mice were injected i.p. with 600 
µg human factor H in 600 µl PBS (control mice received 600 µl PBS alone). At the 
same time mice were injected with ceftriaxone 25 mg/kg intramuscular (Fresenius 
Kabi Nederland B.V.). Antibiotic treatment allowed to examine the effect of human 
factor H modulation of complement activity on the inflammatory response while 
avoiding differences in bacterial CFU counts due to potential inhibition of bacterial 
clearance by human factor H. At 26 h after infection the experiment was ended 
and CFU, vascular leakage in the liver, cytokine and complement protein levels 
were measured as described below. Pilot experiments demonstrated that mice in 
general did not reach the humane endpoint at this time point.
Measurement of disease score 
During the experiment, mice were monitored for clinical signs and disease severity 
each hour and weighted at t=0, t=17, t=21 and t=26 hours. Mice were scored 
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according to their condition. The following score was used: Ruffled coat: showing 
signs of a ruffled coat (1); Dull ruffled coat, observed mildly around neck and back 
(2); Ruffled coat (3); Hunched back: Mildly hunched back (2); Hunched back (3); 
Reduced mobility: Less mobile but still being active and reacts to any handling (3); 
Aberrant and slower movement with back legs (4); Hardly walking, needs to be 
pushed to get going (5); Weight loss: >5 % body weight loss from t=0 (2); >10 % 
body weight loss from t=0 (3); >15 % body weight loss from t=0 (5); >20 % body 
weight loss from t=0 (15); Skin temperature: <35.5 °C (15); Overall state: no signs 
of disease (0); Moribund state (15). Based on the disease score humane endpoints 
were defined. An overall disease score ≥ 15 was used as a surrogate marker of 
mortality and animals with a disease score ≥ 15 were killed to minimize animal 
pain, distress and discomfort. 
Colony forming units count 
At t=26 h, mice were anesthetized with 2.5% (vol/vol) isoflurane over oxygen 
and blood was collected by sub-mandibular bleeding. Blood was collected in 
Eppendorf safe lock tubes. Bacteria were recovered from the blood by plating 
serial dilutions on blood agar plates. Following overnight incubation of the plates 
at 37°C, CFU were counted. 
Measurement of cytokines and complement proteins in mice
Blood samples were kept on ice and were centrifuged at 4°C 10.000 rpm after 
coagulation of the blood. Serum was collected, aliquoted and stored at -80°C 
for further analysis. To investigate the immune response in mice infected with 
S. pneumoniae TIGR4, the general inflammatory markers interleukin 6 (IL-6) and 
macrophage inflammatory protein 2 (MIP-2) were measured in post-infectious 
serum samples using ELISA assays (Mouse IL-6 ELISA, Ebioscience, 88-7064; Mouse 
CXCL2/MIP-2 Quantikine ELISA Kit, R&D Systems, MM200). In addition, the following 
complement proteins were measured with ELISA assays; mouse C3a (mC3a) (USCN 
life science, E90387Mu), mouse C3 (mC3) (Mybiosource, MBS564065) and human 
factor H (Hycult, HK342).
Measuring vascular permeability 
Vascular leakage in the liver was measured by the method described by Von 
Drygalski et al., 2012 31. Infrared fluorescence measurements (IRF) were performed 
to determine Evans blue albumin extravasation to quantify vascular permeability. 
At t=26 h, mice were treated under anesthesia with 100 µL of 1% Evans blue 
dye (Sigma Aldrich) in PBS via retro orbital injection and mice remained under 
anesthesia. Prior to injection, the Evans blue solution was filter-sterilized (Millex, 
0.22 µm; Millipore). At 15 min after the Evans blue injection the abdominal cavity 
and chest were opened by blunt dissection. The vena cava inferior was visualized 
and cut through. The liver was flushed via the portal vein with a total volume of 
40 mL PBS containing heparin at 120mm Hg, thereby removing the Evans blue dye 
from the vasculature in the liver, followed by harvesting the liver. Mice remained 
under anesthesia during the whole procedure until the mice died by the perfusion 
and cervical dislocation. The liver was weighted and placed in a 6 wells tissue 
culture plate (Co-star). The liver was scanned using the Odyssey infrared imager 
(LI-COR, Lincoln, NE, USA) with Application software version 2.1.15, 700 channel, 
focal plane set at 3 mm and laser intensities set at L1.5. Area intensities from the 
bottom of each well were recorded as integrated fluorescence intensities (I.I) per 
well area. After scanning the organ was encircled and raw fluorescence intensities 
(RFI) were recorded and multiplied by the wet organ weight to estimate the 
concentration of Evans blue in the organ 31.
Statistical analysis
Data of the mice experiments are expressed as median and interquartile range. 
Difference between mice groups were analyzed using the Mann-Whitney test 
with a Bonferroni correction in case of multiple comparisons. Differences were 
considered statistically significant when p < 0.05.
Results
Exogenous human factor H fails to attenuate disease scores, 
inflammatory cytokine production, and vascular leakage in 
the liver. 
At 17 hours post-infection, before the treatment with antibiotics, the pneumococcal 
load in the control group and the human factor H treatment group were similar 
(median and interquartile range) control group 5.7x105 (1.6 x105 - 1.8x106) CFU/mL 
vs. treatment group 7.1x105 (2.7x105 - 4.5x106) CFU/mL, p=0.6, Mann-Whitney test. 
In both groups no viable bacteria were detectable 9 h after antibiotic treatment 
at termination of the experiment (t=26 h). The first onset of clinical symptoms 
of disease occurred at around 17 h post inoculation. The clinical disease score 
continued to increase rapidly within the first four hours after initiation of antibiotic 
treatment (t=21 h) and slowly continued to increase between four and nine hours 
after initiation of antibiotic treatment (t=26 h) (Figure 1A). One infected mice of the 
PBS treated group reached the humane endpoint at t=22 h. At 26 h after infection 
clinical disease scores, serum cytokines (IL-6 and MIP-2), and vascular permeability 
in the liver were all significantly elevated in infected untreated animals compared 
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Figure 1. Exogenous human factor H fails to attenuate disease scores, inflammatory cytokine 
production, and vascular leakage in the liver. Mice infected with 1x107 CFU of S. pneumoniae (TIGR4) 
and sham infected control mice were all treated with antibiotics at t=17 h and indicated groups 
received an injection with human factor H (hFH) or PBS as control (n=10). The disease score was 
monitored at t=17, t=21 and t=26 hours after inoculation (A). The black bar represents uninfected 
mice, gray bar infected control mice and white bar human factor H treated mice. Data points 
represent the median value with interquartile range. At t=26 h, serum  proinflammatory cytokines 
IL-6 and MIP-2 were measured by ELISA (B, C). Liver vascular leakage was measured by Evans Blue-
albumin extravasation to quantify vascular permeability (D). Raw fluorescence intensities (RFI) were 
recorded and multiplied by the wet organ weight to estimate the concentration of Evans Blue in 
the organ. Each point depicted in graphs B,C and D indicates one mouse. One infected mice of the 
PBS treated group reached the humane endpoint at t=22 h and was excluded from the graphs. 
Furthermore one (IL-6 Figure 1B) respectively two data points (MIP-2 Figure 1C) are missing, as 
insufficient serum was available. In addition, one data point is missing in the vascular leakage 
graph, because of a technical failure during injection of Evans Blue in one mouse. Cytokine values 
were analyzed after logarithmic transformation; the horizontal line represents the median. Dash 
line indicates lower limit of detection. Comparison between groups were performed by using the 
non-parametric Mann-Whitney test with Bonferroni correction * p < 0.05 was considered significant. 
** p< 0.01, *** p<0.001, ns = not significant. 
Figure 2. Exogenous human factor H 
administered at onset of clinical symptoms 
has no effect on complement activation 
protein levels. Mice infected with 1x107 CFU 
of S. pneumoniae (TIGR4) and sham infected 
control mice, were all treated with antibiotics 
at t=17 h and indicated groups received 
an injection with human factor H or PBS as 
control (n=10). At t=26 h serum mC3a, mC3 
and human factor H levels were measured 
by ELISA. Each point depicted indicates one 
mouse. One infected mice of the PBS treated 
group reached the humane endpoint at t=22 
h and was excluded from the graphs. Two data 
points of mC3 are missing, as insufficient serum 
was available to do all the measurements in all 
mice. Data are individual complement factor 
values and were analyzed after logarithmic 
transformation; the horizontal line represents 
the median. Dash line indicates lower limit 
of detection. Comparison between groups 
were performed by using the non-parametric 
Mann-Whitney test with Bonferroni correction 
* p < 0.05 was considered significant. ** p< 
0.01, *** p<0.001, ns = not significant
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with uninfected mice (Figure 1B-D). Treatment with human factor H did not 
attenuate clinical disease scores, serum  proinflammatory cytokines IL-6 and MIP-
2, or vascular permeability in the liver in infected mice (Figure 1B-D). Exogenous 
human factor H in uninfected control mice had no effect on disease score, serum 
proinflammatory cytokines IL-6 and MIP-2, or vascular permeability in the liver 
(Figure 1B-D).
Exogenous human factor H administered at onset of clinical 
symptoms has no effect on complement activation protein 
levels 
In order to study the effect of exogenous human factor H on complement activation, 
levels of complement proteins were measured. Mouse serum C3a and C3 levels were 
significantly elevated in the infected mice (Figure 2 A,B). Exogenous human factor 
H had no effect on mouse C3a and C3 levels. The estimated concentration of human 
factor H present in mice directly after injection is about 400 µg/mL, since a dose of 
600 µg intraperitoneal was given to mice with an estimated blood volume of 1,5 mL. 
The presence of target concentration human factor H in treated mice at the end of 
the experiment was confirmed by ELISA showing high human factor H levels (median 
and interquartile range) 445 (235-534) µg/mL serum at 9 hours after injection (Figure 
2C). 
Discussion
It is well established that excessive complement activation contributes to 
an enhanced inflammatory response and tissue damage in sepsis 12-14,32. The 
amplification mechanism of the alternative pathway is believed to play a major 
role in the release of complement activation products contributing to the 
overwhelming inflammatory response in sepsis 18. The main finding in this study 
is that inhibition of the alternative complement pathway by exogenous human 
factor H at a clinical relevant time point at the first onset of symptoms failed to 
attenuate inflammation and vascular leakage in a pneumococcal sepsis model in 
mice.
Complement activation is important in the clearance of endogenous and pathogen 
derived debris and toxins. Effective clearance of these substances may prevent 
ongoing induction of inflammation by this debris. In our experimental setting we 
did not observe increased  proinflammatory activity resulting from less effective 
clearance of pathogen debris in mice in which alternative pathway activity was 
inhibited with factor H, however the duration of observation may have been too 
short to completely exclude this.
In previous studies, it was shown that human factor H regulates mouse alternative 
pathway activity 29,30. Potentially, the effect of human factor H treatment in 
our study was limited by the timing of administration. Human factor H was 
administered at time of clinical symptoms, 17 h after infection, when physiological 
dysregulation already had occurred. Administration of human factor H might have 
greater potential when given earlier during the course of disease. Attenuation of 
inflammation and vascular leakage targeting alternative pathway activation by 
exogenous human factor H treatment may be more successful in situations where 
treatment can be administered prophylactic as in cardiopulmonary bypass surgery 
33. However, early human factor H treatment at time of infection is clinically not 
relevant for invasive pneumococcal infection because patients with sepsis will only 
present with apparent clinical signs and symptoms. Furthermore, others described 
previously that an abrogated alternative pathway activity in mice genetically 
lacking alternative pathway activity enhanced pneumococcal outgrowth and the 
severity of disease 15,34. These studies demonstrate the importance of alternative 
pathway activation in the host defence against pneumococcal invasive infection 
and early human factor H administration may enhance pneumococcal outgrowth.
Enhancement of pneumococcal outgrowth by human factor H is especially relevant 
as the pneumococcal virulence factor pneumococcal surface protein C (pspC) binds 
human factor H, as an immune evasion strategy 35. This pneumococcal binding 
capacity is species specific and unique for human factor H, and pneumococci do 
not bind mouse factor H 36. 
Other studies targeting complement activation by inhibition early in the 
complement cascade with C1 esterase inhibitor (C1INH) or C3 convertase inhibitor 
were successful in contrast to our study 25,26. C1INH treatment was beneficial on 
outcome of Gram-negative bacterial sepsis and endotoxin shock in several animal 
studies 26,37. Interestingly, a recent small open label clinical trial described increased 
survival rates in patients with surgical sepsis treated with C1INH, indicating that 
intervention might be beneficial in a clinical setting 38. C1INH has many different 
anti-inflammatory functions, including non-complement related functions 39. 
The beneficial effect of C1INH is therefore not exclusively due to complement 
inhibition 26. 
In addition, early complement inhibition by using compstatin, a C3 convertase 
inhibitor, was shown protective during E. coli sepsis in baboons 25. Interestingly, 
it was found that complement inhibition was still effective when administered 
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during the second stage of progressive organ failure 25. Since compstatin blocks 
the C3 convertase it inhibits all three complement activation pathways and may 
therefore be more effective in comparison with alternative pathway inhibition 
alone as in the current study. 
Our study targeted complement activation, aiming to decrease the activation 
of complement effector molecules. Potentially it may be more effective to 
directly block the complement effector molecules such as C3a or C5a. Recently, 
the potential efficacy of blocking C5a or its receptors in improving outcome in 
experimental sepsis models was demonstrated. Blocking C5a or its receptors 
preserved neutrophil function resulting in lower bacterial loads and less severe 
disease 23,24,40. In cecal ligation and puncture-induced sepsis in rats, it was shown 
that blocking C5a was even beneficial after the onset of symptoms of sepsis 27.
Complement activity has not only detrimental effects, but is also essential for an 
effective host defence against invading pathogens such as S. pneumoniae 14,41. 
Interestingly several novel experimental therapies for sepsis entail stimulating 
complement activation. Administration of recombinant properdin, a positive 
regulator of alternative pathway activation, resulted in enhanced protection 
against S. pneumoniae infection 42. The use of properdin may be important in the 
context of antimicrobial resistance in sepsis, however, thus far it has not been 
assessed whether properdin treatment has an additive effect in combination with 
antibiotic treatment in sepsis. Additionally, the recombinant properdin used in 
that study contained a histidine tag 42. Recently several studies raised concerns 
about the use of proteins containing a histidine tag, since this may convey anti-
microbial activity 43,44. 
To our knowledge this is the first study to assess human factor H treatment as 
adjuvant therapy in sepsis. Our results show that inhibition of the alternative 
complement pathway by exogenous human factor H at a clinical relevant time 
point at the first onset of symptoms failed to attenuate inflammation and vascular 
leakage in a pneumococcal sepsis model in mice. 
64 65
3
Exogenous factor H in experimental pneumococcal sepsis in mice
References
1 O’Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger 
than 5 years: global estimates. Lancet 374, 893-902, doi:10.1016/s0140-6736(09)61204-6 
(2009).
2 Jansen, A. G. et al. Invasive pneumococcal disease among adults: associations among serotypes, 
disease characteristics, and outcome. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 49, e23-29, doi:10.1086/600045 (2009).
3 Muhammad, R. D. et al. Epidemiology of invasive pneumococcal disease among high-risk 
adults since the introduction of pneumococcal conjugate vaccine for children. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America 56, e59-
67, doi:10.1093/cid/cis971 (2013).
4 Angus, D. C. & van der Poll, T. Severe sepsis and septic shock. The New England journal of 
medicine 369, 2063, doi:10.1056/NEJMc1312359 (2013).
5 Brandtzaeg, P., Hogasen, K., Kierulf, P. & Mollnes, T. E. The excessive complement activation 
in fulminant meningococcal septicemia is predominantly caused by alternative pathway 
activation. The Journal of infectious diseases 173, 647-655 (1996).
6 Pettigrew, H. D., Teuber, S. S. & Gershwin, M. E. Clinical significance of complement 
deficiencies. Annals of the New York Academy of Sciences 1173, 108-123, doi:10.1111/j.1749-
6632.2009.04633.x (2009).
7 Hajishengallis, G. & Lambris, J. D. Crosstalk pathways between Toll-like receptors and the 
complement system. Trends in immunology 31, 154-163, doi:10.1016/j.it.2010.01.002 (2010).
8 Riedemann, N. C. et al. Increased C5a receptor expression in sepsis. The Journal of clinical 
investigation 110, 101-108, doi:10.1172/jci15409 (2002).
9 Younger, J. G. et al. Complement activation in emergency department patients with severe 
sepsis. Academic emergency medicine : official journal of the Society for Academic Emergency 
Medicine 17, 353-359, doi:10.1111/j.1553-2712.2010.00713.x (2010).
10 Guo, R. F. & Ward, P. A. Role of C5a in inflammatory responses. Annual review of immunology 23, 
821-852, doi:10.1146/annurev.immunol.23.021704.115835 (2005).
11 Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by 
complement in vivo. Blood 110, 228-236, doi:10.1182/blood-2006-12-063636 (2007).
12 Liu, Z. M. et al. Silencing of C5a receptor gene with siRNA for protection from Gram-negative 
bacterial lipopolysaccharide-induced vascular permeability. Molecular immunology 47, 1325-
1333, doi:10.1016/j.molimm.2009.11.001 (2010).
13 Niederbichler, A. D. et al. An essential role for complement C5a in the pathogenesis of 
septic cardiac dysfunction. The Journal of experimental medicine 203, 53-61, doi:10.1084/
jem.20051207 (2006).
14 Lappegard, K. T. et al. Human genetic deficiencies reveal the roles of complement in the 
inflammatory network: lessons from nature. Proceedings of the National Academy of Sciences of 
the United States of America 106, 15861-15866, doi:10.1073/pnas.0903613106 (2009).
15 Brown, J. S. et al. The classical pathway is the dominant complement pathway required 
for innate immunity to Streptococcus pneumoniae infection in mice. Proceedings of the 
National Academy of Sciences of the United States of America 99, 16969-16974, doi:10.1073/
pnas.012669199 (2002).
16 Ali, Y. M. et al. The lectin pathway of complement activation is a critical component of the innate 
immune response to pneumococcal infection. PLoS pathogens 8, e1002793, doi:10.1371/
journal.ppat.1002793 (2012).
17 Harboe, M. & Mollnes, T. E. The alternative complement pathway revisited. Journal of cellular 
and molecular medicine 12, 1074-1084, doi:10.1111/j.1582-4934.2008.00350.x (2008).
18 Harboe, M., Ulvund, G., Vien, L., Fung, M. & Mollnes, T. E. The quantitative role of alternative 
pathway amplification in classical pathway induced terminal complement activation. Clinical 
and experimental immunology 138, 439-446, doi:10.1111/j.1365-2249.2004.02627.x (2004).
19 Weiler, J. M., Daha, M. R., Austen, K. F. & Fearon, D. T. Control of the amplification convertase of 
complement by the plasma protein beta1H. Proceedings of the National Academy of Sciences of 
the United States of America 73, 3268-3272 (1976).
20 Makou, E., Herbert, A. P. & Barlow, P. N. Functional anatomy of complement factor H. Biochemistry 
52, 3949-3962, doi:10.1021/bi4003452 (2013).
21 Pangburn, M. K., Schreiber, R. D. & Muller-Eberhard, H. J. Human complement C3b inactivator: 
isolation, characterization, and demonstration of an absolute requirement for the serum 
protein beta1H for cleavage of C3b and C4b in solution. The Journal of experimental medicine 
146, 257-270 (1977).
22 Whaley, K. & Ruddy, S. Modulation of the alternative complement pathways by beta 1 H 
globulin. The Journal of experimental medicine 144, 1147-1163 (1976).
23 Czermak, B. J. et al. Protective effects of C5a blockade in sepsis. Nature medicine 5, 788-792, 
doi:10.1038/10512 (1999).
24 Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature medicine 14, 551-557, 
doi:10.1038/nm1753 (2008).
25 Silasi-Mansat, R. et al. Complement inhibition decreases the procoagulant response and 
confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002-1010, 
doi:10.1182/blood-2010-02-269746 (2010).
26 Liu, D. et al. C1 inhibitor-mediated protection from sepsis. Journal of immunology (Baltimore, 
Md. : 1950) 179, 3966-3972 (2007).
27 Huber-Lang, M. S. et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. 
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 
15, 568-570, doi:10.1096/fj.00-0653fje (2001).
28 Tettelin, H. et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. 
Science (New York, N.Y.) 293, 498-506, doi:10.1126/science.1061217 (2001).
29 Fakhouri, F. et al. Treatment with human complement factor H rapidly reverses renal complement 
deposition in factor H-deficient mice. Kidney international 78, 279-286, doi:10.1038/ki.2010.132 
(2010).
30 Ding, J. D. et al. Expression of human complement factor h prevents age-related macular 
degeneration-like retina damage and kidney abnormalities in aged cfh knockout mice. The 
American journal of pathology 185, 29-42, doi:10.1016/j.ajpath.2014.08.026 (2015).
31 von Drygalski, A. et al. Infrared fluorescence for vascular barrier breach in vivo--a novel method 
for quantitation of albumin efflux. Thrombosis and haemostasis 108, 981-991, doi:10.1160/
th12-03-0196 (2012).
32 Woehrl, B. et al. Complement component 5 contributes to poor disease outcome in humans 
and mice with pneumococcal meningitis. The Journal of clinical investigation 121, 3943-3953, 
doi:10.1172/jci57522 (2011).
66 67
3
Exogenous factor H in experimental pneumococcal sepsis in mice
33 Baig, K. et al. Complement factor 1 inhibitor improves cardiopulmonary function in neonatal 
cardiopulmonary bypass. The Annals of thoracic surgery 83, 1477-1482; discussion 1483, 
doi:10.1016/j.athoracsur.2006.10.049 (2007).
34 Dahlke, K. et al. Distinct different contributions of the alternative and classical complement 
activation pathway for the innate host response during sepsis. Journal of immunology 
(Baltimore, Md. : 1950) 186, 3066-3075, doi:10.4049/jimmunol.1002741 (2011).
35 Hyams, C. et al. Streptococcus pneumoniae capsular serotype invasiveness correlates with the 
degree of factor H binding and opsonization with C3b/iC3b. Infection and immunity 81, 354-
363, doi:10.1128/iai.00862-12 (2013).
36 Lu, L. et al. Species-specific interaction of Streptococcus pneumoniae with human complement 
factor H. Journal of immunology (Baltimore, Md. : 1950) 181, 7138-7146 (2008).
37 Jansen, P. M. et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in 
primates suffering from lethal septic shock. Journal of immunology (Baltimore, Md. : 1950) 160, 
475-484 (1998).
38 Igonin, A. A. et al. C1-esterase inhibitor infusion increases survival rates for patients with 
sepsis*. Critical care medicine 40, 770-777, doi:10.1097/CCM.0b013e318236edb8 (2012).
39 Davis, A. E., 3rd, Cai, S. & Liu, D. C1 inhibitor: biologic activities that are independent of protease 
inhibition. Immunobiology 212, 313-323, doi:10.1016/j.imbio.2006.10.003 (2007).
40 Flierl, M. A. et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary 
cells during experimental sepsis. PloS one 3, e2560, doi:10.1371/journal.pone.0002560 (2008).
41 Ram, S., Lewis, L. A. & Rice, P. A. Infections of people with complement deficiencies and patients 
who have undergone splenectomy. Clinical microbiology reviews 23, 740-780, doi:10.1128/
cmr.00048-09 (2010).
42 Ali, Y. M. et al. Low-dose recombinant properdin provides substantial protection against 
Streptococcus pneumoniae and Neisseria meningitidis infection. Proceedings of the 
National Academy of Sciences of the United States of America 111, 5301-5306, doi:10.1073/
pnas.1401011111 (2014).
43 Rowinska-Zyrek, M., Witkowska, D., Potocki, S., Remelli, M. & Kozlowski, H. His-rich sequences 
- is plagiarism from nature a good idea? New Journal of Chemistry 37, 58-70, doi:10.1039/
C2NJ40558J (2013).
44 Zimmer, J., Hobkirk, J., Mohamed, F., Browning, M. J. & Stover, C. M. On the Functional 
Overlap between Complement and Anti-Microbial Peptides. Frontiers in immunology 5, 689, 
doi:10.3389/fimmu.2014.00689 (2014).
68 69
Chapter 4 
Complement factor H serum 
levels determine resistance to 
pneumococcal invasive disease 
Erika van der Maten, Dineke Westra, Saskia van Selm, Jeroen D. Langereis,
Hester J. Bootsma, Fred J.H. van Opzeeland, Ronald de Groot, Marieta M. Ruseva, 
Matthew C. Pickering, Lambert P.W.J. van den Heuvel, Nicole C.A.J. van de Kar, 
Marien I. de Jonge, Michiel van der Flier
 
J Infect Dis. 2016 Jun 1;213(11):1820-7. 
70 71
4
Complement factor H and pneumococcal infection
Abstract
Streptococcus pneumoniae is a major cause of life-threatening infections. 
Complement activation plays a vital role in opsonophagocytic killing of 
pneumococci in blood. Initial complement activation via the classical and lectin 
pathways is amplified through the alternative pathway amplification loop. 
Alternative pathway activity is inhibited by complement factor H. Our study 
demonstrates the functional consequences of the variability in human serum factor 
H levels on host defense. Using an in vivo mouse model combined with human in 
vitro assays, we show that the level of serum factor H correlates with the efficacy 
of opsonophagocytic killing of pneumococci. In summary, we found that factor H 
levels determine a delicate balance of alternative pathway activity, thus affecting 
the resistance to invasive pneumococcal disease. Our results suggest that variation 
in factor H expression levels, naturally occurring in the human population, plays 
a thus far unrecognized role in the resistance to invasive pneumococcal disease.
Introduction
The Gram-positive pathogen Streptococcus pneumoniae is one of the major 
human bacterial pathogens. It normally colonizes the nasopharynx, but can 
cause life-threatening infections such as pneumonia, meningitis and sepsis 1. 
Within the population there is a large variation in the susceptibility for invasive 
pneumococcal disease indicating that the host immune defence against invading 
pathogens differs between individuals 2. The complement system, part of the 
innate immunity, is of major importance in host defence against S. pneumoniae. 
Complement opsonization plays a vital role in opsonophagocytic killing of gram-
positive bacteria such as S. pneumoniae.
The production of the major opsonin, C3b, can occur through the classical, 
lectin and alternative pathway. Surface C3b can be rapidly amplified through 
the alternative amplification loop irrespective of the pathway through which 
it was generated 3. The quantitative contribution of the alternative pathway 
amplification loop to classical pathway-induced complement activation can be 
up to 80% 4. 
Because alternative pathway activity has major implications for complement 
activation, it is tightly regulated. Complement factor H is an abundant plasma 
protein essential for inhibition of alternative pathway activation in the fluid phase 
and on cellular surfaces 5. Factor H binds to C3b, accelerates the degradation of 
alternative pathway C3 convertase and factor H acts as a cofactor for complement 
factor I mediated proteolysis of C3b to form iC3b. The formation of iC3b stops the 
alternative pathway amplification loop as iC3b cannot be formed into the alternative 
pathway C3 convertase. Both C3b and iC3b act as opsonins for phagocytosis 6,7. 
Factor H recognizes host cell surface patterns and protects against complement 
activation. In the fluid phase, factor H is important for regulation of spontaneous 
alternative pathway activation. This is apparent in individuals with complete 
factor H deficiency; uncontrolled alternative pathway activation results in marked 
secondary C3 deficiency 8. These individuals are susceptible to meningococcal 
infections, C3 glomerulopathy and haemolytic uraemic syndrome (HUS) 8. 
Various polymorphisms in the gene encoding complement factor H ( CFH) have 
been identified to be associated with human diseases 5. Polymorphisms may affect 
factor H binding to host cells, regulation of alternative pathway activity, or factor H 
expression levels 9-11. These influence the susceptibility to diseases such as HUS 12,13, 
age-related macular degeneration, and dense deposit disease 14. Factor H plasma 
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levels show a large variation (range, 63.5-847.6 µg/mL) 15-19. This variation is due to 
both environmental factors (e.g. smoking) and genetic factors 17.
 
We hypothesized that the inter-individual variation in plasma complement 
factor H levels affects resistance to invasive pneumococcal disease. In the 
human population it is difficult to study the sole effect of factor H levels on 
susceptibility for infectious diseases, owing to variation in many other factors 
affecting complement activity, such as concentrations of opsonizing antibodies 
and polymorphisms in other complement components. Therefore, we compared 
the resistance of genetically modified mice with different factor H expression 
levels to invasive pneumococcal disease in vivo. In addition, under controlled 
conditions we studied the effects of variation in the factor H level in human serum 
on C3b opsonization and opsonophagocytic killing in vitro, using human factor 
H-depleted serum reconstituted with factor H various amounts of purified human 
factor H. Our data demonstrate a critical role for serum factor H levels in the host 
response to invasive pneumococcal infections. 
Material and Methods
Ethics Statement
This study was carried out in accordance with the recommendations of ‘OECD 
Guidance Document on the Recognition, Assessment, and Use of Clinical Signs 
as Humane Endpoints for Experimental Animals Used in Safety Evaluation’ (OECD 
Guidance Document 19, 2000). The protocols were approved by the Animal Ethics 
Committee of Radboud University, Nijmegen, The Netherlands (Permit Numbers: 
RU-DEC 2011-050, 2012-274, 2014-156).
Animals
The development of the factor H knockout mice (Cfh -/- ) has been described 
previously 20. C57BL/6 mice were obtained from Charles River Laboratories. During 
the experiment, mice were monitored and scored for clinical signs and humane 
endpoints were predefined. A >20% decrease in body weight from baseline, 
a moribund state, a skin temperature of <35°C, and a substantial reduction in 
motility, and animals with any of these characteristics were sacrificed to minimize 
animal pain, distress, and discomfort. 
Pneumococcal Strains and Growth Conditions
The S. pneumoniae strain TIGR4 was used in all experiments 21. The bacteria were 
first passaged in mice to maintain virulence, as described elsewhere 22. The 
pneumococcal strain was grown in Todd-Hewitt broth supplemented with 5 g/L 
yeast extract or on Columbia blood agar plates (Becton Dickinson) at 37°C and 
5% CO2. TIGR4 was grown to an OD620 of 0.2 and stored in aliquots at -80°C in 15% 
glycerol. The number of colony-forming units (CFU) per milliliter was determined 
by plating serial 10-fold dilutions of test aliquots on blood agar plates. 
Pneumococcal Invasive Disease
S. pneumoniae TIGR4 stocks were thawed, spun down by centrifugation, and 
resuspended in sterile phosphate-buffered saline (PBS) to the required dilution 
for infection (infectious dose, 1x107 CFU). In experiment 1, 10 Cfh+/+, 10 Cfh +/- and 
10 Cfh -/- C57BL/6 male mice aged 6-8 weeks were infected intravenously in the tail 
vein with 107 CFU TIGR4 in 100 µL of PBS. At 19 hour after infection, Cfh +/+, Cfh +/- 
and Cfh -/- mice were anesthetized with 2.5% (vol/vol) isoflurane over oxygen, and 
blood specimens were collected by orbital puncture following cervical dislocation. 
The number of CFU per milliliter of blood was determined by plating serial 10-
fold dilutions on blood agar plates. Residual blood was allowed to clot on ice, 
followed by serum separation (10 min 3,000 x g at 4°C), and aliquots were stored 
at -80°C. Levels of Mouse interleukin-6 (IL-6; eBioscience) and mouse macrophage 
inflammatory protein 2 (CXCL2/MIP-2; R&D Systems) in serum was measured by 
enzyme-linked immunosorbent assays.
In experiment 2, 20 wild-type 8-weeks-old female C57BL/6 mice were infected 
intravenously in the tail vein with 107 CFU TIGR4 in 100 µL of PBS as in experiment 
1. Of these mice, 10 mice were injected intraperitoneally with 600 µg of purified 
human factor H (CompTech) diluted in 600 µL of PBS immediately after infection, 
while the other mice received PBS alone as control. Previous studies demonstrated 
the ability of human factor H to control mouse C3 activation 23,24. In one of these 
studies, complement C3 levels in Cfh -/- mice were restored by 500 µg of exogenous 
human factor H 23. In the present study, a slightly higher dose of 600 µg was chosen 
to inhibit C3 activation during infection. At 21 hour after infection, the number 
of bacterial CFU per milliliter of blood was measured, and a serum specimen was 
collected to determine cytokine levels as described under experiment 1.
C3 Binding Assay
Pneumococcal surface C3 opsonization was performed by incubating bacteria in 
murine or human serum. To assay C3 deposition on the surface of S. pneumoniae, 
TIGR4 stocks were thawed and washed in PBS. Bacteria (5x106) were pelleted 
in a 96-well plate and resuspended in 20% (vol/vol) mouse serum or 10% (vol/
vol) human factor H-depleted serum in veronal buffer (Lonza) containing 5 mM 
74 75
4
Complement factor H and pneumococcal infection
ethylene glycerol tetraacetic acid and 5 mM MgCl2 to a total volume of 100 µL. 
The bacterial suspension was incubated for 90 min in mouse serum or for 30 min 
in human serum at 37°C in 5% CO2. After C3 opsonization, complement activation 
was blocked by incubation in 10 mM ethylenediaminetetraacetic acid for 10 min 
on ice, followed by centrifugation at 3,000 x g at 4°C for 10 min. Bacteria were 
labeled with diluted fluorescein-conjugated goat IgG to mouse (1:200) or human 
(1:800) complement C3 (MPbio, Cappel) in PBS/2%BSA followed by fixation in 2% 
paraformaldehyde. C3 opsonization was measured using a FACScan flow cytometer 
(BD Biosciences). Data were analysed using FlowJo version X.
Pneumococcal C3b opsonization was measured in pooled serum specimens from 
at least 9 male C57BL/6 Cfh +/+, Cfh +/-, and Cfh -/- mice and in pooled Cfh +/+ C57BL/6 
mouse serum (Innovative Research), with or without exogenous human factor H 
(CompTech), with a final concentration of 25 µg/mL. In addition, pneumococcal 
C3b opsonization in human factor H-depleted serum (CompTech) was measured. 
The human factor H-depleted serum was substituted with purified human factor 
H, full reconstitution required 500 µg/mL human factor H. To study the effect of 
higher or lower factor H concentrations on pneumococcal C3 opsonization, the 
serum was reconstituted with 100, 200, 300, 400, 500, 600 or 1000 µg/mL human 
factor H (CompTech). 
Pneumococcal Killing Assay 
A pneumococcal killing assay was performed by incubating bacteria in human 
blood, in which the plasma was replaced by factor H-depleted serum reconstituted 
with various amounts of human factor H. After informed consent was obtained, 
a venous blood specimen was collected from the median cubital vein of healthy 
volunteers (age, 20-40 years; both males and females) into a 4-mL tube containing 
50 µg/mL lepirudin (Refludan; Pharmion). A total of 100 µL of blood was added 
per well in a 96-well plate, followed by centrifugation at 10 min 3,000 x g at room 
temperature. Plasma was removed, 150 µl of PBS was added, and centrifugation was 
performed to wash the blood cells and remove residual factor H-containing fluid. 
The blood cells were resuspended in human factor H-depleted serum reconstituted 
with 0, 300, 500 or 1000 µg/mL human factor H, after which S. pneumoniae TIGR4 
(106 CFU/mL) and 1 mM of MgCl2 were added. The 96-well plate was incubated 
at 37°C for 4 hours under continuous shaking. The number of bacterial CFU 
was determined before incubation and 4 hours after incubation by plating serial 
10-fold dilutions on blood agar plates. The percentage of bacteria that survived 
was calculated. 
Statistical Analysis 
Differences between groups of mice were analyzed using the nonparametric 
Mann-Whitney test a Bonferroni correction in case of multiple comparisons. 
Results of In vitro experiments performed with mouse or human serum or blood 
specimens were analyzed using the Student t test, for comparison of 2 groups, or 
analysis of variance with the Bonferroni correction, for analysis of multiple groups. 
Differences were considered statistically significant when P < 0.05.
Results 
Clearance of S. pneumoniae From Plasma Is Enhanced in 
Heterozygous Factor H-Deficient Mice 
Mice with absent (Cfh-/-), reduced (Cfh +/-), or normal (Cfh +/+) plasma factor H 
levels were infected intravenously with S. pneumoniae. The Cfh +/- mice showed 
significantly reduced numbers of CFU compared to Cfh +/+ mice, 19 hour after 
inoculation (Figure 1A). In contrast, Cfh -/- mice had higher numbers of CFU than 
Cfh +/+ mice. Furthermore, 4 out of 10 Cfh-/- mice were sacrificed prior to the 19-hour 
time point because they had reached the predefined humane end point. Levels 
of the proinflammatory cytokines IL-6 and MIP-2 were significantly lower in the 
Cfh +/- mice (Figure 1B and 1C) but higher in the Cfh -/- animals. 
Administration of Human Factor H to Wild-Type Mice 
Impaired Plasma Clearance of S. pneumoniae
The effect of increased factor H levels in Cfh +/+ mice was studied by injection of 
human factor H at the time of intravenous injection of S. pneumoniae. Cfh +/+ mice 
injected with human factor H showed significantly higher blood bacterial numbers 
of CFU than control Cfh +/+ mice 21 hour after infection. In addition, these mice had 
significantly higher cytokine IL-6 and MIP-2 serum levels (Figure 2 A-C). 
Pneumococcal C3 Opsonization is Enhanced in Heterozygous 
Factor H-Deficient Mice
We next examined whether factor H levels influenced pneumococcal C3 
opsonization. We measured S. pneumoniae C3 opsonization by mouse sera from 
Cfh +/+, Cfh +/- and Cfh -/- strains. C3 opsonization by Cfh +/- sera was significantly 
greater than that by Cfh +/+ sera (Figure 3 A-C). No C3 deposition was observed with 
pneumococci incubated in Cfh -/- serum, which reflects the complete consumption 
of C3 in Cfh -/- sera 20. Exogenous human factor H in Cfh +/+ mouse serum significantly 
reduced the pneumococcal C3 deposition (Figure 4 A-C). 
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Figure 1. Clearance of Streptococcus pneumoniae from plasma is enhanced in mice heterozygous 
for the gene encoding factor H (Cfh). A–C, Wild-type ( Cfh +/+; n = 10), heterozygous ( Cfh +/−; n = 
10), and homozygous ( Cfh −/− n = 10) FH-deficient C57BL/6 mice were infected with 1 × 107 colony-
forming units (CFU) of S. pneumoniae (TIGR4) and sacrificed 19 hours later. #Four of the 10 Cfh 
−/− animals were sacrificed before this because the predefined humane end point was reached. 
Nineteen hours after infection, the number of CFU per milliliter was determined in blood, and levels 
of proinflammatory cytokines interleukin 6 (IL-6) and macrophage inflammatory protein 2 (MIP-
2) were measured in serum. Each point represents 1 mouse. Cytokine values were analyzed after 
logarithmic transformation; horizontal line represents the median. Comparisons between groups 
were performed using the nonparametric Mann–Whitney test with the Bonferroni correction. 
*P < .05, **P < .01, and ***P < .001.
Figure 2. Administration of human factor H (FH) to wild-type mice impaired plasma clearance of 
Streptococcus pneumoniae. A–C, Wild-type C57BL/6 mice were intravenously infected with 1 × 107 
colony-forming units of S. pneumoniae (TIGR4) and injected with purified human factor H (n = 10) 
or phosphate-buffered saline (n = 10) and sacrificed 21 hour later. Twenty-one hours after infection, 
the number of colony-forming units (CFU) per milliliter was determined in blood, and levels of 
the proinflammatory cytokines IL-6 and MIP-2 were measured in serum. Each point represents one 
mouse; cytokine values were analyzed after logarithmic transformation; horizontal lines represents 
the median. Comparisons between groups were performed using the nonparametric Mann-
Whitney test with the Bonferroni correction. *P < .05, **P < .01, and ***P < .001.
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Figure 3. Pneumococcal C3 opsonization is enhanced in mice heterozygous for the gene encoding 
factor H (Cfh). C3 deposition on the surface of Streptococcus pneumoniae strain TIGR4 in pooled 
mouse serum derived from Cfh +/+, Cfh +/−, or Cfh −/− mice. A total of 5 × 107 colony-forming units/
mL S. pneumoniae TIGR4 were incubated in 20% mice serum in veronal buffer containing Mg2+ 
and ethylene glycol tetraacetic acid. After 90 minutes of incubation at 37°C, pneumococcal C3 
deposition was measured by flow cytometry. A, A representative example of a flow cytometry 
histogram for bacteria incubated in wild-type (Cfh +/+; white peak), heterozygous (Cfh +/−; gray 
peak), and homozygous (Cfh −/−; black peak) factor H-deficient pooled mouse serum. B, Intensity 
of C3 deposition on bacteria. C, Proportion of C3-positive bacteria. For panels B and C, each bar 
represents the mean ± standard error of the mean for results obtained from 5 separate experiments. 
Comparisons between groups were performed using a paired Student t test.*P < .05, **P < .01, ***P 
< .001. Abbreviation: NS, not significant. 
Figure 4. Pneumococcal C3 opsonization in wild-type mice serum is impaired by excess human 
factor H (FH). C3 deposition on the surface of S. pneumoniae strain TIGR4 in pooled wild-type mouse 
serum with additional human factor H. S. pneumoniae TIGR4, 5 × 107 colony-forming units/mL, were 
incubated in 20% mice serum in Veronal buffer containing Mg2+ and ethylene glycol tetraacetic 
acid. After 90 minutes of incubation at 37°C, pneumococcal C3 deposition was measured by flow 
cytometry. A, A representative example of a flow cytometry histogram for bacteria incubated 
in wild-type ( Cfh+/+; white peak), wild-type with exogenous human factor H ( Cfh +/+ [+FH]; gray 
peak), and heat-inactivated mouse serum (HI) as a negative control (black peak). B, Intensity of C3 
deposition on bacteria. C, Proportion of C3-positive bacteria. The bars in panels B and C represent 
the mean ± standard error of the mean of 2 separate experiments in duplicate. Comparisons 
between groups were performed using a paired Student t test. *P < .05,**P < .01, ***P < .001. 
Abbreviation: NS, not significant.
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Human Factor H Levels Influence the Degree of 
Pneumococcal C3 Opsonization and Killing in Human Blood
S. pneumoniae sequesters human factor H, while mouse factor H does not bind to 
the pneumococcal surface 25. We performed opsonization experiments by using 
factor H-depleted human serum reconstituted with different concentrations of 
human factor H. Human serum depleted for factor H showed no C3 opsonization, 
owing to rapid C3 activation that occurs upon reconstitution of cations in vitro 
(Figure 5). Reconstitution of factor H-depleted human serum to physiological 
levels (500 µg/mL) resulted in opsonization of S. pneumoniae (mean 26.5%, ±SEM 
3.2%, Figure 5). Interestingly, reconstitution to a lower factor H level (300 µg/mL) 
significantly elevated S. pneumoniae opsonization (mean 37.8%, ±SEM 2.6%). In 
contrast, reconstitution to a higher level (1000 µg/mL) significantly reduced C3 
opsonization. We next examined bactericidal activity in vitro, using a pneumococcal 
killing assay, in whole blood with factor H-depleted serum reconstituted with 300, 
Figure 5. Alternative pathway modulation by human factor H (FH) levels determines pneumococcal 
C3 opsonization. C3 deposition on the surface of Streptococcus pneumoniae strain TIGR4 in human 
factor H–depleted serum reconstituted with various factor H concentrations. S. pneumoniae TIGR4, 
5 × 107 colony-forming units/mL, were incubated in 10% human serum in Veronal buffer containing 
Mg2+ and ethylene glycol tetraacetic acid. After 30 minutes of incubation at 37°C, pneumococcal 
C3 deposition was measured by flow cytometry. A, A representative example of a flow cytometry 
histogram for bacteria incubated in factor H-depleted serum reconstituted with the physiological 
factor H concentration of 500 μg/mL factor H (light gray), or 0 μg/mL (black), 300 μg/mL (white), or 
1000 μg/mL (dark gray) factor H. B, Proportion of C3-positive cells. Each bar represents the mean 
± standard error of the mean of results obtained from 4 separate experiments. Comparison of 
various factor H concentrations to the physiological factor H concentration of 500 μg/mL (gray bar) 
were performed by using a repeated measures analysis of variance with the Bonferroni correction. 
*P < .05, **P < .01, and ***P < .001. Abbreviation: NS, not significant
500, or 1000 µg/mL factor H. The absence of factor H impaired pneumococcal 
clearance and resulted in pneumococcal growth (Figure 6). In accordance with 
our C3 opsonization data, 300 µg/mL factor H resulted in significantly increased 
bacterial clearance, compared to 500 µg/mL factor H, whereas killing was 
significantly impaired with 1000 µg/ml factor H. 
Discussion
The aim of this study was to investigate whether variation in factor H levels 
influences resistance to S. pneumoniae infection. We demonstrated that factor H 
levels play a critical role in the control of alternative pathway activity and the host 
defense in pneumococcal invasive disease. 
It has previously been shown that increased alternative pathway activity enhances 
pneumococcal killing. Mice injected with recombinant properdin, a positive 
Figure 6. Alternative pathway modulation by human factor H (FH) determines pneumococcal killing 
in blood. Pneumococcal killing in human blood containing factor H-depleted serum reconstituted 
with various factor H concentrations. Streptococcus pneumoniae TIGR4, 1 × 106 colony-forming 
units/mL, were incubated in healthy donor blood in which plasma was replaced by human factor 
H–depleted serum reconstituted with various factor H concentrations or with heat-inactivated 
(HI) serum as a control. The number of colony-forming units were determined by plating serial 
dilutions before incubation and 240 minutes after incubation at 37°C, and the percentage of 
surviving bacteria was calculated. Each dot represents 1 blood donor. Comparisons of various 
factor H concentrations to the physiological factor H concentration of 500 μg/mL (white dots) were 
performed using a repeated measures analysis of variance with the Bonferroni correction. *P < .05 
was considered significant. **P < .01 and ***P < .001.
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regulator of the alternative pathway, resulted in increased alternative pathway-
mediated pneumococcal C3 opsonization and enhanced pneumococcal killing 26. 
We are the first to demonstrate that decreased factor H expression in Cfh +/- mice 
enhances pneumococcal C3 opsonization, resulting in improved pneumococcal 
clearance from the blood. The observed enhanced complement activation in 
Cfh +/- mice is in line with recently reported excess complement activation in 
Cfh +/- mice resulting in age-related macular degeneration-like pathology 27. Our 
study confirms that Cfh -/- mice, which have a secondary C3 deficiency, have severely 
impaired clearance of S. pneumoniae from the blood. We further show that Cfh +/+ 
mice that received exogenous human factor H showed impaired pneumococcal 
clearance from blood as a consequence of reduced pneumococcal C3 opsonization. 
This is in line with previous findings demonstrating that factor B-deficient mice 
with an abrogated alternative pathway activity had increased susceptibility to 
S. pneumoniae infection after intranasal and intraperitoneal inoculation, compared 
to wild-type mice 28. This is also in line with recent studies in transgenic mice 
expressing human factor H, which showed increased bacterial loads and disease 
severity in Streptococcus pyogenes infection 29. In addition, we found that increased 
serum factor H levels in mice are associated not only with a greater pathogen 
burden, but also with greater elevations in levels of the proinflammatory cytokines 
IL-6 and MIP-2. This is consistent with findings by others 29. We also showed that 
decreased expression of factor H and the resultant lower pathogen burden are 
associated with lower proinflammatory cytokines.
Pathogens such as S. pneumoniae have evolved mechanisms to evade complement-
mediated killing by binding of host complement regulators, including factor H, 
factor H-like protein 1, C4-binding protein and plasminogen 30. Various Gram-
negative pathogens, such as Neisseria meningitidis and Haemophilus influenzae, 
and gram-positive pathogens, including S. pneumoniae, Staphylococcus aureus, 
and S. pyogenes, bind human factor H to evade complement-mediated killing 31-35. 
S. pneumoniae binds human factor H by means of pneumococcal surface protein 
C (PspC) 36. Like other pathogens, S. pneumoniae displays species specificity in the 
binding of factor H 25. Pneumococci bind human factor H but do not bind mouse 
factor H 25,37,38. Therefore, a characteristic of the mouse model is that factor H 
binding to the bacterial surface is limited because S. pneumoniae cannot sequester 
mouse factor H. The mice model allowed us to assess the influence of mouse factor 
H expression levels on the fluid-phase control of alternative pathway activity on 
bacterial C3 opsonization and clearance from the blood by comparing Cfh +/- and 
Cfh +/+ mice. 
Pneumococcal C3 deposition was measured using a polyclonal antibody against 
human or mouse C3, as described by others 39,40. This antibody binds C3b and iC3b 
deposited on the bacterial surface, both of which act as opsonins for phagocytosis 
6,7. Independent of factor H, iC3b can be further degraded into C3c and C3dg and 
then to C3d 7. We chose to measure C3b and iC3b deposition since our aim was 
to measure pneumococcal C3 opsonisation resulting in killing by phagocytosis. 
Importantly, we observed that pneumococcal C3 opsonization was associated 
with pneumococcal killing in human blood and mice.
Among humans, there is a large variation in factor H levels in blood, ranging from 
63.5 to 847.6 µg/mL 15-19. We found a delicate balance in which human factor H 
levels of 300 µg/mL in serum resulted in optimal pneumococcal C3 opsonization 
and clearance, whereas 100 µg/mL or 500 µg/mL resulted in significantly lower 
opsonization. A strength of our study is that we varied the human factor H 
concentration while keeping all other serum components, such as levels of 
opsonizing antibodies and other complement components, identical. Experiments 
were performed using the pneumococcal TIGR4 strain, since this strain is virulent 
in mice. Previous studies demonstrated variation in C3 opsonization and factor H 
binding between pneumococcal strains, owing to variation in capsular serotype, 
capsular expression, PspC variant, and pspC expression 39-43. This may contribute to 
differences in virulence between strains.
 
Our results demonstrate that, within the normal range of human factor H levels, 
there is a significant difference in the ability to C3 opsonize and to kill S. pneumoniae 
TIGR4. This suggests that when pneumococci enter the bloodstream, human factor 
H levels are of major importance for optimal pneumococcal clearance and thus 
affect an individual’s susceptibility to invasive pneumococcal disease and severity 
of infection. 
Common polymorphisms in CFH have been described and were associated 
with susceptibility to various diseases. Based on the different functional 
effects of different types of factor H deficiencies resulting from mutations or 
polymorphisms known for human factor H, we propose to classify them into 
3 groups: 1) polymorphisms affecting cell surface binding, either host or bacterial; 
2) polymorphisms affecting the ability of factor H to regulate alternative pahtway 
activation; and 3) polymorphisms affecting factor H expression levels. A similar 
classification is already being used for properdin deficiencies 44. The current study 
demonstrates the critical role of factor H serum levels in pneumococcal invasive 
disease. These findings are supported by previous work that demonstrated that a 
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single-nucleotide polymorphism in the promoter region of CFH increases serum 
levels of human factor H, resulting in reduced bactericidal activity against N. 
meningitidis 15 However, binding affinity of human factor H to the bacterial surface 
may also play an important role in the outcome of infectious diseases. An example 
of this phenomenon is a common variant of human factor H Y402H described to 
be associated with increased group A streptococcal killing in blood due to reduced 
binding of the human factor H variant to the bacterial surface 32,45. As this human 
factor H variant also shows decreased binding to host cells and thus less protection 
of cells from complement activation, the Y402H polymorphism increases the risk 
of developing age-related macular degeneration presumably caused by elevated 
ocular complement activation 46. Individuals carrying the Y402H variant also have 
lower serum levels of factor H 11. Further research is needed to determine whether 
common or rare variants in CFH that affect the functionality or expression levels 
of factor H are associated with the susceptibility to infectious diseases, such as 
pneumococcal invasive disease. 
Many genetic factors contribute to an individual’s complement activity, also 
referred to as complotype 10. Combinations of polymorphisms in alternative 
pathway proteins have been described to enhance alternative pathway activity 
and predispose for chronic inflammatory diseases, such as haemolytic uremic 
syndrome, age-related macular degeneration, and dense deposit disease. Our 
findings support the hypothesis that an individual’s alternative pathway activity 
may affect not only the susceptibility to chronic inflammatory diseases, but also 
the susceptibility to infectious diseases 10. Genome-wide association studies are 
of importance to increase the understanding of how an individual’s complement 
activity affects the susceptibility to infectious diseases. Furthermore, this study, 
together with previous studies, demonstrates the importance of alternative 
pathway activation in the defence against invading pathogens 26. Therefore, 
modulation of alternative pathway activity may be an effective therapy to 
enhance clearance of invasive infections. Enhanced alternative pathway activity 
by exogenous properdin has been demonstrated to increase pneumococcal and 
meningococcal clearance in mice 26. However, therapies involving factor H may 
be more challenging to develop, since we demonstrate a delicate balance in 
which higher or lower factor H levels may impair pneumococcal clearance. 
Overall, a better understanding of host factors that influence the susceptibility 
to infection would support prediction of disease and could also contribute to the 
development of therapies to reduce the susceptibility to disease.
We found that human and mice factor H levels determine a delicate balance of 
alternative pathway activity affecting the resistance to invasive pneumococcal 
disease. Our results suggest that polymorphisms in CFH affecting factor H 
expression levels may play a thus far unrecognized role in the resistance to invasive 
pneumococcal disease. 
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Abstract
Most bacteria entering the bloodstream will be eliminated through complement 
activation on the bacterial surface and opsonophagocytosis. However, when these 
protective innate immune systems do not work optimally, or when bacteria are 
equipped with immune evasion mechanisms that prevent killing, this can lead to 
serious infections such as bacteremia and meningitis, which is associated with high 
morbidity and mortality. In order to study the complement evasion mechanisms 
of bacteria and the capacity of human blood to opsonize and kill bacteria, we 
developed a versatile whole blood killing assay wherein both phagocyte function 
and complement activity can easily be monitored and modulated. In this assay we 
use a selective thrombin inhibitor hirudin to fully preserve complement activity of 
whole blood. This assay allows controlled analysis of the requirements for active 
complement by replacing or heat-inactivating plasma, phagocyte function and 
bacterial immune evasion mechanisms that contribute to survival in human blood.
Introduction
Blood is normally sterile, but in cases when epithelial barriers are compromised 
and the immune system is not optimally equipped to fight pathogens, bacteria can 
be present in the blood, which is called bacteremia. Bacteria have evolved various 
mechanisms that prevent opsonophagocytosis, contributing to their ability to 
colonize their host, but also occasionally resulting in severe infections. Overall, 
Gram-positive bacteria are protected from complement-mediated lysis by the 
presence of a thick outer cell wall consisting of peptidoglycan, which prevents the 
bacterial membrane from lysis by the pore-forming membrane attack complex 1. 
Conversely, Gram-negative bacteria, which are characterized by an outer membrane 
surrounding the bacterial cell wall, are vulnerable to complement-mediated killing 
due to assembly and insertion of the membrane attack complex on the bacterial 
surface 2. Several bacterial species express a polysaccharide capsule, that protects 
them from recognition by opsonizing antibodies and in Gram-negative bacteria 
such as Haemophilus influenzae from insertion of the membrane attack complex 3. 
Besides a protective capsule, which can be found on both Gram-positive and Gram-
negative bacteria, many invasive bacteria are able to hijack human complement 
regulatory proteins, thereby decreasing complement activation on their bacterial 
surface. For instance, Streptococcus pneumoniae, H. influenzae, Escherichia coli 
and Neisseria meningitidis are able to bind human factor H 4-7, which decreases 
alternative complement activation and thereby reduces C3 opsonization. 
In order to study the complement evasion mechanisms of bacteria, or the capacity 
of complement to opsonize and kill bacteria, most in vitro studies performed 
to date are using serum, plasma or baby rabbit complement containing active 
complement for complement opsonization. For opsonophagocytosis, isolated 
phagocytes or phagocyte-like cell lines such as HL-60 are used 8-11. However, 
this is by no means representative to the real live situation in whole blood. For 
instance, the isolation of neutrophils leads to priming, which affects the ability 
of the neutrophils to form reactive oxygen species and changes their responses 
to cytokines 12. In addition, serum has altered levels of coagulation proteins 
compared to plasma in whole blood. An example is plasminogen 13, which can 
bind to the bacterial surface of S. pneumoniae and is involved in bacterial virulence 
14,15. Another example is fibrinogen, shown to bind to Streptococcus pyogenes M 
protein, which decreases C3b deposition and opsonophagocytosis 16,17. 
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To circumvent these limitations in order to study complement-mediated 
opsonophagocytosis of bacteria, we explored the possibility to use whole blood 
directly after venous puncture for use in opsonophagocytosis assays. Here, we 
describe a versatile and easy to perform whole blood killing assay in which both 
phagocyte function and complement activity can be monitored and modulated. 
We used a selective thrombin inhibitor hirudin, which preserved complement 
activity of whole blood, in contrast to lithium heparin, sodium heparin, EDTA or 
sodium citrate. 
Material and methods
Ethics statement
After informed consent, a venous blood specimen was collected from the 
median cubital vein of healthy volunteers (age, 20–40 years; both males and 
females). Collection of blood was approved by the Ethics Committee of the 
Radboud University, Nijmegen, the Netherlands and experiments were carried 
out in accordance with local guidelines and regulations and complies with the 
Declaration of Helsinki and the Good Clinical Practice guidelines.
Bacterial growth conditions
Streptococcus pneumoniae strain TIGR4 18, Streptococcus pneumoniae strain 
TIGR4ΔpspC 19, Klebsiella pneumoniae RUMC-KP01 (Clinical isolate Medical 
Microbiology, Radboud UMC Nijmegen, the Netherlands), Staphylococcus aureus 
strain NCTC 8178 (National Collection of Type Cultures), Escherichia coli BL21 
DE3 (Agilent), Neisseria meningitidis serogroup B strain H44/67 20, Pseudomonas 
aeruginosa ATCC15692 (American Type Culture Collection), H. influenzae type A 
strain ATCC 9006 (American Type Culture Collection), H. influenzae type B strain 
ATCC 10211 (American Type Culture Collection), non-typeable H. influenzae (NTHi) 
strain R2866 3, NTHi strain 3655 21 and NTHi strain 11P6H 22 were used in this study. 
H. influenzae was grown under shaking conditions at 37°C in brain heart infusion 
(BHI) broth (Becton Dickinson) supplemented with 10 μg/mL haemin (Sigma-
Aldrich) μg/mL β-nicotinamide adenine dinucleotide (Merck) (sBHI). S. pneumoniae 
was grown under static conditions at 37°C with 5% CO2 in Todd-Hewitt broth 
supplemented with 5 g/L yeast extract. N. meningitidis was grown on blood agar 
plates and collected directly from overnight plates. K. pneumoniae, S. aureus, E. coli 
and P. aeruginosa were grown under shaking conditions at 37°C in Luria-Bertani 
(LB) broth. 
IgG, IgM and C3 opsonization assays
Blood for serum collection was collected in SST II Advance tubes (BD, Ref 367953). 
Tubes were inverted after blood was drawn, incubated for 15 minutes at room 
temperature to clot, centrifuged with 3000g for 15 min at room temperature and 
serum was stored in small aliquots at -80°C. Blood for plasma preparation was 
collected in K2E (EDTA) tubes (BD Ref 367864), Trisodium citrate tubes (BD Ref 
363047), Sodium heparin tubes (BD Ref 367869), Lithium heparin tubes (BD Ref 
368496) or S-Monovette r-Hirudin tubes (Sarstedt, Ref 04.1944.001). Tubes were 
inverted after blood was drawn, centrifuged with 3000 x g for 15 min at 4°C and 
plasma was stored in small aliquots at -80°C. 
For human IgG, human IgM and human C3 binding, bacteria (1.10E7 in 100 µL) 
were incubated with 10% plasma or serum in Hank’s Balanced Salt Solution 
(HBSS) without phenol red containing Ca2+/Mg2+ + 0.1% gelatin (HBSS3+) for 30 
min at 37°C. Bacteria were washed and incubated with 1:500 diluted FITC-labelled 
polyclonal goat anti-human C3 (MP biomedicals), 1:100 diluted FITC-labelled 
Fc-specific goat anti-human IgG (Sigma-Aldrich) or 1:100 diluted FITC-labelled 
μ-chain-specific goat anti-human IgM (Sigma-Aldrich) in PBS with 2% BSA for 30 
min at 4°C. Bacteria were washed and fixed for 20 min with 2% paraformaldehyde. 
Bacteria were taken up in PBS for flow cytometry.
Whole blood killing assay
After informed consent was obtained, a venous blood specimen was collected 
from the median cubital vein of healthy volunteers (age, 20–40 years; both males 
and females) into S-Monovette r-Hirudin tubes (Sarstedt). Blood was kept at room 
temperature on a roller bench until used. For the whole blood killing assay, 100 μL 
of hirudin-anticoagulated blood was added per well in a 96-well plate. Bacterial 
suspensions in PBS, containing 1.10E5 colony forming units (CFU), were added in 
a maximum volume of 5 μL and immediately mixed with the blood. The 96-well 
plate was incubated for the indicated time at 37°C under continuous shaking. The 
number of bacterial CFU was determined at start and after incubation by plating 
serial 10-fold dilutions. The percentage of bacteria that survived was calculated.
For plasma inactivation, 100 μL of hirudin-anticoagulated blood was added per 
well in a 96-well plate and centrifuged at 1000 x g for 5 min. Plasma was removed 
and heat-inactivated for 20 min at 56°C. Blood cells were washed by adding 100 μL 
PBS and centrifuged with 1000 g for 5 min. PBS was removed and heat-inactivated 
plasma was mixed with the pelleted cells and used for the killing assay. To examine 
the effect of plasma alone on bacterial clearance, 200 μL hirudin-anticoagulated 
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blood was centrifuged 1 min at 16.000 x g and 100 μL plasma was used for the 
killing assay in the absence of blood cells. For 50%, 25% and 10% active plasma, 
50 μL, 25 μL and 10 μL active plasma was mixed with 50 μL, 75 μL and 90 μL heat-
inactivated plasma, respectively, and was mixed with the pelleted blood cells and 
used for the killing assay. For plasma replacement, 100 μL of hirudin-anticoagulated 
blood was added per well in a 96-well plate and centrifuged at 1000 x g for 5 min. 
Plasma was removed and cells were washed by adding 100 µL PBS and centrifuged 
at 1000 x g for 5 min. PBS was removed and pooled hirudin-anticoagulated plasma 
was mixed with the pelleted cells and used for the killing assay. For C6-depleted 
serum (CompTech) and C6-deficient patient serum 23, serum was diluted in PBS to 
10%. Reconstitution of C6 was performed by supplementing 6.4 µg/mL purified C6 
(CompTech) in 10% serum because manufacturer’s product description states full 
reconstitution of serum was achieved with 64 µg/mL.
Inhibitor cytochalysin D (cyto D) (Sigma-Aldrich), anti-complement receptor 3 (CR3) 
subunit CD11b antibody clone 44a (α-CD11b) (Gift from Prof. Leo Koenderman), 
4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich), factor H (FH) (CompTech) or an equal 
volume of PBS were added to the hirudin-anticoagulated blood before adding the 
bacteria. 
Phagocytosis of CFSE-loaded S. pneumoniae
S. pneumoniae was grown in Todd-Hewitt broth supplemented with 5 g/L yeast 
extract to OD620 = 0.2, washed with PBS and labelled with carboxyfluorescein 
succinimidyl ester  (CFSE) (Sigma-Aldrich) as previously described 24. Five microliter 
(~1.106 CFU) CFSE-labelled bacteria were added to 100 uL hirudin-anticoagulated 
whole blood and incubated for 30 min. Red blood cells were lysed in ice-cold NH4Cl 
solution (8.3 g/L NH4Cl, 1 g/L KHCO3 and 37 mg/L EDTA) and washed once with 
ice-cold NH4Cl solution followed by a wash with PBS. Cells were stained with 1:200 
diluted Alexa647-labelled α-CD16 (BD biosciences), 1:50 diluted V500-labelled 
α-CD3 (BD biosciences), 1:50 diluted PE-Cy7-labelled α-CD14 (Biolegend), 1:100 
diluted BV421-labelled α-CD66b (BD biosciences) for 15 min. at room temperature. 
Cells were washed with PBS and analyzed by flow cytometry using a FACS LSR II 
(BD Biosciences). Data were analyzed using FlowJo v10.1.
Results and discussion
Hirudin-anticoagulated blood is optimal for complement 
preservation
We used Streptococcus pneumoniae as model organism to set-up a whole blood 
killing assay because this bacterium is causing bacteremia in immune competent 
individuals 25,26. In order to survive in blood, this bacterium has developed 
various mechanisms that inhibit recognition by the immune system 27. For 
efficient opsonophagocytic killing, C3b opsonization of the bacterial surface 
of S. pneumoniae is required 28. To determine which anticoagulants preserved 
complement C3b opsonization capacity, we determined IgG, IgM and C3 binding 
to the bacterial surface of S. pneumoniae after 30 minutes with 10% human serum 
or 10% human plasma anticoagulated with hirudin, lithium heparin, sodium 
heparin, EDTA or sodium citrate (Figure 1 A-C). 
Binding of IgG to the bacterial surface of S. pneumoniae incubated with 10% 
hirudin or EDTA anticoagulated human plasma was slightly increased compared 
to 10% human serum, whereas no significant differences for IgM were observed. 
More striking were the differences in C3 opsonization. Here, hirudin anticoagulated 
plasma showed the highest C3 opsonization of S. pneumoniae, whereas all other 
anticoagulants showed a significant decrease in C3 opsonization. Complement 
activity was preserved for at least 2 hours when blood was kept at room temperature 
(Figure 1D). From these data, we conclude that hirudin anticoagulated plasma is 
superior in preserving complement activity. 
Previously, Ison et al determined killing of Neisseria meningitidis in citrate and 
heparin-anticoagulated whole blood 29. In this study, heparin-anticoagulated 
whole blood was superior in killing N. meningitidis serogroup A compared to 
citrate-anticoagulated whole blood. In subsequent experiments, the same group 
compared this whole blood killing assay to serum bactericidal assay with blood 
from vaccinated children and consistently showed increased sensitivity for 
the whole blood killing assay 30,31. Also, they showed a reduction of survival of 
N. meningitidis in the whole blood killing assay with increasing age of patients 32. 
Whole blood killing of N. meningitidis has also been performed with hirudin-
anticoagulated whole blood. Welsch et al showed efficient killing of N. meningitidis 
serogroup B with whole blood from adults 33. A slightly modified whole blood 
killing assay, with 25% heat-inactivated serum, showed increased killing with 
post-immunization serum compared to pre-immunization serum 34. Comparisons 
in whole blood killing between huridin and other anticoagulants have not been 
studied previously.
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Figure 1. Plasma and serum IgG, IgM, C3 opsonization of S. pneumoniae. Bacteria (1.10E7) were 
incubated for 30 minutes in HBSS3+ containing 10% plasma anticoagulated with hirudin, lithium 
heparin, sodium heparin, EDTA or sodium citrate or serum from the same donor and binding 
of (A) IgG, (B) IgM, and (C) C3 was determined by flow cytometry (n=3). One-way analysis of 
variance (ANOVA) with Dunnett’s Multiple Comparison Test was used for statistical analysis. 
* = p<0.05, ** = p<0.01. (D) Hirudin anticoagulated blood was immediately (0h) or after 2 hours 
rolling on a roller mixer (2h) centrifuged and plasma was stored. Bacteria (1.10E7) were incubated 
for 30 minutes in HBSS3+ containing 10% of the plasma that was immediately or after 2 hours 
stored , and binding C3 was determined by flow cytometry (n=3). A one-tailed student t-test was 
used for statistical analysis. NS = not significant.
The differences in complement activity preservation can largely be explained by 
the function of the different anticoagulants. Lithium heparin and sodium heparin 
induce a conformational change of antithrombin III to accelerate the inhibition of 
thrombin and factor Xa, thus preventing thrombin activation and the generation 
of fibrin.  However, heparin is known to bind different proteins in the complement 
cascade 35, as well as calcium and magnesium ions 36, thereby affecting complement 
activity. Sodium citrate prevents blood from clotting through chelation of calcium 
ions by forming calcium citrate and EDTA scavenges bi-valent cations, such as 
calcium and magnesium, both are also required for complement activation. In 
contrast, hirudin (also known as lepirudin) is a highly specific thrombin inhibitor 
that does not interfere with complement activation 37. Hirudin has previously also 
been used in whole blood stimulation assays 33,38-40. This enables to determine the 
contribution of cross-talk between complement and other factors such as cytokine 
release 38, oxidative burst 40 and phagocytosis 39. 
Even though thrombin is not directly involved in complement activation, there are 
some reports where it has shown to modulate complement activity. For instance, 
in C3-/- mice, thrombin was overexpressed and showed to cleave C5 into C5a and 
C5b 41. In these studies, hirudin reduced acute lung inflammatory injury in C3-/- 
mice, but had no effect in C3+/+, indicating that thrombin-mediated cleavage of 
C5 only contributed to acute lung inflammatory injury when C3 is absent. 
Whole blood killing assay
Many bacterial pathogens such as S. pneumoniae, Staphylococcus aureus, Klebsiella 
pneumoniae N. meningitidis and H. influenzae frequently cause invasive disease, 
including sepsis 42-44. When present in the blood, bacteria need to withstand the 
bactericidal activity of the complement system, and phagocytosis by peripheral 
blood neutrophils. We used hirudin anticoagulated blood to determine the 
survival of invasive bacterial pathogens in blood. For these experiments, we used 
S. pneumoniae strain TIGR4, originally isolated from the blood of a 30-year-old 
male 18,45. 
The whole blood killing assay is an easy-to-use opsonophagocytic assay to 
determine survival of bacterial pathogens in blood. Bacteria are added to 100 µL 
hirudin anticoagulated blood in a 96-wells round bottom plate and incubated at 
37°C while shaking to prevent sedimentation. Different inoculums  (103-105 CFU / 
100 µL blood) were tested and all showed a decrease in CFU counts over time (data 
not shown). For subsequent experiments, 105 CFU / 100 µL blood were used.
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We determined killing of S. pneumoniae in whole blood and observed significant 
killing already after 1 hour, which increased further in time (Figure 2A). In order to 
determine the role of complement activity and phagocyte function, we performed 
the whole blood killing assay with either heat-inactivated plasma (see Material and 
Methods section for procedure) or with only plasma containing active complement. 
Whereas S. pneumoniae was killed in blood, no killing was observed with plasma 
only, indicating that phagocytes are required for efficient killing (Figure 2B). When 
heat-inactivated plasma was mixed with blood cells, S. pneumoniae was able to 
grow very rapidly. This indicates that active complement is required for effective 
opsonophagocytosis as well, but also shows that whole blood contains sufficient 
nutrients for fastidious growth. The contribution of active complement in 
S. pneumoniae opsonophagocytosis is known for a long time 46-48, and our results 
are consistent with these studies.
We determined whole blood killing after 1 hour for different pathogens that cause 
bacteremia 42-44. Survival of S. pneumoniae strain TIGR4 was 20%. Similar survival 
was found for K. pneumoniae (16%) and P. aeruginosa (7%), whereas survival for 
S. aureus (85%) or H. influenzae serotype B (41%) were higher. Survival of 
H. influenzae serotype A (2%), E. coli (0.03%) and N. meningitidis (0.1%) was much 
lower. Survival of NTHi was strain dependent, 9% for R2886, but only 0.2% and 
0.3% for strains 3655 and 11P6H, respectively. These strain-dependent differences 
in survival are probably due to variance in complement resistance since we have 
previously shown that survival in pooled human serum was much lower for NTHi 
strains 3655 and 11P6H as compared to strain R2866 4.
In order to compare complement-mediated killing and opsonophagocytic-
dependent killing for Gram negative and Gram positive bacteria, we determined 
survival of S. pneumoniae and NTHi strain 3655 with heat-inactivated plasma, 
plasma and whole blood. Both plasma and whole blood showed significant 
killing of NTHi strain 3655, whereas this was only the case with whole blood for 
S. pneumoniae (Figure 2D). These data clearly indicate that killing of Gram negative, 
unencapsulated, NTHi strain 3655 was largely dependent on complement-
mediated killing, whereas killing of S. pneumoniae was dependent on complement 
activation and opsonophagocytosis.
Modulation of bacterial, cellular and humoral factors 
contributing to whole blood killing.  
With this whole blood killing assay, bacterial factors as well as host cellular 
and humoral factors can be modulated to determine their contribution to 
Figure 2. Phagocytes and active complement are required for efficient opsonophagocytic killing 
of S. pneumoniae in whole blood. (A) Bacterial survival in hirudin anticoagulated whole blood was 
determined after 1, 2 and 4 hours incubation (n=3). One-way analysis of variance (ANOVA) with 
Dunnett’s Multiple Comparison Test was used for statistical analysis. *** = p<0.001. (B) Bacterial 
survival in whole blood, blood with heat-inactivated plasma and plasma only was determined 
after 1, 2 and 4 hours incubation (n=7). (C) Killing in hirudin anticoagulated whole blood of 
S. pneumoniae, S. aureus, K. pneumoniae, P. aeruginosa, E. coli, N meningitidis and H. influenzae 
were determined after 1 hour incubation (n=3). (D) Killing of S. pneumoniae and non-typeable 
H. influenzae influenzae (NTHi) strain 3655 was determined with heat-inactivated (HI) hirudin 
plasma, hirudin plasma and hirudin anticoagulated whole blood after 1 hour incubation (n=2).
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opsonophagocytic killing. For instance, blocking complement receptor 3 (CR3) with 
α-CD11b antibody 44a decreased killing of S. pneumoniae (Figure 3A), indicating 
that recognition of C3b on the bacterial surface by phagocytes contributes to 
killing. The contribution of the CR3 in opsonophagocytosis is S. pneumoniae by 
neutrophils and macrophages is widely investigating 49-51, and our results are 
consistent with these studies.
In addition, treatment of blood with cytochalysin D, an inhibitor for actin 
polymerization, also decreased killing of S. pneumoniae (Figure 3A), indicating 
that killing was dependent on phagocytosis. 
Recently, Corriden et al showed that tamoxifen augmented neutrophil-mediated 
killing of S. aureus, E. coli and Pseudomonas aeruginosa through enhancing 
several pro-inflammatory pathways in human neutrophils, including chemotaxis, 
phagocytosis and neutrophil extracellular trap (NET) formation 52. Here, we 
show that adding 10 µM 4-hydroxytamoxifen significantly augmented killing of 
S. pneumoniae in whole blood (Figure 3B). 
Killing of S. pneumoniae, but also other pathogens, is affected by the presence 
of opsonizing antibodies and the overall complement activity. To determine the 
role of complement activity, we used whole blood of which plasma was removed 
by centrifugation and replaced with 50%, 25% or 10% plasma containing active 
complement (see Material and Methods section for procedure). Replacement of 
the total amount of active plasma with 50% active plasma clearly decreased the 
killing capacity, which was even more apparent for 25% and 10% active plasma 
(Figure 3C), indicating that decreasing the level of active complement reduces the 
capacity to clear S. pneumoniae from blood in a dose dependent manner.
Previously, we have used the whole blood killing assay to assess the contribution 
of human factor H in controlling complement activity and killing of S. pneumoniae 
by replacing plasma with factor H-depleted serum and supplementation with 
different concentrations of purified human factor H. In this assay, we showed that 
increasing human factor H to blood increased survival of S. pneumoniae, whereas 
decreasing factor H levels increased killing 53. Adding 100 µg/mL factor H to whole 
blood decreased killing of S. pneumoniae significantly (Figure 3D), which is in 
accordance with the findings that higher factor H levels decreased bacterial killing 
53. Binding of factor H to the bacterial surface was shown to protect many bacteria 
from complement-mediated opsonization 4,5,7,54-58. Pneumococcal surface protein 
C (PspC) of S. pneumoniae is known to bind human factor H. In order to determine 
Figure 3. Modulation of S. pneumoniae killing by modulating phagocytosis or complement activity. 
Bacterial survival in hirudin anticoagulated whole blood was determined after 2 hours incubation 
in the presence of (A) 10 mg/mL CD11b blocking antibody (α-CD11b), 10 mM actin polymerization 
inhibitor cytochalysin D (CytoD), (B) 10 mM 4-hydroxitamoxifen (4-OHT) or (D) 100 mg/mL human 
factor H (fH). (C) Bacterial survival in hirudin anticoagulated whole blood and blood with 50%, 25% 
and 10% active plasma was determined after 2 hours incubation (n=4). (E) Bacterial survival of 
TIGR4 wild-type (WT) and TIGR4ΔpspC were determined after 2h in hirudin anticoagulated whole 
blood. (F) Bacterial survival of TIGR4 was determined after 2h in hirudin anticoagulated whole 
blood with or without plasma replacement. One-way analysis of variance (ANOVA) with Dunnett’s 
Multiple Comparison Test was used for statistical analysis (A and C). A one-tailed student t-test was 
used for statistical analysis (B, D, E and F). * = p<0.05.
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the role for factor H binding in whole blood killing we determined survival of a 
ΔpspC mutant and found that this mutant, as expected, had a decreased survival 
in whole blood (Figure 3E). Overall, this demonstrates several possibilities in 
studying functions of complement in bacterial clearance using the whole blood 
killing assay.
While performing our whole blood killing experiments, we observed large inter-
patient differences in S. pneumoniae survival (% survival 0.03 - 2.00) (Figure 3F). 
To determine whether these differences can mainly be attributed to differences 
in plasma content or phagocyte function, we used whole blood from which 
plasma was removed by centrifugation and replaced it with pooled plasma in 
which the concentrations of opsonizing antibodies and the complement activity 
are constant (see Material and Methods section for procedure). In this assay, 
killing of S. pneumoniae was more consistent (% survival 0.39 - 1.30), compared to 
survival in blood from the four single donors (% survival 0.03 - 2.00) (Figure 3F). 
These data indicate that mainly differences in plasma components (opsonizing 
antibodies and complement activity) between these four donors attribute to the 
inter-donor variation in whole blood killing capacity. This approach can also be 
used to determine vaccine-induced protection. Previously, Welsch et al showed 
that supplementation of whole blood with 25% heat-inactivated post-vaccination 
serum increased killing of N. meningitidis compared to pre-immunization serum 34. 
This approach enables comparison of whole blood killing of pathogens with 
different serum samples in combination with a single fresh blood donor.
Contribution of C6 in opsonophagocytic-mediated killing of 
N. meningitidis. 
Patients with deficiencies in the terminal complement components are more 
susceptible to invasive infections by N. meningitidis 59. To mimic this in our 
whole blood killing assay, we replaced plasma with 10% C6-depleted serum and 
determined survival of N. meningitidis serogroup B strain H44/76 after 30 minutes. 
The presence of 10% heat-inactivated C6-depleted serum showed 9.1% survival 
(Figure 4A), indicating that N. meningitidis serogroup B strain H44/76 is killed by 
complement-independent mechanisms, which has been described in literature 
previously. For instance, N. meningitidis serogroup C was killed by antibody-
dependent cell-mediated antibacterial activity 60 as well as opsonin-independent 
phagocytosis 61. Opacity (Opa) proteins have been implicated to be important 
in opsonin-independent phagocytosis of N. meningitidis 62,63 through neutrophil 
surface receptors CD66 and CR3 64,65, whereas macrophages  bind unopsonized N. 
meningitidis almost exclusively via the class A macrophage scavenger receptor 66. 
Although not investigated in detail, we show that N. meningitidis serogroup B 
strain H44/76 is efficiently killed through complement-independent mechanism.
To study the contribution of complement in addition to complement-independent 
mechanisms, we used 10% C6-depleted serum in the whole blood killing assay. 
When 10% C6-depleted serum was used, survival was significantly lower (4.0%) 
compared to heat-inactivated serum (Figure 4A). Since C6-depleted serum is not 
able to form a membrane attack complex, this increased killing is likely due to 
complement-dependent opsonophagocytosis. In order to restore terminal complex 
activity, we supplemented C6-depleted serum with C6 and observed a significant 
increase in killing, implicating that formation of membrane attack complex, next 
to opsonin-dependent and opsonin-independent killing, contributed to overall 
clearance of N. meningitidis from whole blood. 
Figure 4. Contribution of C6 in opsonophagocytic-mediated killing of N. meningitidis. Bacterial 
survival of N. meningitidis strain H44/76 was determined after 30 minutes in hirudin anticoagulated 
whole blood with (A), 10% heat-inactivated serum, 10% C6-depleted serum, 10% C6-depleted 
serum supplemented with normal concentration C6 (see Material and Methods), (B), 10% C6-
deficient patient serum, 10% C6-deficient patient serum supplemented with normal concentration 
C6. A one-tailed student t-test was used for statistical analysis. * = p<0.05, ** = p<0.01.
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Previously, we have described a patient with a novel heterozygous missense 
mutation in the C6 gene. Next to this novel heterozygous C6 mutation, a known 
heterozygous splice site variation was also identified, resulting in a C6 molecule 
that is 14% shorter due to a premature stop codon, but can still be build into the 
terminal complement complex, can kill bacteria, and is hemolytically active 67,68. But, 
both mutations resulted in a lower (5%) C6 protein level. Normal immunoglobulin 
levels (IgG/IgA/IgM/IgE) and other complement factors (C3, C4) were found. When 
10% C6-deficient patient serum was used, survival was low (2.3%) (Figure 4B), 
which was consistent with results obtained with C6-depleted serum. Survival was 
significantly lower when C6 was reconstituted (0.7%) (Figure 4B), indicating that 
C6 supplementation increased bacterial killing in whole blood. 
Altogether, these results with C6-depleted serum and C6-deficient patient serum 
obtained similar results; decreased killing as compared to C6-reconstituted serum, 
which is consistent with the clinical phenotype of these patients. 
Monocytes and neutrophils contribute to opsonophagocytosis 
of S. pneumoniae.
In order to address which cell type was predominantly responsible for 
opsonophagocytosis of S. pneumoniae in whole blood, we labelled S. pneumoniae 
with CFSE as previously described 24. CFSE-labelled bacteria were added to 
whole blood in the absence or presence of cytochalysin D to block phagocytosis. 
Especially monocytes (74%) and neutrophils (72%) were found to bind and 
phagocytose S. pneumoniae, which was only 9% for lymphocytes (Figure 5A). 
Cytochalysin D decreased S. pneumoniae association to monocytes, neutrophils 
and lymphocytes to 24%, 42% and 5%, respectively, indicating that half of the cells 
in the control condition actually phagocytosed S. pneumoniae, whereas the other 
half of the CFSE-labelled bacteria were cell-associated. When the total percentage 
of S. pneumoniae association with cells was determined, most of them, 85%, 
were neutrophils, 10% monocytes and 5% lymphocytes (Figure 5B), indicating 
that neutrophils are the most important cell type for opsonophagocytosis of 
S. pneumoniae in whole blood. These results are consistent with previous 
literature where phagocytosis experiments showed efficient uptake of opsonized 
S. pneumoniae by both macrophages and neutrophils 69-71. The important role for 
neutrophils in opsonophagocytic killing and protection against pneumococcal 
disease is supported by in vivo models wherein neutrophils were depleted 72,73.
Conclusion
The use of hirudin-anticoagulated whole blood enabled us to study the 
contribution of both bacterial and host factors in the  killing of several pathogens, 
including S. pneumoniae,  K. pneumoniae, S. aureus and H. influenzae. Complement 
activity preservation of hirudin was superior compared to lithium heparin, 
sodium heparin, EDTA or sodium citrate. Altogether, we describe a versatile assay 
to determine bacterial and host factors affecting opsonophagocytic killing of 
bacteria in hirudin-anticoagulated whole blood as a model for bacteremia.
Figure 5. Whole blood killing of S. pneumoniae is mainly dependent on neutrophil-mediated 
opsonophagocytosis. (A) S. pneumoniae was loaded with 10 mM CFSE and incubated 30 min in 
hirudin anticoagulated whole blood. Erythrocytes were removed by hypotonic shock and the 
percentage CFSE positive lymphocytes (CD3 positive), monocytes (CD14 positive / CD16 negative) 
and neutrophils (CD16 positive / CD66b positive) were determined by flow cytometry. (B) 
Percentage of CFSE positive cells were determined.
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Abstract 
Pneumococcal capsular serotype is an important determinant of complement 
resistance and invasive disease potential, but other virulence factors have also 
been found to contribute. Pneumococcal surface protein C (PspC), a highly variable 
virulence protein that binds complement factor H to evade C3 opsonization, is 
divided into two subgroups: choline-bound subgroup I and LPxTG-anchored 
subgroup II. The prevalence of different PspC subgroups in invasive pneumococcal 
disease (IPD) and functional differences in complement evasion are unknown. 
Prevalence of PspC subgroups in IPD isolates was determined in a collection 
of 349 sequenced strains of S. pneumoniae isolated from adult patients. PspC 
deletion and isogenic pspC-switch mutants were constructed to study differences 
in factor H binding and complement evasion in relation to capsule thickness. 
Subgroup I pspC was far more prevalent in IPD isolates than subgroup II pspC. 
Increased capsular thickness was associated with a greater ability of bound factor 
H to reduce complement opsonization. Pneumococcal subgroup I PspC bound 
significantly more factor H and showed more effective complement evasion 
compared to subgroup II PspC in isogenic encapsulated pneumococci. Variation in 
PspC subgroup, independent of capsule serotypes, affects pneumococcal factor H 
binding and its ability to evade complement deposition. 
Introduction
Streptococcus pneumoniae is an important human pathogen that colonizes the 
upper respiratory tract. This pathogen is also an important cause of invasive diseases 
such as pneumonia, sepsis and meningitis. The pneumococcal polysaccharide 
capsule affects complement resistance and protects against phagocytic killing 1,2. 
Epidemiological studies found that particular capsular serotypes are dominant 
in invasive disease whereas others are associated with nasopharyngeal carriage 
3,4. Besides the important role of the pneumococcal capsule, the genotype also 
affects complement resistance. Within the same serotype, significant differences 
in complement C3 deposition between isolates have been observed, indicating 
that the genetic background of the strain also affects complement resistance 5. A 
recent study suggests that within the same serotype and clonal complex, genetic 
differences in virulence genes encoding pneumococcal surface protein A and C 
(PspA and PspC), affect the invasive disease potential 6. It is therefore of interest to 
gain more insight into how genetic variation in these genes affects complement 
resistance and contribute to pneumococcal virulence. 
The complement system is an essential component of the host defense against S. 
pneumoniae 7. Complement activation by one of the three pathways: the classical, 
the lectin and the alternative pathway, leads to opsonization of the bacterial surface 
with C3 activation products C3b and iC3b. These opsonins mediate phagocytosis 
mainly through complement receptors CR1 and CR3. Importantly, the alternative 
pathway amplifies the initial complement activation 8. C3b deposited on the 
bacterial surface is formed into an alternative pathway C3 convertase cleaving 
more C3, which enhances C3b opsonization 9. The importance of the alternative 
pathway in complement activation is emphasized by the fact that many pathogens 
possess mechanisms to inhibit alternative pathway activation by binding of the 
host alternative pathway inhibitor factor H 10-14.
S. pneumoniae binds human factor H by PspC, also referred to as CbpA, SpsA, 
PbcA and Hic 15-19. Factor H binding by PspC is a mechanism to evade complement 
deposition. In addition, PspC acts as an adhesion molecule by interacting with the 
secretory component of human IgA, the laminin receptor and epithelial/endothelial 
polymeric immunoglobulin receptor (pIgR), which may be an entry vehicle for 
PspC mediated invasion 16,17,20-25. In vitro studies using human serum demonstrate 
that factor H binding by S. pneumoniae strains is dependent on the presence of 
PspC, but that the level of binding is influenced by the capsular serotype 1,26. In 
addition, within a serotype, spontaneous opaque/transparent phase variation 
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occurs, which affects complement deposition 27,28. An important characteristic of 
the pneumococcal phase variation is the difference in capsule thickness. Opaque 
phase pneumococci with increased amounts of capsular polysaccharide show 
enhanced complement resistance, which has been associated with better survival 
in blood 29-31. Other differences between opaque and transparent phases, besides 
the capsule thickness, have been described. For example transparent phase 
pneumococci have higher levels of lipoteichoic acid with phosphorylcholine 
residues27,32. 
The pspC gene shows large allelic variation. Eleven different types of pspC have been 
identified based on clusters of sequence homology. PspC consists of a C-terminal 
repeat region, a proline-rich domain, and a N-terminal α-helical domain 33. A 
factor H binding region of 121 amino acids has been identified at the N-terminal 
region (residues 38-158), containing multiple epitopes for factor H binding 21. At 
the C-terminal region, a major difference in anchor sequence has been identified 
dividing pspC into two subgroups; allelic variants with a choline binding domain 
(classical, subgroup I) or a LPxTG anchoring domain (non-classical, subgroup II) 33. 
The prevalence and distribution of the different PspC subgroups and types in 
invasive disease or carriage isolates has not been characterized thoroughly. 
Though, Iannelli et al demonstrated a predominance of subgroup I PspC (74%) in 
a collection of 43 strains containing randomly chosen clinical isolates, standard 
laboratory strains and American Type culture Collection strains 33. However, it is not 
known whether variation in PspC type, independent of capsule differences, affects 
pneumococcal factor H binding and its ability to evade complement deposition. 
Here we describe a far greater prevalence of choline bound subgroup I PspC types 
as compared to LPxTG anchored subgroup II PspC types in invasive pneumococcal 
disease isolates. In addition, using isogenic pspC switch mutants, we demonstrate 
that subgroup I PspC is more effective in complement evasion than subgroup II 
PspC. These findings indicate that PspC-specific differences contribute to intra-
serotype variation in complement resistance. 
Material and Methods
Pneumococcal strain collection, sequence typing and PspC 
typing
The prevalence of various pspC types was studied in 349 sequenced S. pneumoniae 
isolates from invasive pneumococcal disease (IPD) patients in Nijmegen, the 
Netherlands, (2001 -2011; All bacteraemia isolates from patients with pneumonia 
(n=312), meningitis (n=30) and endocarditis (n=4)) 34,35. The median age was 67 
years (53-78 interquartile range), male/female ratio 0.86. This observational cohort 
study was approved by the Local Medical Ethics Committees of both participating 
hospitals. Genome sequences, serotypes and sequence types were obtained 
from Cremers et al., 2015 34. PspC coding genes were identified from the genome 
sequences by aligning the 40 amino acid conserved N-terminus of PspC against 
all protein coding sequences of the genomes using BLASTP 36. PspC types were 
determined by aligning the PspC coding proteins against the known PspC protein 
sequences 33 using BLASTP and the blast results were manually inspected. 
Construction of pspC deletion and isogenic pspC-switch 
mutants
Four different pspC types were selected from the bacteraemia cohort and 
constructed into an isogenic background. The pspC types have been described by 
Ianelli et al., 2002 33. Based on this description we selected two PspC types with a 
choline binding anchor and two PspC types with a LPxTG binding anchor at the 
C-terminal domain with differences in the N-terminal factor H binding domain. 
To obtain these PspC types, we searched our strain collection and found isolates 
containing pspC genes belonging to the previously described PspC types. PspC 
type 2 was obtained from strain PBCN0094 (10050_2#53) and was 100% identical 
to the previously described pspC 2.2 33, also found in TIGR4. PspC types 6 and 9 were 
both obtained from strain PBCN0133 (10050_2#83) and were cloned separately 
into an isogenic background. The pspC 9 showed 91% identity with previously 
described pspC 9.1 with all differences in the repeat region and pspC 6 showed 
100% identity with the previously described pspC 6.1. The pspC 11, also known as 
hic, was found in strain PBCN0031 (10050_2#18) and showed 97% identity with 
previously described pspC 11.3. The pspC types found in these strains were cloned 
into an encapsulated TIGR4 strain and an unencapsulated R6 strain. 
TIGR4ΔpspC and R6ΔpspC deletion mutants were constructed by allelic replacement
of the target gene with an antibiotic resistance marker as described previously 37.
The various pspC types were cloned into the pspC deletion mutants to avoid 
recombination with the original pspC gene. Again, a megaprimer PCR product 
was constructed, but contained besides the pspC flanking regions and the 
spectinomycin cassette, the selected pspC type originated from the above 
mentioned clinical isolates. The spectinomycin cassette and the right flank were 
PCR amplified from the TIGR4ΔpspC containing the spec cassette. The megaprimer 
PCR product was used to transform R6ΔpspC (kanamycin resistant). Directed 
mutants were obtained by selective plating (spectinomycin) and were checked for 
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correct integration of the antibiotic resistance cassette and pspC variant gene by 
PCR using control primers located inside the genes. A PCR product from the left 
flank to the right flank containing the inserted pspC type and the spectinomycin 
cassette was used to transform TIGR4ΔpspC (kanamycin resistant). Mutants were 
obtained by selective plating and were checked for correct integration of the 
antibiotic resistance cassette and pspC variant gene by PCR using control primers 
located inside the genes and sequencing. The primer sequences (obtained from 
Biolegio, Nijmegen, The Netherlands) are indicated in supplementary table 1. 
Correct integration of the pspC gene was confirmed by sequencing.
Bacterial strains and culture conditions
Bacteria were grown on Columbia blood agar plates (Becton Dickinson) and in 
Todd-Hewitt broth supplemented with 5 g/L yeast extract (THY) at 37°C and 5% 
CO2 to an OD620 of 0.2 was reached. The number of colony forming units per 
milliliter was determined by plating serial 10-fold dilutions on blood agar plates. 
To obtain opaque and transparent phase TIGR4 wild-type and ΔpspC, frozen stock 
cultures were plated on THY agar supplemented with 5000 U of catalase (Sigma) 
and incubated at 37°C and 5% CO2. Colony morphology of variants on THY-catalase 
plates was determined as described previously 28. Opaque and transparent variants 
were selected and subcultured two times and grown in THY broth as described 
above. 
Factor H binding and C3 deposition assay
TIGR4 or R6 strains wild-type or mutant (1x107) were pelleted in a 96-well plate 
and resuspended in 10% (vol/vol) pooled normal human serum (GTI Diagnostic) 
in Hanks Buffered Salt Solution containing Ca2+ and Mg2+ to a total volume of 100 
µL. The bacterial suspension was incubated for 30 min at 37°C in 5% CO2. After 
incubation, the bacteria were washed and labelled with polyclonal sheep anti 
human factor H (Abcam; cat#8842) or with the FITC-conjugated goat anti-human 
C3 (Cappel; cat#55197) diluted in PBS + 2% BSA. After 30 min incubation, bacteria 
were washed and the anti-factor H antibody was labelled with FITC-donkey anti-
sheep IgG antibody (Jackson immunoresearch; #713-095-003). Bacteria were fixed 
with 2% paraformaldehyde. Factor H binding and C3 deposition were measured 
using a LSR II flow cytometer (BD Biosciences). Data were analysed using FlowJo 
v10.1. 
Real-time RT-PCR
RNA from overnight grown strains of TIGR4 and R6 expressing pspC type 2, 6, 9 
or 11 was extracted using RNAeasy Minikit (Qiagen) and DNA was removed with 
Turbo-DNAse (Ambion). RNA (1µg) was reverse transcribed in cDNA using iScript 
cDNA Synthesis Kit (Bio-Rad). qPCR was performed using SYBR green chemistry 
(Bio-Rad) and PspC specific primers on a CFX-96 real-time PCR machine (Bio-Rad) 
(supplementary table 1). GyrA was used as reference gene. Quantification cycle 
(Cq) values and relative expression values were calculated using the CFX Manager 
software (Bio-Rad).
Statistics 
Differences between strains were analyzed using repeated measures ANOVA with 
Bonferroni corrections for multiple comparisons. Differences were considered 
statistically significant when P < 0.05.
Results
PspC subgroup I is most prevalent in invasive pneumococcal 
disease isolates 
Analysis of the 349 invasive disease strains demonstrated that PspC subgroup I 
was present in 298 isolates (85,4%) and in an additional 19 isolates (5,4%) that 
contained both subgroup I and subgroup II PspC. Only 22 of the isolates (6,3%) 
contained subgroup II and 10 isolates (2,9%) had no pspC (Table 1). Strains 
containing two pspC genes were mainly of serotypes 2, 6A, 6B, 19A and 19F. Strains 
containing subgroup II were mostly serotype 3 with sequence type (ST) 180 (18 out 
of 22). Within a serotype, we found large variations in PspC types, whereas some 
serotypes contained only a single PspC type. Most sequence types were associated 
with a specific PspC type, though also variation in PspC type within sequence types 
was observed (supplementary Table 2). We observed no association between PspC 
subgroups and disease outcome. 
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Table 1. PspC subgroup I is most prevalent in invasive pneumococcal disease isolates. The 
prevalence of various pspC subgroups was studied in 349 sequenced S. pneumoniae isolates from 
invasive pneumococcal disease (IPD) patients in Nijmegen, the Netherlands 34,35.
Number of isolates (n= 349) Percentage of total
PspC subgroup I
Choline binding domain
298 85.4
PspC subgroup II
LPXTG binding anchor 
22 6.3
PspC Subgroup I and II 19 5.4
No PspC 10 2.9
Capsular thickness and PspC-mediated factor H binding 
contributes to complement evasion
Capsular polysaccharide is known to inhibit complement opsonization 29. In 
addition, factor H binding by PspC is influenced by capsular serotype 1,2. We 
assessed the effect of pneumococcal capsule thickness on factor H binding to PspC. 
We compared factor H binding to wild-type and ΔpspC in thick encapsulated TIGR4 
(opaque phase), thin encapsulated TIGR4 (transparent phase), unencapsulated 
mutant TIGR4 (TIGR4 Δcps) and in unencapsulated R6. In all backgrounds, 
deletion of pspC resulted in significantly reduced factor H binding measured 
by flow cytometry following incubation in pooled human serum (Figure 1A,B), 
demonstrating that PspC is the main factor H binding protein. Factor H binding to 
transparent phase, unencapsulated TIGR4 or R6 was significantly higher compared 
to the opaque phase TIGR4.
We assessed the effect of pneumococcal capsule thickness and pspC expression on 
complement resistance by comparing C3 opsonization of TIGR4 wild-type and pspC 
deletion mutants in the opaque and transparent phase and of unencapsulated TIGR4 
and R6. Opaque TIGR4 showed significantly reduced C3 opsonization compared to 
the opaque TIGR4 ΔpspC mutant (Figure 1C). This demonstrates that for TIGR4 with 
a thick capsule, factor H binding contributes to complement evasion by reducing 
C3 opsonization. Transparent phase TIGR4 bacteria showed significantly enhanced 
C3 deposition compared to the TIGR4 opaque phase bacteria. Loss of pspC had no 
effect on C3 opsonization in TIGR4 transparent phase, as no significant difference 
in C3 deposition was measured between transparent TIGR4 wild-type and ΔpspC 
(Figure 1C). This indicated that factor H binding to PspC of TIGR4 with a thin 
capsule did not contribute to complement resistance. This was further confirmed 
with unencapsulated TIGR4 and the unencapsulated R6 strain, as loss of pspC did 
not enhance complement C3 deposition (Figure1D). R6ΔpspC even showed a 
slightly reduced C3 deposition compared to the wild-type R6.
Figure 1. The effect of factor H binding on complement deposition is dependent on capsule 
thickness. Factor H binding and C3 deposition on the surface of Streptococcus pneumoniae strain 
TIGR4 wild-type opaque/transparent phase, unencapsulated TIGR4 (Δcps) and unencapsulated R6 
and its pspC deletion mutants (pspC-) was measured. Factor H (FH) binding and C3 deposition were 
measured by flow cytometry following incubation of the bacteria for 30 min at 37 °C in 10% pooled 
human serum diluted in HBSS. Panel A and B represent the factor H binding and panel C and D the 
C3 deposition both in mean fluorescence intensity (MFI). Each bar represents the mean ± standard 
deviation for results obtained from three or four separate experiments. Comparisons between 
strains was performed using an ANOVA for repeated measurements with a Bonferroni correction 
for multiple comparisons. *P < .05, **P < .01, ***P < .001. Abbreviation: ns, not significant 
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PspC subgroup specific differences in factor H binding and 
complement resistance 
PspC types 2, 6, 9 and 11 were selected because PspC type 2 and 6 (subgroup 
I) have a choline binding domain and PspC type 9 and 11 (subgroup II) have an 
LPxTG binding anchor and these types are heterogeneous in their factor H binding 
region. The four pspC types were cloned into TIGR4 replacing the original pspC 
gene in order to study PspC type specific differences in complement evasion 
Figure 2. PspC subgroup specific differences affect factor H binding and complement resistance 
in encapsulated TIGR4 but not in unencapsulated R6. Factor H binding and C3 deposition on the 
surface of Streptococcus pneumonia TIGR4 ΔpspC (white bars) or TIGR4 containing pspC type 2 and 
6 of subgroup I (black bars) and PspC type 9 and 11 of subgroup II (gray bars). Factor H (FH) binding 
and C3 deposition were measured by flow cytometry following incubation of the bacteria for 30 
min at 37 °C in 10% pooled human serum diluted in HBSS. Panel A and B represent the factor H 
binding and panel C and D the C3 deposition both in mean fluorescence intensity (MFI). Each bar 
represents the mean ± standard deviation for results obtained from three separate experiments. 
Comparisons between pspC types were performed using an ANOVA for repeated measurements 
with a Bonferroni correction for multiple comparisons. *P < .05, **P < .01, ***P < .001. Abbreviation: 
ns, not significant 
within the same genetic background. We found significantly enhanced factor H 
binding to pneumococci expressing subgroup I PspC types (2 and 6), compared 
to subgroup II PspC types (9 and 11) in the TIGR4 genetic background (Figure 
2A). Consistently, factor H binding inversely correlated with C3 deposition on the 
bacterial surface, thus subgroup I PspC types 2 and 6 showed significantly reduced 
C3 deposition compared to subgroup II PspC types 9 and 11 in the encapsulated 
mutants (Figure 2C). This demonstrated that PspC-specific differences affected 
factor H binding and complement resistance in encapsulated pneumococcus. In 
an unencapsulated background, no difference in factor H binding between the 
various PspC types of subgroup I and II was found (Figure 2B). In addition, no 
difference in C3 opsonization was found between the subgroup I and subgroup 
II PspC types in the unencapsulated R6 strains (Figure 2D). qPCR confirmed that 
pspC expression levels of the 4 different PspC types within TIGR4 or R6 were equal 
(Supplementary figure 1). 
Discussion
In this study we found that subgroup I PspC types are more prevalent in IPD 
isolates than subgroup II PspC types. Expression of different PspC types in isogenic 
encapsulated pneumococci showed that subgroup I PspC types are more effective 
in complement evasion compared to subgroup II PspC types. In addition, we found 
that capsule thickness affects PspC-mediated complement evasion. Previous 
studies examining the role of PspC in complement evasion have been performed 
in encapsulated, opaque phase, strains 1,26. Different serotypes showed large 
variation in the effect on complement deposition upon loss of PspC, even though 
all serotypes were shown to bind factor H by PspC 26. In line with this, we found 
that pneumococcal factor H binding is mainly PspC dependent, although some 
residual factor H binding was observed. This may be explained by factor H binding 
to elongation factor Tu (Tuf ), which was recently found to bind human factor H 38. 
In this study, we demonstrate that absence of a capsule or transparent phase 
capsule within the same genetic background, voids the ability of factor H binding 
to reduce complement deposition. These findings are in line with previous studies 
demonstrating that transparent phase pneumococci as well as unencapsulated 
strains are more sensitive for complement deposition 2,29. This might be explained 
by the fact that transparent phase capsule or the absence of a capsule enhances 
antibody binding to subcapsular antigens and increased binding of complement 
mediators such as C-reactive protein, both known to activate the complement 
classical pathway 2,27. Enhanced classical pathway activation may minimize 
126 127
6
PspC-subgroup differences in contribution to complement evasion
the effect of alternative pathway inhibition by factor H binding on the overall 
complement deposition. This may explain why factor H binding had no effect on 
complement C3 deposition for the unencapsulated strains 2,29. 
The current study demonstrates that phase variation affects factor H binding and 
its role in complement evasion. Even though opaque phase TIGR4 bound less factor 
H as compared to the transparent phase TIGR4, the binding of factor H resulted in 
reduced complement deposition, suggesting that complement evasion by factor H 
binding is mainly of importance in the opaque phase. This is further supported by 
the observation that opaque phase variants are often found in invasive infections, 
in which pneumococcal complement evasion is vital for survival 27,29-31. Carriage 
isolates, however, are mostly transparent phase bacteria 28. We found increased 
factor H binding for transparent phase pneumococci, which is consistent with the 
observation by others that carriage isolates bind more factor H compared to systemic 
isolates 39. However, our findings indicate that factor H binding to transparent 
phase pneumococci does not reduce C3 deposition on the bacterial surface. 
During nasopharyngeal carriage, other functions of PspC have been indicated by 
previous reports showing its importance in adherence 16,17,20-23,40. In addition, our 
observation that PspC binding of factor H by unencapsulated strains had no effect 
on complement resistance may help to understand the loss of PspC in naturally 
occurring unencapsulated S. pneumoniae strains 41,42. Other genes in the naturally 
occurring unencapsulated strains, such as the PspC-like protein PspK, were shown to 
play a role in colonization and adherence, but does not bind factor H 43-45.
We demonstrate that genetic differences in pspC affect complement resistance. 
Previous studies found differences in pneumococcal factor H binding between 
clinical isolates 1. This could not, however, only be attributed to differences in pspC 
alone since also other factors such as the capsule type varied 1,21,26. In the current 
study, four PspC types selected from a cohort with IPD isolates were cloned into an 
isogenic background, isolating the effect of PspC type difference on factor H binding 
and complement resistance. Remarkably, in the absence of capsule, we found no 
differences in factor H binding between strains expressing the various PspC types, 
even though the sequence of the previously defined 121 amino acid long factor H 
binding region varied extensively 21. This indicates that all four PspC types have the 
same ability to bind factor H, but PspC in combination with the serotype 4 capsule 
resulted in differences in factor H binding. The length of the coding sequence varies 
between the PspC types, as pspC type 2 and 6 are 2082bp and 2046bp, respectively, 
whereas pspC group 9 and 11 are 1458bp and 1245bp, respectively. This differences 
in lengths may explain the observed differences in factor H binding in combination 
with capsule thickness. Some clinical isolates contain both PspC 6 and 9. Our 
findings demonstrate that both are able to bind factor H for unencapsulated strains, 
but in the presence of capsule, PspC type 6 binds more factor H and decreases C3 
deposition to the bacterial surface to a larger extent compared to PspC 9. 
Another important difference between the high and low factor H binding PspC 
types in our study is the PspC C-terminal domain, as PspC types 2 and 6 (subgroup 
I) have a choline binding domain and PspC types 9 and 11 (subgroup II) have a 
LPXTG binding anchor. Interestingly, the IPD isolates cohort described in this paper 
consists mainly of PspC types of subgroup I, whereas a much lower percentage of 
the PspC types belonging to subgroup II. Analysis of strain collections including 
carriage and invasive isolates from the same region and time period may help to 
further dissect the contribution of PspC subgroup and types to invasive disease 
potential. Additionally, more insight in epidemiological differences in PspC type 
prevalence and their contribution to invasive disease may have implications for 
vaccine design because PspC is an important vaccine candidate 46-48. Our study 
demonstrates PspC subgroup and type distribution in invasive disease, in analogy 
to serotype distribution in invasive disease. No comparative data from a large set 
of clinical invasive disease isolates has been published to date. Though, Iannelli et 
al demonstrated a predominance of subgroup I PspC (74%) in a collection of 43 
strains containing randomly chosen clinical isolates, standard laboratory strains and 
American Type culture Collection strains 33. 
A strength of our study is that we studied various PspC types in an isogenic 
background. Others have demonstrated that capsule type affect factor H binding 
to PspC and complement evasion in capsule switch mutants 1. Our findings are 
complementary to these data and demonstrate that genetic differences in pspC, 
using pspC-switch mutants, affects complement resistance in the presence of 
polysaccharide capsule. This is in line with a previous pediatric study in which 
genetic variation in pspC was suggested to explain differences in invasiveness 
within the same serotype and clonal complex 6. 
In conclusion, we found a higher prevalence of subgroup I PspC types compared 
to subgroup II PspC types in IPD isolates. Expression of different PspC types in 
isogenic encapsulated pneumococci showed that subgroup I PspC types are more 
effective in complement evasion compared to subgroup II PspC types. In addition, 
we show that capsule thickness affects PspC-mediated complement evasion. These 
findings indicate that PspC type-specific differences contribute to intra-serotype 
variation in complement resistance. 
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Supplementary table 1. Primers used to construct pneumococcal mutants. 
Strain or primer Relevant features or nucleotide sequence
(5’to 3’)a
Reference/ source or target 
geneb
PBCN0094 Serotype 4 34
PBCN0133 Serotype 6B 34
PBCN0031 Serotype 3 34
TIGR4 Serotype 4 49
R6 Unencapsulated 50
TIGR4Δcps Unencapsulated TIGR4 with kanamycin 51
TIGR4ΔpspC (spec) Serotype 4 This study
TIGR4ΔpspC (kan) Serotype 4 This study
TIGR4 pspC2 Serotype 4 This study
TIGR4 pspC6 Serotype 4 This study
TIGR4 pspC9 Serotype 4 This study
TIGR4 pspC11 Serotype 4 This study
R6 pspC2 Unencapsulated This study
R6 pspC6 Unencapsulated This study
R6 pspC9 Unencapsulated This study
R6 pspC11 Unencapsulated This study
Primers mutant 
construction
Spn2190_L1 TTG AGG CAA TGG TGC ACA AG TIGR4 pspC; left flank
EMspn2190_L2 CCACTAGTTCTAGAGCGGCTACACTAGCTACTCCAACAC TIGR4 pspC; left flank; overlap 
Specres cassette
EMspn2190_R1 CAAGATGAAGATCGCCTACG TIGR4 pspC; right flank
EMspn2190_R2a GCGTCAATTCGAGGGGTATCGCTATGGAGTCAATGCCAAT TIGR4 pspC; right flank; overlap 
Specres cassette 
EMspn2190_C TCG TTC TCT GTC GCA TGA AC TIGR4 pspC; control
PBMrTn9 CAATGGTTCAGATACGACGAC Specres cassette; control
PBpR412_L GCCGCTCTAGAACTAGTGG Specres cassette; pR412 plasmid
PBpR412_R GATACCCCTCGAATTGACGC Specres cassette; pR412 plasmid
HBKanF4 GGAATTCGATATCAAGCTTA Kanrescassette; pR410 plasmid
HBKanR AGGTACTAAAACAATTCATCC Kanrescassette; pR410 plasmid
HBKanR3 ATCCACATCGGCCAGATCGT Kanrescassette; control
EMspn2190_pspC_kan_L2 TAAGCTTGATATCGAATTCCTACACTAGCTACTCCAACAC TIGR4 pspC; left flank; overlap Kanres 
cassette
EMspn2190_pspC_kan_R2 GGATGAATTGTTTTAGTACCTGCTATGGAGTCAATGCCAAT TIGR4 pspC; right flank; overlap 
Kanres cassette
EM_pspC_2_3_L2 new CTTTCGCTTTTTGATGCAAACATGTTTATTTCCTTCTATATTT TIGR4; left flank; overlap pspC 
PBCN0094 
EM_pspC_6_11_L2 CTTTCGTTTTTTGATGCAAACATGTTTATTTCCTTCTATATTT TIGR4; left flank; overlap pspC 
PBCN000133 & PBCN0031
EM_pspC_9_L2 CGCTCATGATTTGATTTAAACATGTTTATTTCCTTCTATATTT TIGR4; left flank; overlap pspC 
PBCN0133
EM_pspC_2_3_Fw ATGTTTGCATCAAAAAGCGAAAG PBCN0094 pspC; forward 
EM_pspC_6_11_Fw ATGTTTGCATCAAAAAACGAAAG PBCN0133 & PBCN0031
pspC; forward
EM_pspC_9_Fw ATGTTTAAATCAAATCATGAGCG PBCN0133 pspC; forward
EM_pspC_2_3_6_R2_spec CAATGGTGAATGGGTAAACTAAGCCGCTCTAGAACTAGTGG TIGR4; right flank; overlap 
PBCN0094 & PBCN0133
EM_pspC_9_11_R2_spec CTTGCTAAGAAAAGAATGAAATAGGCCGCTCTAGAACTAGTGG TIGR4; right flank; overlap 
PBCN0133 & PBCN0031
EM_pspC_2_3_6_Rev TTAGTTTACCCATTCACCATTG PBCN0094 & PBCN0133 pspC; reverse
EM_pspC_9_11_Rev CTATTTCATTCTTTTCTTAGCAAG PBCN0133 & PBCN0031; pspC 
reverse
EM_pspC_2_Crev GGTACTTGGGTAGCTCCCTC pspC2; control
EM_pspC_3_9_Crev CTGCTTGGGTACTTCCCTC pspC6; control
EM_pspC_6_Crev CGTGGAGTTATTCCCAATTCT pspC9; control
EM_pspC_11_Crev GCTACTTGGGTAGTTACCTC pspC11; control
Mutant validation by qPCR
Q-pspC-V2-F CAGGCAGAACAAGGAGAACA pspC2; forward
Q-pspC-V2-R GCATAGCTCTCACCCACTATTT pspC2; reverse
Q-pspC-V6-F ACCGTAACTACCCAACCAATAC pspC6; forward
Q-pspC-V6-R CGAGATTCCTTAGCTTCCTCTTT pspC6; reverse
Q-pspC-V9-F TGGAAGTCAGGCAGAACAAC pspC9; forward
Q-pspC-V9-R GCATAGCTCTCACCCACTATTT pspC9; reverse
Q-pspC-V11-F TGGTTCATGCGACAGAGAAG pspC11; forward
Q-pspC-V11-R CATCGACTTGTTTAGCAGCTTTC pspC11; reverse
Q-Sp-gyrA-F AATGAACGGGAACCCTTGGT gyrA; forward
Q-Sp-gyrA-R CCATCCCAACCGCGATAC gyrA; reverse
a  Underlined sequences are complementary to primers used for amplification of antibiotic resistant 
cassette or the selected pspC variant.
b Left flank and right flank indicate positions relative to the target gene.
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Supplementary Table 2. 
Serotype Sequence type Number of isolates pspC number in genome best hit
1 9 1 1 Variant_4
1 304 5 1 Variant_2
1 306 27 1 Variant_2
1 350 1 1 Variant_2
3 180 4 0
3 180 18 1 Variant_8
3 260 1 1 Variant_3
3 505 1 1 Variant_10
3 1220 3 1 Variant_3
3 6014 1 1 Variant_11
3 207 1 2 Variant_10 and variant_3
3 1377 1 2 Variant_3 and variant_9
4 162 1 1 Variant_3
4 205 12 1 Variant_2
4 206 1 1 Variant_2
4 246 3 1 Variant_2
4 247 9 1 Variant_2
5 289 2 0
5 289 2 1 Variant_3
8 53 3 1 Variant_6
8 53 34 1 Variant_3
8 944 1 1 Variant_3
13 70 1 1 Variant_3
13 923 1 1 Variant_3
14 9 1 0
14 124 1 0
14 9 11 1 Variant_4
14 124 18 1 Variant_4
14 409 1 1 Variant_3
20 235 1 1 Variant_3
27 1475 1 1 Variant_3
27 4676 1 1 Variant_3
34 478 1 1 Variant_5
999 113 1 1 Variant_3
999 162 1 1 Variant_3
11A/D 62 1 1 Variant_3
12A/F 218 2 1 Variant_3
12A/F 989 1 1 Variant_3
15A 58 2 1 Variant_3
15B/C 1262 1 0
15B/C 199 1 1 Variant_5
15B/C 3976 1 1 Variant_1
16F 3450 1 0
18C 113 6 1 Variant_3
18C NA 1 1 Variant_3
19A 66 1 1 Variant_3
19A 199 2 1 Variant_3
19A 230 1 1 Variant_5
19A 416 1 1 Variant_3
19A 667 1 1 Variant_3
19A 1201 1 1 Variant_3
19A 1848 1 1 Variant_4
19A 3017 3 1 Variant_3
19A 994 1 2 Variant_3 and variant_9
19A 3009 1 2 Variant_9 and variant_3
19F 51 1 1 Variant_9
19F 79 1 1 Variant_3
19F 162 1 1 Variant_3
19F 179 1 1 Variant_3
19F 230 1 1 Variant_5
19F 309 3 1 Variant_3
19F NA 1 1 Variant_6
19F 51 1 2 Variant_9 and variant_3
19F 1045 1 2 Variant_3 and variant_9
19F 5827 1 2 Variant_10 and variant_4
22A/F 433 12 1 Variant_4
22A/F 3705 2 1 Variant_5
22A/F 4110 1 1 Variant_4
23A 42 3 1 Variant_3
23A 97 1 1 Variant_5
23B 439 1 1 Variant_5
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23B 1602 1 1 Variant_3
23F 36 7 1 Variant_6
23F 37 1 1 Variant_5
23F 60 1 1 Variant_5
23F 311 3 1 Variant_5
23F 1011 2 1 Variant_3
23F 1011 1 1 Variant_6
24A/B/F 53 1 1 Variant_3
24A/B/F 230 1 1 Variant_5
33A/F 60 2 1 Variant_5
33A/F 673 2 1 Variant_3
33A/F 2705 1 1 Variant_3
35B 162 1 1 Variant_3
35B 309 1 1 Variant_3
35B 446 1 1 Variant_5
35B 1635 2 1 Variant_5
6A 53 1 1 Variant_3
6A 138 1 1 Variant_3
6A 329 1 1 Variant_1
6A 690 1 1 Variant_3
6A NA 1 1 Variant_3
6A 207 2 2 Variant_3 and variant_10
6A 327 1 2 Variant_7 and variant_5
6A 490 1 2 Variant_3 and variant_9
6A NA 1 2 Variant_3 and variant_5
6B 176 1 1 Variant_3
6B 176 2 1 Variant_6
6B 176 7 2 Variant_6 and variant 9
6C 1379 2 1 Variant_4
7F 191 36 1 Variant_3
7F 1589 2 1 Variant_3
7F 2331 2 1 Variant_3
7F NA 1 1 Variant_2
9N 66 4 1 Variant_3
9V 53 1 1 Variant_3
9V 60 1 1 Variant_5
9V 162 14 1 Variant_3
9V 162 1 1 Variant_7
9V 165 1 1 Variant_3
9V 8038 1 1 Variant_3
9V 8138 1 1 Variant_3
9V 43 1 2 Variant_9 and variant_3
Supplementary figure 1; Real-time RT-PCR using pspC specific primers with a similar binding 
efficiency and GyrA as reference gene. Level of expression is shown as normalized expression ΔΔCq 
– relative quantity normalized to relative quantity of the reference gene. 
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The human pathogen, Streptococcus pneumoniae (pneumococcus), is an important 
contributor to morbidity and mortality worldwide 1,2. This encapsulated Gram-
positive bacterium causes diseases ranging from mild respiratory tract infections 
to pneumonia, sepsis and meningitis, also referred to as invasive pneumococcal 
disease (IPD). The complement system plays an important role in controlling 
infections, including those by S. pneumoniae. This has become evident in humans 
with complement deficiencies and in experiments with complement deficient 
animals. Interestingly, more subtle differences in complement activity by common 
genetic polymorphisms may affect an individual’s susceptibility for infections. 
Complement factor H is a key regulator of the alternative pathway. In a large 
genome-wide association study (GWAS) polymorphisms in the complement factor 
H gene (CFH) region were identified, which were associated with susceptibility for 
meningococcal infection 3. This suggests that polymorphisms in the CFH region 
affect an individual’s susceptibility for infections. In addition, factor H levels, 
measured in blood, vary greatly within the human population 4-8. This thesis aims 
to enhance our understanding of the biological role of complement factor H in 
pneumococcal-host interactions. 
The effect of alternative pathway activity regulated by factor 
H on pneumococcal induced inflammatory responses
Several studies indicate that crosstalk occurs between the complement system, 
Toll-like receptors (TLRs) and Fcγ receptors, leading to modulation of the immune 
response towards a proinflammatory state 9-14. Complement activation product 
C5a binding to its receptor (C5aR) (also called CD88), modulates the inflammatory 
response induced by various pathogens, including Escherichia coli, Staphylococcus 
aureus, Neisseria meningitidis and Candida albicans 12,15-17. The alternative pathway 
amplification loop plays a crucial role in the amplification of the initial activation 
of the classical and lectin pathway. It may account for up to 80% of the total 
complement activation, even if initially triggered by the classical pathway 18,19. 
In chapter 2, we demonstrate that the alternative pathway, modulated by factor 
H levels, plays an important role in pneumococcal induction of proinflammatory 
cytokine responses in human peripheral blood mononuclear cells (PBMCs). 
Inhibition of the alternative pathway by factor H concentrations in the high 
physiological range strongly reduce C5a levels and decrease proinflammatory 
cytokine production by human PBMCs. This suggests that inter-individual variation 
in alternative pathway activity due to variation in factor H plasma levels affects the 
level of cytokine production during infection. The alternative pathway activity is 
determined by a delicate balance between activation and inhibition. The extent 
of this balance is determined by an inherited set of common genetic variants of 
alternative pathway components and regulatory proteins. This can be referred to as 
the complotype 20,21. The complement activity is an important determinant for the 
risk of inflammatory diseases, such as age-related macular degeneration (AMD), 
dense deposit disease (DDD) and atypical haemolytic uremic syndrome (aHus)20. 
In line with this, we demonstrated that modulation of the alternative pathway 
activity affects the extent of inflammatory responses induced by pneumococci. 
Overall this indicates the important role of the alternative pathway activity in 
human inflammatory responses. 
In Chapter 4 we show that higher serum factor H levels in mice are not only 
associated with greater pathogen burden, but also with increased levels of 
proinflammatory cytokines. Unexpectedly, we also found that decreased factor H 
levels resulted in a lower pathogen burden, which was associated with lower levels 
of proinflammatory cytokines. These experiments indicate that variation in factor 
H levels may affect the outcome of bacterial infections. The effect of the alternative 
pathway activity on the magnitude of the inflammatory response is hard to predict 
during natural infection in patients. Reduced alternative pathway activity by higher 
factor H levels may reduce cytokine induction, whereas it may also inhibit bacterial 
clearance and allow greater outgrowth of the bacteria resulting in a stronger 
inflammatory response. Despite the important role of complement activation to 
prevent disease, excessive complement activation may damage host cells and 
increase disease severity. Several studies suggest that complement inhibition may 
be beneficial, especially during bacteraemia, irrespective of the potential danger 
to impair the host defence response against invading pathogens 17,22-24. 
In chapter 3 we examined whether exogenous factor H, at the onset of symptoms, 
can attenuate inflammation and vascular leakage in experimental pneumococcal 
sepsis in mice. Factor H treatment was combined with administration of antibiotics 
to avoid differences in bacterial numbers and to mimic the clinical situation in which 
severely ill patients receive antibiotics immediately upon hospital admission. Our 
data show that inhibition of the alternative complement pathway by exogenous 
human factor H at a clinical relevant time point, at the first onset of symptoms, fails 
to attenuate inflammation and vascular leakage in a pneumococcal sepsis model 
in mice. Recently, the potential efficacy of blocking C5a or its receptors to improve 
outcome in experimental sepsis models was demonstrated. Blocking C5a or its 
receptors preserved neutrophil function resulting in lower bacterial loads and less 
severe disease 22,25,26. In cecal ligation and puncture-induced sepsis models in rats, 
it was shown that blocking of C5a was even beneficial when initiated after the 
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onset of symptoms of sepsis 27. Based on these results, it may be more effective 
to directly block the complement effector molecule C5a, instead of blocking the 
complete complement pathway.
Chapter 4, together with other studies, demonstrates the important role of the 
alternative pathway activation in pneumococcal opsonisation and clearance 28. 
Stimulation of the alternative pathway activity may be an effective therapy to 
enhance clearance of invasive infections and thereby reduce the severity of sepsis. 
Mice injected with recombinant properdin, a positive regulator of the alternative 
pathway, show an increased alternative pathway-mediated pneumococcal C3 
opsonization and enhanced pneumococcal killing 28. Administration of properdin 
may enhance microbial clearance, although, it has thus far not been assessed 
whether properdin treatment affects the host inflammatory response or whether 
it has an additive effect in combination with antibiotic treatment in sepsis. The 
development of therapies involving factor H may be more challenging, since we 
demonstrate in chapter 4 a delicate balance in which higher or lower factor H 
levels may both impair pneumococcal clearance.
Role of factor H levels in pneumococcal complement 
mediated phagocytosis
Mouse model
The role of the complement system and the different complement activation 
routes in infections by S. pneumoniae have been studied in animal models. Several 
studies demonstrate that deficiency or depletion of the central complement 
component C3 severely impairs pneumococcal clearance 29-33. The importance of 
the classical as well as the lectin pathway activity has been illustrated in mouse 
models of pneumococcal invasive disease 29,34,35. It appears that both pathways 
are important to initiate complement activation, whereas the alternative pathway 
determines the final amount of C3 deposition on the bacterial surface 29,36. Serum 
of factor B deficient mice with an abrogated alternative pathway activity showed 
a lower intensity of pneumococcal C3 deposition compared to classical or lectin 
pathway deficient mice serum 29. 
In chapter 4, we studied the function of the alternative pathway activity regulated 
by factor H on pneumococcal clearance. Absence of factor H in homozygous factor 
H deficient humans or mice leads to immediate uncontrolled alternative pathway 
activation and subsequent consumption of fluid-phase C3 37,38. It was previously 
shown that 8 month old mice with a homozygous factor H deficiency develop 
a kidney disease, named membranoproliferative glomerulonephritis, and renal 
injury 37. We found that pneumococcal clearance in homozygous factor H deficient 
mice is impaired. This is in agreement with other reports studying complement 
deficient mice 29-33. Inhibition of the alternative pathway by exogenous human 
factor H administered to wild-type mice also impaired pneumococcal clearance. 
This is due to a reduction in pneumococcal C3 opsonization. More surprisingly, 
we found that reduced factor H levels in heterozygous factor H deficient mice, 
enhanced pneumococcal C3 opsonization and clearance from blood in comparison 
to wild-type mice. In vitro experiments demonstrated that pneumococcal C3 
opsonization was enhanced as a result of increased alternative pathway activity 
in serum of heterozygous factor H deficient mice. Others demonstrated that the 
increased alternative pathway activity in heterozygous factor H deficient mice 
results in age-related macular degeneration-like pathology 39. This suggests that 
reduced factor H levels in mice can be beneficial during infection, but may increase 
the susceptibility for complement-mediated inflammatory diseases. 
Similar to other pathogens, S. pneumoniae binds factor H as a complement evasion 
strategy, it specifically binds to human factor H, but not mouse factor H 40-42. 
Therefore, the mouse model allowed us to assess the influence of mouse factor 
H expression levels on the fluid-phase control of the alternative pathway activity 
and pneumococcal clearance. However, the role of pneumococcal factor H binding 
to PspC in humans cannot be elucidated using the mice model. A possible way to 
circumvent this problem is to use a transgenic mice expressing human factor H. In 
addition, the use of human in vitro assays using human serum or blood may provide 
important insights into the role of factor H in pneumococcal host interactions. 
Human in vitro model
Complement factor H levels vary markedly between humans 4-8. Factor H levels 
measured in 1514 individuals varied between 63.5 μg/mL to 847.6 μg/mL (median 
226.6 µg/mL) 7. Not much is known whether this variation affects the host resistance 
to pneumococcal infections. 
In chapter 4, we demonstrate that human and mice factor H levels determine a 
delicate balance of alternative pathway activity affecting the resistance to invasive 
pneumococcal disease. To gain more insight into how human factor H levels affect 
pneumococcal C3 opsonization and clearance we performed in vitro experiments 
using factor H depleted serum reconstituted with various factor H concentrations. 
We found that human factor H levels of 300 µg/mL in serum results in optimal 
pneumococcal C3 opsonization and clearance, whereas 100 µg/mL or 500 µg/mL 
resulted in significantly lower opsonization. This clearly indicates that effective 
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pneumococcal opsonization depends on a delicate balance of complement factors. 
In order to study whether factor H levels in human serum affect pneumococcal 
clearance, we used a pneumococcal whole blood killing assay (chapter 5). 
In this whole blood model, we replaced plasma by factor H depleted serum 
reconstituted with various factor H concentrations. In accordance with the 
pneumococcal C3 opsonisation results, we found optimal pneumococcal 
clearance at a factor H concentration of 300 µg/mL, whereas lower or higher factor 
H levels reduced pneumococcal clearance (chapter 4). This result suggests that 
when pneumococci enter the bloodstream, human factor H levels are of major 
importance for optimal pneumococcal clearance and thus affect the individual’s 
susceptibility to invasive pneumococcal disease and severity of infection. Figure 1 
shows in a simplified model how factor H levels affect resistance to pneumococcal 
infection.
It has been found that factor H levels in blood are determined by both environmental 
and genetic factors, in which the genetic factors are most dominant 6.  In the same 
study, factor H levels were found to increase with age and to be lower in smokers 6. 
In addition, factor H serum levels may vary depending on the disease state of an 
individual. Reduced factor H levels were observed during acute meningococcal 
disease compared to those at convalescence 4. It has been suggested that human 
factor H levels play a role in the susceptibility for meningococcal disease. A 
functional single-nucleotide-polymophism (SNP) has been found in a presumed 
nuclear-factor –kB responsive element (NF-kB) in the CFH gene, which was 
associated with the susceptibility for meningococcal disease (C-496T) 4. It was 
shown that individuals with the CFH C-496T C/C genotype are more likely to have 
increased serum factor H levels, which was associated with a reduced bactericidal 
activity against N. meningitidis 4. This is in agreement with our findings in which 
high factor H levels reduce pneumococcal clearance (Chapter 4). In addition, a 
large GWAS for meningococcal disease identified SNPs in CFH and factor H related 
3 (CFHR3) associated with increased susceptibility for meningococcal disease 3. 
Additional GWAS studies are needed to determine whether polymorphisms in the 
CFH gene are associated with other infectious diseases, such as pneumococcal 
invasive disease. This is one of the objectives of the European childhood life-
threatening infectious diseases study (EUCLIDS), in which our group participated 43. 
Several studies report that genetic variation not only in CFH, but also in the factor 
H related genes (CFHR1-5) are associated with disease susceptibility 44-48. Factor 
H related genes 1-5 contain surface recognition sites similar to factor H, whereas 
none of the factor H related proteins contains the complement regulatory domains 
of factor H 49. It has been suggested that the factor H related proteins modulate 
complement activation by competing with factor H for binding to ligands, 
including the bacterial surface 50. However the concentration of factor H related 
proteins seems to be much lower than previously expected 51. For instance, the 
molar concentration of FHR-3 is on average more than 100-fold lower compared 
to the factor H concentration in serum 51. This makes it unlikely that ligand binding 
competition plays an important role. More research is needed to elucidate the 
proposed competition. In addition, we suggest to analyze how common or rare 
polymorphisms, may affect the expression and function of factor H and the factor 
H related proteins.
The strength of our study described in chapter 4 is that we varied the human 
factor H concentration while keeping all other serum components, such as levels 
of opsonizing antibodies and other complement components, identical. This 
demonstrates that variation in factor H levels alone has a significant effect on 
pneumococcal clearance in blood. Nevertheless, it is important to answer the 
question whether factor H levels or the alternative pathway activity within the 
human population are associated with susceptibility for infections. In order to do 
so, factor H levels need to be determined in a large group of convalescence patients 
and controls. The presence of specific antibodies with high classical pathway 
activation may compensate for a reduction in alternative pathway activation. 
In addition, many genetic factors contribute to an individual’s complement 
activity. This inherited set of polymorphisms in complement genes is named the 
complotype 20,21. Certain combinations of polymorphisms in alternative pathway 
proteins enhance alternative pathway activity and predispose individuals for 
chronic inflammatory diseases, such as haemolytic uremic syndrome, age-related 
macular degeneration and dense deposit disease 20. On the other hand, it has been 
proposed that the increased alternative pathway activity may reduce the risk for 
infectious diseases 20. This hypothesis is supported by our findings, showing that 
increased alternative pathway activity by a reduction in factor H levels enhances 
pneumococcal clearance. Genetic analysis or measurement of complement levels 
and polymorphic variants at the protein level can provide relevant data about 
an individual’s complotype or complement activity. Genome-wide association 
studies and additional in vitro and in vivo studies are of importance to increase 
the understanding on how an individual’s complement activity affects the 
susceptibility to infectious diseases. Our study, together with previous studies, 
demonstrates the importance of alternative pathway activity in the defence 
against invading pathogens 28.
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Figure 1. Schematic model summarizing how complement factor H levels affect the alternative 
pathway activity and the risk for pneumococcal infection. 
Pneumococcal complement evasion by factor H binding
The pneumococcal polysaccharide capsule affects complement resistance and 
protects against phagocytic killing 52,53. Epidemiological studies showed that 
particular capsular serotypes are dominant in invasive disease whereas others 
are associated with nasopharyngeal carriage 54,55. Pneumococcal resistance to 
complement deposition is an important determinant of its invasive disease 
potential 55. In addition to the capsule, S. pneumoniae has evolved other mechanisms 
to evade complement activation. The pneumococcal surface protein PspC binds 
the alternative complement pathway inhibitor factor H and thereby reduces C3 
deposition. PspC is heterogeneous and has been classified into different PspC 
types based on sequence similarity. In chapter 6 we report that variation in PspC 
type, independent of capsule serotypes, affects the pneumococcal ability to evade 
complement deposition. Others have demonstrated that the capsule type affects 
factor H binding to PspC and complement evasion in capsule switch mutants 
52. Our findings are complementary to these data and demonstrate that genetic 
differences in pspC, using pspC-switch mutants, affect complement resistance in 
the presence of polysaccharide capsule. We demonstrate that PspC types with a 
choline binding domain (subgroup I) are more effective in complement evasion 
than PspC types with a LPxTG binding anchor (subgroup II). These findings 
indicate that PspC type specific differences contribute to intra-serotype variation 
in complement resistance. This is in line with a previous study in which genetic 
variation in pspC was suggested to explain differences in invasiveness within the 
same serotype and clonal complex 56. 
Pneumococcal phase variation is an important strategy to adapt to the different 
local environments during the course of disease pathogenesis 57,58. Consistent 
with previous studies, binding of factor H to opaque phase TIGR4 resulted in 
reduced complement deposition 52,59. The potential role for PspC in complement 
evasion in opaque phase bacteria is supported by the observation that opaque 
phase variants are often found in invasive infections, in which pneumococcal 
complement evasion is vital for survival 57,60-62. Carriage isolates from the upper 
respiratory tract, where complement levels are lower than in serum, are mostly 
transparent phase bacteria 63-65. Due to a thinner capsule, these bacteria may be 
more effective in adherence to human lung epithelial cells 58, which is an essential 
first step in colonization of the human host.
In chapter 6 we demonstrate that absence of a capsule or transparent phase 
capsule within the same genetic background, voids the ability of factor H binding 
to reduce complement deposition. Other studies demonstrated that transparent 
phase pneumococci as well as unencapsulated strains are more sensitive for 
complement deposition 53,60. A thinner capsule may unmask transmembrane 
protein epitopes recognized by immunoglobulins and reveal surface moieties 
recognized by lectin pathway factors. The enhanced classical and lectin pathway 
activation may minimize the effect of alternative pathway inhibition by factor H 
binding on the overall complement deposition 53,61. In addition, in the absence of 
capsule, we found no differences in factor H binding between strains expressing 
the different PspC types, even though the sequence of the previously defined 121 
amino acid long factor H binding region varied extensively 66. This indicates that all 
four selected PspC types have factor H binding sites with similar abilities to bind 
factor H. Differences in factor H binding between the various PspC types was only 
observed in the presence of a capsule. 
Interestingly, naturally occurring unencapsulated S. pneumoniae strains do not 
have PspC. Additional proteins in the naturally occurring unencapsulated strains, 
such as the PspC-like protein PspK, were shown to play a role in colonization and 
adherence, but do not bind factor H 67 68. Our observation in chapter 6 shows that 
PspC binding of factor H by unencapsulated strains has no effect on complement 
resistance. This may explain the loss of PspC in naturally occurring unencapsulated 
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S. pneumoniae strains 67,69. In addition, it is also not known what determines the 
selection for certain PspC types in encapsulated strains. PspC binding of factor 
H contributes to complement evasion and selection may be based on optimal 
pneumococcal factor H binding in combination with its capsule to reduce C3 
deposition. However, increased resistance to complement has been associated 
with a higher invasive disease potential 55. The evolutionary advantage of a high 
invasive disease potential is not directly obvious for S. pneumoniae, since invasive 
disease may not promote pneumococcal transmission or colonization. It therefore 
makes no obvious sense to evolve PspC-mediated complement evasion to enhance 
invasive disease potential. It has been postulated that resistance to complement 
is needed for local invasion of mucosal tissues and long term colonization 64. Local 
invasion may be an intermediate step between surface colonization and systemic 
invasion. This may explain the selection for more complement resistant strains. 
Besides complement evasion PspC has other functions. For instance, PspC acts 
as an adhesion molecule by interacting with the secretory component of human 
IgA and the epithelial polymeric immunoglobulin receptor (pIgR) thus facilitating 
invasion of the mucosa 66,70-74. Interaction of PspC and vitronectin plays a role in 
pneumococcal adherence as well as in complement evasion by inhibiting the 
deposition of the terminal complement complex 75. In addition, PspC binding of 
factor H facilitates adherence to epithelial cells 66,76. Markedly, increased human 
nasal factor H levels by presence of a virus have been associated with increased 
pneumococcal colonization density in the upper airway 65. PspC binding of factor 
H thereby contributes to pneumococcal colonization, supporting the relevance 
of pneumococcal factor H binding in carriage isolates. Overall this demonstrates 
that PspC binding of factor H contributes to complement evasion as well as 
facilitates pneumococcal adherence. Not much is known about the prevalence of 
the different PspC types in carriage or invasive pneumococcal disease isolates.
 
In chapter 6 we show a higher prevalence of PspC types with a choline binding 
domain (subgroup I) compared to PspC types with a LPxTG binding anchor (subgroup 
II) within an invasive pneumococcal disease cohort. To date, no comparative 
data from clinical invasive disease isolates have been published. Iannelli et al. 
demonstrated a predominance of subgroup I PspC (74%) in a collection of 43 
strains containing randomly chosen clinical isolates, standard laboratory strains 
and American Type culture Collection strains 77. It would be interesting to analyze 
strain collections including carriage and invasive isolates from the same region 
and time period to further dissect the contribution of PspC subgroup and types 
to the invasive disease potential. Particular PspC types may more often be found 
in invasive disease compared to other PspC types. More insight in epidemiological 
differences in PspC type prevalence and their contribution to invasive disease 
may have implications for vaccine design because PspC is an important vaccine 
candidate 78-80. Importantly, in vivo PspC binding of factor H has been proposed to 
mask antibody binding epitopes, which could facilitate pneumococcal infection 65. 
Mutations eliminating PspC binding of factor H allow antibody generation against 
the PspC factor H binding region which may be a strategy to enhance protective 
antibody responses to vaccination 65,81. In addition, various studies examined the 
use of factor H fragments fused to Fc as anti-microbial immune therapy 82-85. For 
this purpose, factor H fragments are needed that specifically bind bacteria with 
a greater avidity than the physiological factor H. This shows how knowledge on 
pneumococcal factor H binding can be used to develop therapies to facilitate 
microbial clearance. We contributed by showing PspC types specific differences in 
pneumococcal factor H binding and complement evasion. 
Final conclusions
The complement system is an essential part of the innate immune system, 
with decisive roles in protection against infection and inflammatory responses. 
Imbalance between activation and inhibition due to excessive activation or 
improper regulation has pathological consequences. Complement factor H is a key 
regulator of the alternative pathway. The primary aim of this thesis was to clarify 
the role of complement factor H in pneumococcal-host interactions. Based on the 
studies described in this thesis, we concluded the following:
1.  Inhibition of the alternative pathway by factor H strongly reduces proin-
flammatory cytokine production by human peripheral blood mononuclear 
cells. This finding suggests that inter individual variation in alternative pathway 
activity due to variation in factor H plasma levels affects individual cytokine 
responses during pneumococcal infection.
2.  Inhibition of the alternative complement pathway by exogenous human factor 
H fails to attenuate inflammation and vascular leakage at a clinically relevant 
intervention time point in pneumococcal sepsis in mice.
3.  Factor H levels determine the delicate balance of alternative pathway activity. 
The level of serum factor H affects complement deposition, and correlates with 
pneumococcal opsonophagocytic killing. This suggests that variation in factor 
H expression levels, naturally occurring in the human population, plays a thus 
far unrecognized role in the resistance to invasive pneumococcal disease. 
4.  Choline bound subgroup I PspC types showed a greater prevalence than LPxTG 
anchored subgroup II PspC types in invasive pneumococcal disease isolates. 
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Pneumococcal subgroup I PspC types bind significantly more factor H and 
showed more effective complement evasion compared to subgroup II PspC 
types in isogenic encapsulated pneumococci. This demonstrates that variation 
in PspC type, independent of capsule serotypes, affects pneumococcal factor H 
binding and its ability to evade complement deposition.
Overall, a better understanding of host factors that influence susceptibility to 
infection would support prediction of disease outcome and could also contribute 
to the development of therapies to reduce disease susceptibility. In addition, 
more insight in epidemiological differences in PspC type prevalence and their 
contribution to invasive disease may have implications for protein-based 
pneumococcal vaccine design.
152 153
7
General discussion
References
1 O’Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger 
than 5 years: global estimates. Lancet 374, 893-902, doi:10.1016/s0140-6736(09)61204-6 (2009).
2 Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Releve 
epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations = 
Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 82, 93-
104 (2007).
3 Davila, S. et al. Genome-wide association study identifies variants in the CFH region associated 
with host susceptibility to meningococcal disease. Nature genetics 42, 772-776, doi:10.1038/
ng.640 (2010).
4 Haralambous, E. et al. Factor H, a regulator of complement activity, is a major determinant 
of meningococcal disease susceptibility in UK Caucasian patients. Scandinavian journal of 
infectious diseases 38, 764-771, doi:10.1080/00365540600643203 (2006).
5 Julian, B. A., Wyatt, R. J., McMorrow, R. G. & Galla, J. H. Serum complement proteins in IgA 
nephropathy. Clinical nephrology 20, 251-258 (1983).
6 Esparza-Gordillo, J. et al. Genetic and environmental factors influencing the human factor H 
plasma levels. Immunogenetics 56, 77-82, doi:10.1007/s00251-004-0660-7 (2004).
7 Sofat, R. et al. Distribution and determinants of circulating complement factor H concentration 
determined by a high-throughput immunonephelometric assay. Journal of immunological 
methods 390, 63-73, doi:10.1016/j.jim.2013.01.009 (2013).
8 Silva, A. S. et al. Plasma levels of complement proteins from the alternative pathway in patients 
with age-related macular degeneration are independent of Complement Factor H Tyr(4)(0)(2)
His polymorphism. Molecular vision 18, 2288-2299 (2012).
9 Hajishengallis, G. & Lambris, J. D. Crosstalk pathways between Toll-like receptors and the 
complement system. Trends in immunology 31, 154-163, doi:10.1016/j.it.2010.01.002 (2010).
10 Lappegard, K. T. et al. Human genetic deficiencies reveal the roles of complement in the 
inflammatory network: lessons from nature. Proceedings of the National Academy of Sciences of 
the United States of America 106, 15861-15866, doi:10.1073/pnas.0903613106 (2009).
11 Wang, M. et al. Microbial hijacking of complement-toll-like receptor crosstalk. Science signaling 
3, ra11, doi:10.1126/scisignal.2000697 (2010).
12 Cheng, S. C. et al. Complement plays a central role in Candida albicans-induced cytokine 
production by human PBMCs. European journal of immunology 42, 993-1004, doi:10.1002/
eji.201142057 (2012).
13 Cavaillon, J. M., Fitting, C. & Haeffner-Cavaillon, N. Recombinant C5a enhances interleukin 1 and 
tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. 
European journal of immunology 20, 253-257, doi:10.1002/eji.1830200204 (1990).
14 Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement 
in vivo. Blood 110, 228-236, doi:10.1182/blood-2006-12-063636 (2007).
15 Brekke, O. L. et al. Combined inhibition of complement and CD14 abolish E. coli-induced 
cytokine-, chemokine- and growth factor-synthesis in human whole blood. Molecular 
immunology 45, 3804-3813, doi:10.1016/j.molimm.2008.05.017 (2008).
16 Skjeflo, E. W., Christiansen, D., Espevik, T., Nielsen, E. W. & Mollnes, T. E. Combined inhibition 
of complement and CD14 efficiently attenuated the inflammatory response induced by 
Staphylococcus aureus in a human whole blood model. Journal of immunology (Baltimore, Md. : 
1950) 192, 2857-2864, doi:10.4049/jimmunol.1300755 (2014).
17 Sprong, T. et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated 
bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102, 3702-
3710, doi:10.1182/blood-2003-03-0703 (2003).
18 Harboe, M., Ulvund, G., Vien, L., Fung, M. & Mollnes, T. E. The quantitative role of alternative 
pathway amplification in classical pathway induced terminal complement activation. Clinical 
and experimental immunology 138, 439-446, doi:10.1111/j.1365-2249.2004.02627.x (2004).
19 Harboe, M. & Mollnes, T. E. The alternative complement pathway revisited. Journal of cellular 
and molecular medicine 12, 1074-1084, doi:10.1111/j.1582-4934.2008.00350.x (2008).
20 Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. & Morgan, B. P. The complotype: dictating risk 
for inflammation and infection. Trends in immunology 33, 513-521, doi:10.1016/j.it.2012.06.001 
(2012).
21 Heurich, M. et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine 
systemic complement activity and disease risk. Proceedings of the National Academy of Sciences 
of the United States of America 108, 8761-8766, doi:10.1073/pnas.1019338108 (2011).
22 Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature medicine 14, 551-557, 
doi:10.1038/nm1753 (2008).
23 Riedemann, N. C. et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils 
during sepsis. FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 18, 370-372, doi:10.1096/fj.03-0708fje (2004).
24 Silasi-Mansat, R. et al. Complement inhibition decreases the procoagulant response and 
confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002-1010, 
doi:10.1182/blood-2010-02-269746 (2010).
25 Flierl, M. A. et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary 
cells during experimental sepsis. PloS one 3, e2560, doi:10.1371/journal.pone.0002560 (2008).
26 Czermak, B. J. et al. Protective effects of C5a blockade in sepsis. Nature medicine 5, 788-792, 
doi:10.1038/10512 (1999).
27 Huber-Lang, M. S. et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. 
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 
15, 568-570, doi:10.1096/fj.00-0653fje (2001).
28 Ali, Y. M. et al. Low-dose recombinant properdin provides substantial protection against 
Streptococcus pneumoniae and Neisseria meningitidis infection. Proceedings of the 
National Academy of Sciences of the United States of America 111, 5301-5306, doi:10.1073/
pnas.1401011111 (2014).
29 Brown, J. S. et al. The classical pathway is the dominant complement pathway required 
for innate immunity to Streptococcus pneumoniae infection in mice. Proceedings of the 
National Academy of Sciences of the United States of America 99, 16969-16974, doi:10.1073/
pnas.012669199 (2002).
30 Kerr, A. R. et al. The contribution of PspC to pneumococcal virulence varies between strains and 
is accomplished by both complement evasion and complement-independent mechanisms. 
Infection and immunity 74, 5319-5324, doi:10.1128/iai.00543-06 (2006).
31 Kerr, A. R., Paterson, G. K., Riboldi-Tunnicliffe, A. & Mitchell, T. J. Innate immune defense against 
pneumococcal pneumonia requires pulmonary complement component C3. Infection and 
immunity 73, 4245-4252, doi:10.1128/iai.73.7.4245-4252.2005 (2005).
32 Nakajima, R., Namba, K., Ishida, Y., Une, T. & Osada, Y. Protective role of complement in the 
development of experimental pneumococcal pneumonia in mice. Chemotherapy 36, 287-293 
(1990).
154 155
7
General discussion
33 Rupprecht, T. A. et al. Complement C1q and C3 are critical for the innate immune response to 
Streptococcus pneumoniae in the central nervous system. Journal of immunology (Baltimore, 
Md. : 1950) 178, 1861-1869 (2007).
34 Ali, Y. M. et al. The lectin pathway of complement activation is a critical component of the 
innate immune response to pneumococcal infection. PLoS pathogens 8, e1002793, doi:10.1371/
journal.ppat.1002793 (2012).
35 Endo, Y. et al. Mice deficient in ficolin, a lectin complement pathway recognition molecule, are 
susceptible to Streptococcus pneumoniae infection. Journal of immunology (Baltimore, Md. : 
1950) 189, 5860-5866, doi:10.4049/jimmunol.1200836 (2012).
36 Xu, Y. et al. Complement activation in factor D-deficient mice. Proceedings of the National Academy 
of Sciences of the United States of America 98, 14577-14582, doi:10.1073/pnas.261428398 (2001).
37 Pickering, M. C. et al. Uncontrolled C3 activation causes membranoproliferative 
glomerulonephritis in mice deficient in complement factor H. Nature genetics 31, 424-428, 
doi:10.1038/ng912 (2002).
38 Fijen, C. A. et al. Heterozygous and homozygous factor H deficiency states in a Dutch family. 
Clinical and experimental immunology 105, 511-516 (1996).
39 Toomey, C. B., Kelly, U., Saban, D. R. & Bowes Rickman, C. Regulation of age-related macular 
degeneration-like pathology by complement factor H. Proceedings of the National Academy of 
Sciences of the United States of America 112, E3040-3049, doi:10.1073/pnas.1424391112 (2015).
40 Lu, L. et al. Species-specific interaction of Streptococcus pneumoniae with human complement 
factor H. Journal of immunology (Baltimore, Md. : 1950) 181, 7138-7146 (2008).
41 Achila, D. et al. Structural determinants of host specificity of complement Factor H recruitment 
by Streptococcus pneumoniae. The Biochemical journal 465, 325-335, doi:10.1042/bj20141069 
(2015).
42 Pouw, R. B., Vredevoogd, D. W., Kuijpers, T. W. & Wouters, D. Of mice and men: The factor H 
protein family and complement regulation. Molecular immunology 67, 12-20, doi:10.1016/j.
molimm.2015.03.011 (2015).
43 European childhood life-threatening infectious diseases study (EUCLIDS), <http://www.euclids-
project.eu/> (
44 Abarrategui-Garrido, C., Martinez-Barricarte, R., Lopez-Trascasa, M., de Cordoba, S. R. & Sanchez-
Corral, P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals 
novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 
114, 4261-4271, doi:10.1182/blood-2009-05-223834 (2009).
45 Ansari, M. et al. Genetic influences on plasma CFH and CFHR1 concentrations and their role in 
susceptibility to age-related macular degeneration. Human molecular genetics 22, 4857-4869, 
doi:10.1093/hmg/ddt336 (2013).
46 Bernabeu-Herrero, M. E. et al. Complement factor H, FHR-3 and FHR-1 variants associate in an 
extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Molecular 
immunology 67, 276-286, doi:10.1016/j.molimm.2015.06.021 (2015).
47 Hughes, A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated 
with lower risk of age-related macular degeneration. Nature genetics 38, 1173-1177, doi:10.1038/
ng1890 (2006).
48 Zhu, L. et al. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, 
CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. Journal of the American 
Society of Nephrology : JASN 26, 1195-1204, doi:10.1681/asn.2014010096 (2015).
49 Jozsi, M., Tortajada, A., Uzonyi, B., Goicoechea de Jorge, E. & Rodriguez de Cordoba, S. Factor 
H-related proteins determine complement-activating surfaces. Trends in immunology 36, 374-
384, doi:10.1016/j.it.2015.04.008 (2015).
50 Caesar, J. J. et al. Competition between antagonistic complement factors for a single protein on 
N. meningitidis rules disease susceptibility. eLife 3, doi:10.7554/eLife.04008 (2014).
51 Pouw, R. B. et al. Complement Factor H-Related Protein 3 Serum Levels Are Low Compared 
to Factor H and Mainly Determined by Gene Copy Number Variation in CFHR3. PloS one 11, 
e0152164, doi:10.1371/journal.pone.0152164 (2016).
52 Hyams, C. et al. Streptococcus pneumoniae capsular serotype invasiveness correlates with the 
degree of factor H binding and opsonization with C3b/iC3b. Infection and immunity 81, 354-363, 
doi:10.1128/iai.00862-12 (2013).
53 Hyams, C., Camberlein, E., Cohen, J. M., Bax, K. & Brown, J. S. The Streptococcus pneumoniae 
capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. 
Infection and immunity 78, 704-715, doi:10.1128/iai.00881-09 (2010).
54 Brueggemann, A. B. et al. Clonal relationships between invasive and carriage Streptococcus 
pneumoniae and serotype- and clone-specific differences in invasive disease potential. The 
Journal of infectious diseases 187, 1424-1432, doi:10.1086/374624 (2003).
55 Melin, M. et al. Serotype-related variation in susceptibility to complement deposition and 
opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infection and 
immunity 78, 5252-5261, doi:10.1128/iai.00739-10 (2010).
56 Browall, S. et al. Intraclonal variations among Streptococcus pneumoniae isolates influence 
the likelihood of invasive disease in children. The Journal of infectious diseases 209, 377-388, 
doi:10.1093/infdis/jit481 (2014).
57 Weiser, J. N. Phase variation in colony opacity by Streptococcus pneumoniae. Microbial drug 
resistance (Larchmont, N.Y.) 4, 129-135, doi:10.1089/mdr.1998.4.129 (1998).
58 Weiser, J. N., Austrian, R., Sreenivasan, P. K. & Masure, H. R. Phase variation in pneumococcal 
opacity: relationship between colonial morphology and nasopharyngeal colonization. Infection 
and immunity 62, 2582-2589 (1994).
59 Yuste, J. et al. The effects of PspC on complement-mediated immunity to Streptococcus 
pneumoniae vary with strain background and capsular serotype. Infection and immunity 78, 
283-292, doi:10.1128/iai.00541-09 (2010).
60 Li, Q. et al. Role of the alternative and classical complement activation pathway in complement 
mediated killing against Streptococcus pneumoniae colony opacity variants during acute 
pneumococcal otitis media in mice. Microbes and infection / Institut Pasteur 14, 1308-1318, 
doi:10.1016/j.micinf.2012.08.002 (2012).
61 Kim, J. O. et al. Relationship between cell surface carbohydrates and intrastrain variation on 
opsonophagocytosis of Streptococcus pneumoniae. Infection and immunity 67, 2327-2333 
(1999).
62 Briles, D. E. et al. Immunizations with pneumococcal surface protein A and pneumolysin are 
protective against pneumonia in a murine model of pulmonary infection with Streptococcus 
pneumoniae. The Journal of infectious diseases 188, 339-348, doi:10.1086/376571 (2003).
63 Arai, J. et al. Streptococcus pneumoniae isolates from middle ear fluid and nasopharynx of 
children with acute otitis media exhibit phase variation. Journal of clinical microbiology 49, 
1646-1649, doi:10.1128/jcm.01990-10 (2011).
156 157
7
General discussion
64 Briles, D. E., Novak, L., Hotomi, M., van Ginkel, F. W. & King, J. Nasal colonization with Streptococcus 
pneumoniae includes subpopulations of surface and invasive pneumococci. Infection and 
immunity 73, 6945-6951, doi:10.1128/iai.73.10.6945-6951.2005 (2005).
65 Glennie, S. et al. Modulation of nasopharyngeal innate defenses by viral coinfection predisposes 
individuals to experimental pneumococcal carriage. Mucosal immunology 9, 56-67, doi:10.1038/
mi.2015.35 (2016).
66 Hammerschmidt, S. et al. The host immune regulator factor H interacts via two contact sites with 
the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. 
Journal of immunology (Baltimore, Md. : 1950) 178, 5848-5858 (2007).
67 Keller, L. E. et al. PspK of Streptococcus pneumoniae increases adherence to epithelial cells 
and enhances nasopharyngeal colonization. Infection and immunity 81, 173-181, doi:10.1128/
iai.00755-12 (2013).
68 Valentino, M. D. et al. Unencapsulated Streptococcus pneumoniae from conjunctivitis encode 
variant traits and belong to a distinct phylogenetic cluster. Nature communications 5, 5411, 
doi:10.1038/ncomms6411 (2014).
69 Tavares, D. A. et al. Non-typeable pneumococci circulating in Portugal are of cps type NCC2 and 
have genomic features typical of encapsulated isolates. BMC genomics 15, 863, doi:10.1186/1471-
2164-15-863 (2014).
70 Hava, D. L. & Camilli, A. Large-scale identification of serotype 4 Streptococcus pneumoniae 
virulence factors. Molecular microbiology 45, 1389-1406 (2002).
71 Rosenow, C. et al. Contribution of novel choline-binding proteins to adherence, colonization 
and immunogenicity of Streptococcus pneumoniae. Molecular microbiology 25, 819-829 (1997).
72 Hammerschmidt, S., Talay, S. R., Brandtzaeg, P. & Chhatwal, G. S. SpsA, a novel pneumococcal 
surface protein with specific binding to secretory immunoglobulin A and secretory component. 
Molecular microbiology 25, 1113-1124 (1997).
73 Elm, C., Rohde, M., Vaerman, J. P., Chhatwal, G. S. & Hammerschmidt, S. Characterization 
of the interaction of the pneumococcal surface protein SpsA with the human polymeric 
immunoglobulin receptor (hpIgR). The Indian journal of medical research 119 Suppl, 61-65 
(2004).
74 Zhang, J. R. et al. The polymeric immunoglobulin receptor translocates pneumococci across 
human nasopharyngeal epithelial cells. Cell 102, 827-837 (2000).
75 Voss, S. et al. The choline-binding protein PspC of Streptococcus pneumoniae interacts with 
the C-terminal heparin-binding domain of vitronectin. The Journal of biological chemistry 288, 
15614-15627, doi:10.1074/jbc.M112.443507 (2013).
76 Quin, L. R. et al. Factor H binding to PspC of Streptococcus pneumoniae increases adherence to 
human cell lines in vitro and enhances invasion of mouse lungs in vivo. Infection and immunity 
75, 4082-4087, doi:10.1128/iai.00474-07 (2007).
77 Iannelli, F., Oggioni, M. R. & Pozzi, G. Allelic variation in the highly polymorphic locus pspC of 
Streptococcus pneumoniae. Gene 284, 63-71 (2002).
78 Brooks-Walter, A., Briles, D. E. & Hollingshead, S. K. The pspC gene of Streptococcus pneumoniae 
encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and 
provides immunity to pneumococcal bacteremia. Infection and immunity 67, 6533-6542 (1999).
79 Vadesilho, C. F. et al. Mapping of epitopes recognized by antibodies induced by immunization 
of mice with PspA and PspC. Clinical and vaccine immunology : CVI 21, 940-948, doi:10.1128/
cvi.00239-14 (2014).
80 Moreno, A. T. et al. Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies 
with different strains and evaluation of inhibition of human complement factor H and secretory 
IgA binding via PspC. Clinical and vaccine immunology : CVI 19, 499-507, doi:10.1128/cvi.05706-
11 (2012).
81 Beernink, P. T. et al. A meningococcal factor H binding protein mutant that eliminates factor 
H binding enhances protective antibody responses to vaccination. Journal of immunology 
(Baltimore, Md. : 1950) 186, 3606-3614, doi:10.4049/jimmunol.1003470 (2011).
82 Ram, S. et al. Utilizing complement evasion strategies to design complement-based antibacterial 
immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology 221, 1110-1123, 
doi:10.1016/j.imbio.2016.05.016 (2016).
83 Shaughnessy, J. et al. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against 
Neisseria gonorrhoeae. Journal of immunology (Baltimore, Md. : 1950) 196, 1732-1740, 
doi:10.4049/jimmunol.1500292 (2016).
84 Shaughnessy, J. et al. Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc 
as an antibacterial immunotherapeutic. Clinical and vaccine immunology : CVI 21, 1452-1459, 
doi:10.1128/cvi.00444-14 (2014).
85 Wong, S. M., Shaughnessy, J., Ram, S. & Akerley, B. J. Defining the Binding Region in Factor H 
to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus 
influenzae. Frontiers in cellular and infection microbiology 6, 40, doi:10.3389/fcimb.2016.00040 
(2016).
158 159
  
Summary in English
     
160 161
+
Summary in English
Complement is an essential component of the host defence against pneumococci. 
Complement evasion contributes to pneumococcal virulence and survival in the 
human host. The complement protein factor H is a key inhibitor of the alternative 
complement pathway. The primary aim of this thesis is to clarify the role of 
complement factor H in pneumococcal-host interactions. 
We focused on the following questions: 
-  What is the role of factor H alternative pathway regulation on 
pneumococcal induced inflammation? 
-  What is the effect of natural variation in serum factor H levels on host 
resistance to pneumococcal infection? 
-  Do differences in pneumococcal PspC types affect binding of factor H 
and complement deposition on the pneumococcal surface? 
Chapter 1 provides background knowledge of infections by S. pneumoniae and the host 
immune response. This encapsulated Gram-positive diplococcus shaped bacterium 
causes diseases ranging from mild respiratory tract infections to severe diseases, 
such as pneumonia, sepsis and meningitis, also referred to as invasive pneumococcal 
disease (IPD). An important innate immune response upon S. pneumoniae infection 
is activation of the complement system. The three main pathways for complement 
activation are the classical, lectin and alternative pathway. Complement activation 
contributes to pneumococcal clearance by phagocytosis and to the induction 
of inflammatory responses. Initial complement activation via the classical and 
lectin pathways is amplified through the alternative pathway amplification loop. 
A key negative regulator of the alternative pathway and the alternative pathway 
amplification loop is complement factor H. S. pneumoniae has the ability to bind 
human factor H as an immune evasion strategy. For another encapsulated bacterial 
pathogen, Neisseria meningitidis, also known as the meningococcus, a genome 
wide associations study (GWAS) identified risk polymorphisms in the complement 
factor H gene (CFH) and the complement factor H related protein 3 (CFHR3) gene 
associated with meningococcal disease. These GWAS results indicate that genetic 
variation in the CFH gene may affect an individual’s resistance for invasive infections, 
including invasive pneumococcal disease. In addition, complement factor H levels 
vary markedly within the human population. 
In chapter 2 we demonstrate that inhibition of the alternative pathway by factor H 
concentrations in the high physiological range strongly reduces proinflammatory 
cytokine production by human peripheral blood mononuclear cells. The 
complement activation product C5a is known to modulate the inflammatory 
response by binding its receptor (C5aR) (or CD88). We show that alternative 
pathway inhibition by exogenous factor H strongly reduces C5aR crosstalk. Both 
alternative pathway activity and the plasma factor H levels show large variation 
between individuals. These findings suggest that inter individual variation in 
alternative pathway activity due to variation in factor H plasma levels may affect 
the individual’s cytokine responses during infection.
In chapter 3 we hypothesized that at onset of sepsis and initiation of antibiotic 
therapy, inhibition of alternative pathway activation is desirable to ameliorate 
sepsis associated inflammation and vascular leakage. The induction of cytokines 
and chemokines conveys important signals to other immune cells needed for 
activation and coordination of host immune responses. However, the inflammatory 
response can be excessive and can contribute to local tissue damage in focal 
infections or be detrimental in patients with sepsis. High inflammatory responses 
by massive secretion of cytokines and excessive complement activation may result 
in fever, vascular permeability, tissue damage and organ failure. However, mice 
treated with human factor H at the onset of clinical symptoms of sepsis showed 
no decrease in disease scores, serum proinflammatory cytokines, or vascular 
permeability. Factor H administration did also not significantly affect C3 and C3a 
production at 26 h post-infection. We therefore conclude that inhibition of the 
alternative complement pathway by exogenous human factor H fails to attenuate 
inflammation and vascular leakage at a clinically relevant intervention time point 
in pneumococcal sepsis in mice.
A large variation in plasma factor H levels is observed between different 
individuals. In Chapter 4, the functional consequences of the variability in human 
serum factor H level on host defence are demonstrated. Using an in vivo mouse 
model combined with human in vitro assays, we show that the level of serum 
factor H affects complement deposition, which correlates with pneumococcal 
opsonophagocytic killing. We found that plasma factor H levels determine a 
delicate balance of alternative pathway activity, thus affecting the resistance to 
invasive pneumococcal disease. Our results suggest that variation in factor H 
expression levels, naturally occurring in the human population, plays a thus far 
unrecognized role in the resistance to invasive pneumococcal disease. 
In chapter 5, we describe the use of a versatile whole blood killing assay which 
is a method that allowed us to study bacterial clearance in human blood with 
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an intact complement system in vitro. By using a selective thrombin inhibitor 
hirudin, complement activity of whole blood is preserved, in contrast to other 
anticoagulants. With this whole blood killing assay, bacterial factors as well as host 
cellular and humoral factors can be modulated to determine their contribution to 
opsonophagocytic killing. In addition, this assay allows to substitute the plasma 
content of one donor with serum or plasma from another source before initiating 
the whole blood killing assay. This enables manipulation of the concentration 
of different complement factors. Therefore, this assay can be used to study the 
requirements for active complement, phagocyte function and bacterial immune 
evasion mechanisms that contribute to survival in human blood. 
In chapter 6, we focus on the ability of pneumococci to bind human factor H. 
S. pneumoniae binds human factor H mainly by PspC, which is considered a 
mechanism to evade complement deposition. PspC is heterogeneous and has 
been classified into different PspC types based on sequence similarity. We found 
a far greater prevalence of choline bound (subgroup I) PspC types as compared 
to LPxTG anchored (subgroup II) PspC types in invasive pneumococcal disease 
isolates. In addition, applying isogenic pspC switch mutants, we demonstrate that 
subgroup I PspC is more effective in complement evasion than subgroup II PspC. 
These findings indicate that PspC type specific differences contribute to intra-
serotype variation in complement resistance.
In chapter 7, we discuss the findings of the research described in this thesis. 
Imbalance due to excessive activation or improper regulation of the complement 
system has pathological consequences. We demonstrated the importance of 
alternative pathway activity in the defence against invading pathogens. Increased 
alternative pathway activity may reduce the risk for infectious diseases, whereas 
it may enhance host inflammatory responses. Genetic analysis or measurement 
of complement levels and polymorphic variants at the protein level can provide 
relevant data about an individual’s complotype or complement activity. Genome-
wide association studies and additional in vitro and in vivo studies are of importance 
to increase the understanding on how an individual’s complement activity affects 
the susceptibility to infectious diseases. A better understanding of host factors that 
influence susceptibility to infection would support prediction of disease outcome 
and could also contribute to the development of therapies to reduce disease 
susceptibility. In addition, more insight in epidemiological differences in PspC 
type prevalence and their contribution to invasive disease may have implications 
for protein-based pneumococcal vaccine design.
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De gekapselde Gram-positieve Streptococcus pneumoniae bacterie (pneumokok) 
is een belangrijke verwekker van zowel milde luchtweginfecties als ernstige 
ziektes, zoals longontsteking (pneumonie), hersenvliesontsteking (meningitis) 
en bloedvergiftiging (sepsis). Deze ernstige ziektes worden ook wel invasieve 
pneumokokkeninfecties genoemd. Hoofdstuk 1 geeft achtergrondinformatie 
over pneumokokkeninfectie en de afweerreacties van de mens. Een belangrijke 
aangeboren immuunreactie tijdens pneumokokkeninfectie is de activering van 
het complementsysteem. Activering van het complementsysteem resulteert in de 
depositie van complement eiwitten op de bacterie. Deze complementdepositie 
draagt bij aan het verwijderen van de bacterie door middel van fagocytose. 
Daarnaast draagt activatie van het complementsysteem bij aan ontstekingsreacties. 
De drie belangrijkste activatie routes van het complementsysteem zijn de 
klassieke-, de lectine- en de alternatieve route. Complementactivatie via de 
klassieke- en lectine route wordt versterkt door de alternatieve route. Complement 
factor H is een belangrijke negatieve regulator van de alternatieve route en van 
de amplificatie door de alternatieve route. S. pneumoniae kan menselijk factor H 
binden om immuunreacties te ontwijken. S. pneumoniae bindt factor H, via het 
bacteriële oppervlakte-eiwit PspC. Voor Neisseria meningitidis (meningokok), 
een andere gekapselde bacteriële ziekteverwekker, heeft een grote studie 
polymorfismen in het complement factor H gen gevonden die geassocieerd zijn 
met meningokokkeninfecties. Deze resultaten duiden aan dat genetische variaties 
in het complement factor H gen mogelijk effect hebben op de gevoeligheid voor 
invasieve infecties, waaronder mogelijk ook invasieve pneumokokkeninfecties. 
Daarnaast is er veel variatie in factor H plasma concentraties tussen personen. 
Het doel van dit proefschrift is om de rol van complement factor H in 
pneumokokkeninfecties te verduidelijken. Daarbij zijn de volgende vragen van 
belang:
-  Wat is de rol van de alternatieve route, gereguleerd door factor H, bij 
ontstekingsreacties tijdens pneumokokken infectie?
-  Wat is het effect van natuurlijke variatie in factor H concentraties op de 
afweer tegen pneumokokken infectie? 
-  Heeft het pneumokokken PspC type effect op de binding van factor H 
en de complement depositie op het oppervlak van pneumokokken? 
In hoofdstuk 2 laten we zien dat remming van de alternatieve route door toevoeging 
van factor H sterk de pro-inflammatoire cytokineproductie door mononucleaire 
cellen uit perifeer bloed (PBMCs) verlaagt. Het complementactivatie product C5a 
moduleert de ontstekingsreactie door middel van binding aan de C5a receptor. 
Wij laten zien dat remming van de alternatieve route, door toevoeging van factor 
H, de ontstekingsreactie sterk vermindert via de C5a receptor. Zowel de activiteit 
van de alternatieve route als de factor H concentraties in plasma verschillen 
sterk tussen individuen. Onze resultaten suggereren dat variatie in activiteit van 
de alternatieve route tussen individuen door variatie in factor H concentraties 
mogelijk effect heeft op ontstekingsreacties tijdens infecties. 
In hoofdstuk 3 was onze hypothese dat remming van de alternatieve route 
activiteit, bij de eerste sepsis symptomen en antibiotica behandeling, de sterkte 
van ontstekingreacties en de mate van vaatlek zou verminderen. De inductie van 
cytokines en chemokines brengen belangrijke signalen over naar immuuncellen 
die nodig zijn voor de activatie en coördinatie van immuunreacties. Echter, de 
ontstekingsreacties kunnen overmatig zijn en daarmee weefselschade veroorzaken 
waardoor ze levensbedreigend kunnen zijn. Sterke ontstekingsreacties door hoge 
productie van cytokines en overmatige complementactivatie kunnen koorts, 
vaatlek, weefselschade en orgaanuitval veroorzaken. Echter, muizen behandelt 
met menselijk factor H, op het moment dat de eerste symptomen van sepsis 
zichtbaar waren, hadden geen vermindering in ziektescore, cytokines of vaatlek. 
Factor H toediening had 26 uur na de infectie geen significant effect op C3 en 
C3a productie. Daarom concluderen wij dat remming van de alternatieve route 
door middel van factor H toediening, op een klinisch relevant tijdstip, niet de 
ontstekingsreactie en vaatlek vermindert bij pneumokokkensepsis in muizen. 
Er is veel variatie tussen mensen in de plasmaconcentratie van factor H. In 
hoofdstuk 4 laten we de functionele consequenties van deze variatie in factor H 
concentratie op de afweerreacties van de gastheer zien. Door middel van in vivo 
muismodellen gecombineerd met humane in vitro experimenten laten we zien 
dat de factor H concentratie effect heeft op de complementdepositie. De mate 
van complementdepositie op de pneumokok komt overeen met overleving van 
de bacterie in bloed. We vonden dat plasma factor H concentraties belangrijk 
zijn in de balans van de alternatieve route activiteit en daarmee kan de factor H 
concentratie effect hebben op de afweer tegen invasieve pneumokokkeninfectie. 
Onze resultaten suggereren dat variatie in factor H expressie, die van nature 
voorkomt in de populatie, mogelijk een belangrijke rol speelt in de afweer tegen 
invasieve pneumokokken infecties. 
In hoofdstuk 5 beschrijven we het gebruik van een methode om de doding 
van de bacterie in bloed te bepalen, een ‘killing assay’. Deze methode maakt het 
mogelijk om in vitro, in de aanwezigheid van een intact complement systeem, 
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de doding van bacteriën in menselijk bloed te bestuderen. Door gebruik te 
maken van een selectieve trombine remmer, hirudin, blijft de complement 
activiteit behouden, in tegenstelling tot andere antistollingsmiddelen. Met 
deze killing assay kunnen zowel bacteriële factoren als cellulaire of humorale 
gastheerfactoren gemoduleerd worden om hun rol in de doding van de bacterie 
door middel van fagocytose te bestuderen. Daarnaast kan in deze assay het 
plasma van een donor vervangen worden door het plasma van een andere donor 
vóór het begin van de killing assay. Dit maakt het mogelijk om de concentratie 
van verschillende complementfactoren te variëren. Deze test kan daarom gebruikt 
worden om de rol van complementactiviteit, fagocytosefunctie en bacterie 
immuun ontwijkingmechanismen op de overleving van de pneumokok in bloed 
te bestuderen. 
In hoofdstuk 6 hebben we gekeken naar het vermogen van pneumokokken om 
menselijk factor H te binden. S. pneumoniae bindt factor H met het oppervlakte-
eiwit ‘pneumococcal surface protein C’ (PspC). Omdat factor H de alternatieve 
route activatie remt, wordt dit beschouwd als een mechanisme van de bacterie 
om complementdepositie te ontwijken. PspC is heterogeen en is gegroepeerd in 
verschillende PspC types gebaseerd op sequentieovereenkomsten. Wij vonden dat 
in een collectie van invasieve pneumokok isolaten choline bindende PspC types 
(subgroep I) veel vaker voorkwamen dan LPxTG geankerde PspC types (subgroep 
II). Daarnaast, door gebruik te maken van isogene PspC switchmutanten hebben 
we laten zien dat subgroep I PspC types beter complementactivatie ontwijken 
dan subgroep II PspC types. Deze bevindingen duiden aan dat PspC-specifieke 
verschillen bijdragen aan variatie in complementgevoeligheid.
In hoofdstuk 7 bediscussiëren we de bevindingen die beschreven zijn in dit 
proefschrift. Wanneer het complementsysteem uit balans is, door overmatige 
activatie of afwijkingen in de regulatie, kan dit pathologische consequenties 
hebben. Wij laten het belang van de alternatieve route in de afweer tegen invasieve 
pneumokokkeninfecties zien. Verhoogde activiteit van de alternatieve route 
beschermt mogelijk beter tegen invasieve infecties. Daarentegen, een verhoogde 
activiteit van de alternatieve route leidt mogelijk tot sterkere ontstekingsreacties. 
De combinatie van genetische factoren die de complement activiteit bepalen 
wordt ook wel ‘complotype’ genoemd. Genetische analyses of het meten van 
complementcomponenten inclusief polymorfismen op eiwitniveau geven 
mogelijk relevante data over iemands complotype of complement activiteit. GWAS 
(genome-wide association studies) en additionele in vitro en in vivo studies zijn 
van belang om beter te begrijpen hoe iemands complement activiteit effect heeft 
op de gevoeligheid voor infectieziekten. Meer kennis over welke factoren effect 
hebben op iemands gevoeligheid voor infecties zouden kunnen bijdragen aan 
het voorspellen van het ziekteverloop en kunnen bijdragen en de ontwikkeling 
van therapieën. Daarnaast heeft meer inzicht in de epidemiologische verschillen 
in PspC types en hun rol bij invasieve ziekten mogelijke implicaties voor de 
ontwikkeling van pneumokokken vaccins. 
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bij LKI, maar gelukkig komen we elkaar soms nog tegen. Saskia, je hebt me veel 
geholpen. Het toppunt was wel dat je aanbood om ‘s nachts bij de muizen te 
slapen op een stretcher, omdat we ze ook ‘s nachts elk uur moesten controleren. 
Maar ook je gezelligheid heeft zeker bijgedragen. En niet te vergeten Fred, je 
hebt me door de muisexperimenten heen gesleept. Ik werkte met veel plezier 
samen. Het is inmiddels wel een paar jaar geleden, maar ik ben je echt heel erg 
dankbaar. Dineke, jou wil ik ook graag bedanken voor de goede samenwerken. 
Aldert, bedankt voor je hulp bij het uitzoeken van de PspC varianten. Marc en 
Elles, bedankt voor jullie hulp op het lab en natuurlijk ook voor de gezelligheid. 
Lieve Ada, bedankt, we missen je.
Dan kantoor 2.58A; Marloes, Corné, Jeroen, Inge Ahout en Marrit. Met 
jullie samen op een kantoor was veel te gezellig! Bedankt voor de adviezen, 
gesprekken, afleiding en vooral gezelligheid! Ook de andere PhD’s, postdocs en 
andere collega’s wil ik graag bedanken; Daan, Stefan, Stan, Lilly, Jop, Kirsten 
Kuipers, Amelieke, Dimitri, Fredrick, Esther Willems, Evi, Lucille, Gerben en 
Sandra. Lieve Hanneke, met jou kon ik alles goed bespreken en dat heeft me 
veel geholpen, dankjewel. En de collega’s van LKO, wat een geluk dat LKI en LKO 
de labs delen. Bedankt Dorette, Liesbeth, René, Miriam, Yuni, Laurens, Kirsten 
Vrenken, Jeroen Middelbeek, Arthur, Esther, Blanca en Frank ik vond het leuk 
met jullie. En natuurlijk allemaal bedankt voor jullie bloeddonaties. 
Lieve Ria, ik vond het altijd supergezellig met jou, vooral tijdens onze EUCLIDS 
meetings. In Siena in de zon op het terras en vervolgens rennen om de trein 
te halen! This brings me to the Euclids members. I am very impressed by this 
consortium. It was great to see so many good and smart people working together, 
and I am very thankful that I could be part of this group. The annual meetings were 
great, with fantastic dinners and lots of fun in the evenings. So thank you Euclids 
members! 
Marjolein, Cynthia en Kim, ik heb jullie als studenten mogen begeleiden. Bedankt 
voor jullie goede werk en bijdrage aan de publicaties en dit proefschrift. Ik vond 
het erg leuk toen jullie er waren. 
Niek, niet alleen was het handig om met je mee te rijden, maar dat was ook heel 
gezellig en onze gesprekken hebben me veel geholpen. Dankjewel! Ik hoop jou 
en Francine nog vaak in Wageningen te zien. Niels, Arieke, Josse, Thomas, 
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Annelies, Thijs, Charlotte, Lodewijk, Nienke bedankt voor de gezellige avonden. 
Jullie zijn altijd welkom en ik hoop dat we nog vaak samen spelletjes spelen, 
klimmen, biertjes drinken en samen eten met groenten uit onze eigen tuin. En 
‘kleprozen’, Julie-Anne, Marit en Debby, lieve meiden, het is altijd heel leuk als we 
weer samen zijn. Ik ben super trots op jullie! Bas en Pola, helemaal in Schotland. 
Ik mis jullie wel, maar ik vind het super goed dat jullie het avontuur samen zijn 
aangegaan. Jullie zijn erg belangrijk voor mij. Nadine, Stèphanie en Mirjam ook 
jullie wil ik graag bedanken, omdat jullie me veel hebben geholpen al sinds de 
middelbare school. Ik hoop dat het ons lukt contact te houden. 
Tot slot wil ik graag mijn familie bedanken. Bedankt voor jullie interesse en ik vind 
het altijd erg leuk als we elkaar zien. Hetty en Gerrit, bedankt dat jullie altijd voor 
me klaar staan! Zelfs bij al mijn verhuizingen stonden jullie klaar om te helpen 
(ongeveer 8x).
Rens, lievelingspersoon, jij hebt me ontzettend veel geholpen en ik ben je heel 
erg dankbaar. 
